Fabry disease

🔗

Mappings

MONDO

MONDO:0010526 Fabry disease

Orphanet lists MONDO:0010526 as an exact cross-reference for Fabry disease.

ICD-10-CM

ICD10CM:E75.2 Other sphingolipidosis

Orphanet lists ICD-10 E75.2 as a narrower cross-reference for Fabry disease.

ICD-11 Foundation

icd11f:66996647 Fabry disease

Orphanet lists ICD-11 5C56.01 as an exact cross-reference for Fabry disease; the local ICD-11 Foundation ontology represents this as icd11f:66996647.

📘

Definitions

1

Orphanet disease definition

Orphanet defines Fabry disease as a rare genetic, multisystemic lysosomal disease with cutaneous, neurological, renal, cardiovascular, cochleo-vestibular, and cerebrovascular manifestations.

CASE_DEFINITION

Show evidence (1 reference)

ORPHA:324 SUPPORT Other

"A rare genetic, multisystemic lysosomal disease characterized by specific cutaneous (angiokeratoma), neurological (pain), renal (proteinuria, chronic kidney failure), cardiovascular (cardiomyopathy, arrhythmia), cochleo-vestibular and cerebrovascular manifestations (transient ischemic attacks, strokes)."

Orphanet's definition supports the multisystem lysosomal storage disease framing of this entry.

👪

Inheritance

2

X-linked recessive inheritance HP:0001419

X-linked recessive inheritance

Show evidence (1 reference)

ORPHA:324 SUPPORT Other

"X-linked recessive"

Orphanet records X-linked recessive inheritance for Fabry disease.

X-linked dominant inheritance HP:0001423

X-linked dominant inheritance

Show evidence (1 reference)

ORPHA:324 SUPPORT Other

"X-linked dominant"

Orphanet records X-linked dominant inheritance for Fabry disease, reflecting that heterozygous females can develop significant organ damage.

◆

Subtypes

2

Classic Fabry disease

Classic Fabry disease is the early-onset, multisystem phenotype associated with absent or severely reduced alpha-galactosidase A activity.

Show evidence (1 reference)

PMID:35926321 SUPPORT Other

"In classic Fabry disease, α-galactosidase A (α-Gal A) activity is absent or severely reduced and disease manifestations have an early onset that can affect multiple organs."

Expert consensus defines the classic Fabry phenotype as early-onset, multisystem disease with absent or severely reduced enzyme activity.

Late-onset cardiac Fabry disease

Late-onset cardiac Fabry disease preserves residual alpha-galactosidase A activity and presents predominantly with cardiac involvement rather than the full early-onset multisystem classic phenotype.

Show evidence (1 reference)

PMID:35926321 SUPPORT Other

"In contrast, in later-onset Fabry disease, patients have residual α-Gal A activity and clinical features are primarily confined to the heart."

Expert consensus distinguishes later-onset Fabry disease as a phenotype with residual enzyme activity and predominantly cardiac clinical features.

◈

Mechanistic Hypotheses

1

Canonical α-Galactosidase A / Gb3 Lysosomal Storage Model

canonical_gla_deficiency_gb3_lysosomal_storage_model CANONICAL

Fabry disease is an X-linked lysosomal storage disorder caused by loss-of-function variants in GLA on Xq22.1 encoding the lysosomal enzyme α-galactosidase A (α-Gal A). Loss of α-Gal A catalytic activity prevents lysosomal hydrolysis of globotriaosylceramide (Gb3) and related glycosphingolipids, leading to progressive accumulation in lysosomes of vascular endothelium, podocytes, cardiomyocytes, dorsal root ganglion neurons, and other cell types. Substrate accumulation causes endothelial dysfunction, microvascular ischemia, cardiomyopathy, progressive renal failure, small-fiber neuropathy, and stroke. Enzyme replacement therapy (agalsidase alfa/beta), pharmacological chaperone therapy (migalastat for amenable mutations), and substrate reduction trials all corroborate the α-Gal A deficiency / Gb3 accumulation axis as the canonical pathogenic mechanism.

Retained as CANONICAL but flagged as "mechanistically incomplete as a storage-only model." The 2026 falcon hypothesis-search report (kb/hypotheses/Fabry_Disease/canonical_gla_deficiency_gb3_lysosomal_storage_model; openscientist timed out at 3600s) confirms α-Gal A restoration → reduced Gb3/lyso-Gb3 burden across tissues via enzyme replacement (agalsidase alfa/beta, pegunigalsidase alfa), pharmacological chaperone (migalastat for amenable mutations), substrate reduction, and gene therapy — with EM reduction of storage inclusions in preclinical AAV-GLA models. However, the storage model is qualified by four refinements: (1) downstream programs — inflammation, oxidative stress / NO dysregulation, ER stress / unfolded protein response ('agalopathy'), autophagy-lysosomal dysfunction, fibrosis — can persist despite biochemical normalization and may become partially self-sustaining, limiting reversibility in advanced disease; (2) lyso-Gb3 (globotriaosylsphingosine) is not only a pharmacodynamic biomarker but a likely bioactive mediator that propagates pathology even when total Gb3 is reduced; (3) tissue-specific responses differ markedly — vascular endothelium clears Gb3 readily with ERT while podocytes and cardiomyocytes show only partial clearance, explaining persistent nephropathy/cardiomyopathy on long-term therapy; (4) inflammation/innate immune activation in Fabry cardiomyopathy and nephropathy reframes the canonical storage-only model as a storage + cytokine/oxidative-axis disorder requiring combined therapeutic strategies.

Deep research

Falcon citations 61 citations 2026-05-23T23:35:47.345613

Show evidence (1 reference)

PMID:28613767 SUPPORT Other

"Fabry disease represents an X-linked, multisystem lysosomal storage disorder caused by defective function of the enzyme alpha-galactosidase A (α-Gal A)."

Canonical mechanism reference used as the seed for the hypothesis-search deep-research run.

⚙

Pathophysiology

16

Decreased alpha-galactosidase A activity

Pathogenic GLA variants reduce or abolish α-galactosidase A activity, impairing lysosomal catabolism of neutral glycosphingolipids. This is the upstream enzymatic lesion that explains both the biochemical substrate burden and the genotype-dependent response to chaperone or gene-restorative therapies.

GLA hgnc:4296

glycolipid catabolic process GO:0019377

alpha-galactosidase activity GO:0004557

Experimental models

Fabry patient iPSC-derived cardiomyocyte GLA modRNA rescue model IPSC DERIVED MODEL The model assays restoration of alpha-galactosidase A activity after GLA modRNA treatment.

Downstream

Lysosomal Gb3 and lyso-Gb3 accumulation Reduced alpha-galactosidase A activity prevents normal lysosomal clearance of Gb3 and related glycosphingolipids.

Endoplasmic reticulum stress and unfolded protein response Misfolded alpha-galactosidase A variants can trigger ER stress and UPR activation.

Show evidence (2 references)

PMID:28613767 SUPPORT Other

"Fabry disease represents an X-linked, multisystem lysosomal storage disorder caused by defective function of the enzyme alpha-galactosidase A (α-Gal A)."

StatPearls directly supports deficient alpha-galactosidase A function as the proximal biochemical cause of Fabry disease.

PMID:33602475 SUPPORT Other

"Fabry disease (FD) is a rare X-linked inherited lysosomal storage disorder caused by deficient α-galactosidase A activity"

Cardiac review evidence independently frames deficient alpha-galactosidase A activity as the cause of Fabry disease.

Lysosomal Gb3 and lyso-Gb3 accumulation

Deficient α-galactosidase A activity causes progressive lysosomal accumulation of globotriaosylceramide (Gb3/GL-3) and related metabolites including lyso-Gb3. This node captures the shared biochemical storage lesion before it is specialized into organ and cell-type contexts.

glycosphingolipid metabolic process GO:0006687

lysosome GO:0005764

Downstream

Lyso-Gb3 Impaired alpha-galactosidase A activity produces accumulation of Gb3 and its deacylated biomarker lyso-Gb3.

Tissue-specific glycosphingolipid storage The shared lysosomal storage lesion occurs in multiple organ systems and must be interpreted in local tissue contexts.

Innate immune activation and inflammation Gb3 and lyso-Gb3 accumulation promotes inflammatory mediator production.

Show evidence (2 references)

PMID:31939530 SUPPORT Other

"Mutations in the GLA gene lead to the progressive accumulation of globotriaosylceramide (Gb3)."

The review directly connects GLA mutation to progressive Gb3 accumulation.

PMID:36334424 SUPPORT Other

"Fabry disease (FD) is a rare lysosomal storage disorder, characterized by a reduction in α-galactosidase A enzyme activity and the progressive accumulation of globotriaosylceramide (GL3) and its metabolites in the cells of various organs."

This review supports the shared biochemical step from enzyme reduction to GL3/metabolite accumulation across organs.

Tissue-specific glycosphingolipid storage

The same lysosomal substrate burden occurs across kidney, heart, blood vessels, neurons, skin, ocular tissues, and other affected compartments. This branch point represents the generic multisystem storage state before downstream damage is specialized by organ location, cell type, and local stress-response biology.

Downstream

Renal glycosphingolipid storage and podocyte injury Kidney and podocyte substrate accumulation defines the renal branch and is the context for renal GL-3 tissue readouts.

Cardiac glycosphingolipid storage and myocardial remodeling Cardiac substrate accumulation drives the branch leading to hypertrophic and fibrotic Fabry cardiomyopathy.

Vascular endothelial glycosphingolipid storage and dysfunction Vascular and endothelial substrate accumulation defines the branch leading to cerebrovascular and cochleo-vestibular manifestations.

Peripheral small-fiber and autonomic glycosphingolipid storage Neuronal and autonomic substrate accumulation defines the pain, sweating, heat-intolerance, and gastrointestinal branches.

Ocular glycosphingolipid deposition Ocular substrate deposition defines the corneal and lenticular opacity branch.

Cutaneous vascular glycosphingolipid storage Cutaneous vascular substrate accumulation defines the angiokeratoma branch.

Show evidence (2 references)

PMID:36334424 SUPPORT Other

"Accumulation of GL3 in the kidney, heart, vasculature, neurons, skin, gastrointestinal tract and auditory system correlates to cellular damage and irreversible organ damage"

This review directly supports a multisystem branch point in which the same storage substrate is present in several affected organ and cell compartments.

PMID:31939530 SUPPORT Other

"Gb3 accumulates in lysosomes of different types of cells of the heart, kidneys, skin, eyes, central nervous system, and gastrointestinal system"

The review supports tissue-specific branching from a shared lysosomal storage lesion.

Renal glycosphingolipid storage and podocyte injury

GL-3 accumulation in kidney cells, especially podocytes, injures the glomerular filtration barrier. Podocyte storage connects the shared Fabry substrate burden to renal GL-3 biopsy readouts, proteinuria, and progressive chronic kidney disease.

podocyte CL:0000653

kidney UBERON:0002113

Downstream

Autophagy impairment Fabry podocyte injury includes lysosomal and autophagy dysfunction.

Mitochondrial dysfunction and oxidative stress Fabry podocyte models show oxidative-stress and mitochondrial-abnormality pathways downstream of GLA deficiency.

Proteinuria Podocyte injury damages the filtration barrier and contributes to proteinuria.

Chronic kidney disease Persistent renal cellular injury contributes to Fabry nephropathy progression.

Renal Globotriaosylceramide Inclusions Renal podocyte GL-3 storage can be observed as biopsy-level renal globotriaosylceramide inclusions.

Show evidence (2 references)

PMID:27129690 SUPPORT Human Clinical

"renal biopsy showed abnormal structure, with marked accumulation of GL-3 in podocytes, partial effacement of foot processes and irregularly reduced expression of nephrin in the slit diaphragm."

Human biopsy evidence directly supports renal podocyte GL-3 accumulation and podocyte structural injury.

PMID:36334424 SUPPORT Other

"Damage leads to renal dysfunction and end-stage renal disease"

The GL3 clinical relevance review links storage-associated tissue damage to renal dysfunction.

Cardiac glycosphingolipid storage and myocardial remodeling

Gb3 accumulation in cardiac tissue contributes to Fabry cardiomyopathy, with cardiomyocyte hypertrophy, myocardial fibrosis, heart failure risk, and arrhythmogenic remodeling. This branch separates cardiac outcome biology from the renal substrate-clearance surrogate.

cardiomyocyte CL:0000746

heart UBERON:0000948

Experimental models

Fabry patient iPSC-derived cardiomyocyte GL-3 clearance model IPSC DERIVED MODEL The model recapitulates cardiac-cell GL-3 accumulation and can assay GL-3 clearance after substrate-reduction therapy.

Fabry patient iPSC-derived cardiomyocyte GLA modRNA rescue model IPSC DERIVED MODEL Fabry iPSC-cardiomyocytes accumulate GB3, providing a cardiac substrate readout for the disease branch.

Female Fabry iPSC-cardiomyocyte high-content drug-screening model IPSC DERIVED MODEL The model measures Gb3 accumulation and molecular cardiomyopathic change in Fabry iPSC-derived cardiomyocytes.

GLA-null hESC-derived cardiomyocyte autophagy and ROS model CELL LINE GLA-null cardiomyocytes accumulate Gb3 and show hypertrophic cellular features.

GLA p.N215S iPSC-derived atrial cardiomyocyte arrhythmia model IPSC DERIVED MODEL The atrial model validates upstream Fabry enzyme deficiency and substrate accumulation in cardiac cells.

Downstream

Fibrosis and extracellular matrix remodeling Cardiac storage and injury promote myocardial fibrosis and remodeling.

Cardiomyocyte autophagy impairment and oxidative stress Cardiomyocyte storage models show autophagy impairment, ROS production, cell death, and hypertrophic changes.

Atrial cardiomyocyte electrophysiological remodeling Atrial cardiomyocyte storage models show electrophysiological and calcium-handling changes linked to arrhythmia risk.

Show evidence (2 references)

PMID:33602475 SUPPORT Other

"globotriasylceramide (Gb3) in affected tissues, including the heart."

Cardiac review evidence directly supports heart involvement in the Fabry substrate-accumulation branch.

PMID:33602475 SUPPORT Other

"Cardiovascular involvement usually manifests as left ventricular hypertrophy, myocardial fibrosis, heart failure, and arrhythmias"

The review supports the cardiac branch leading to hypertrophy, fibrosis, heart failure, and arrhythmias.

Cardiomyocyte autophagy impairment and oxidative stress

In cardiac pluripotent-stem-cell models of Fabry disease, GLA deficiency and Gb3 accumulation impair autophagic flux and protein turnover, increase mitochondrial reactive oxygen species, and promote apoptosis/necrosis and hypertrophic cellular features. This node captures a cardiac intracellular mechanism that is not measured by the renal GL-3 surrogate.

cardiomyocyte CL:0000746

autophagy GO:0006914 ↕ DYSREGULATED reactive oxygen species metabolic process GO:0072593 ↑ INCREASED apoptotic process GO:0006915 ↑ INCREASED

heart UBERON:0000948

Experimental models

GLA-null hESC-derived cardiomyocyte autophagy and ROS model CELL LINE The model assays GLA-null cardiomyocyte autophagic flux, ROS production, apoptosis, necrosis, and hypertrophic changes.

Downstream

Left ventricular hypertrophy Cardiomyocyte hypertrophic changes contribute to the LVH branch of Fabry cardiomyopathy.

Show evidence (2 references)

PMID:30965672 SUPPORT In Vitro

"cardiomyocytes differentiated from these hESCs (GLA-null CMs) were characterized by the accumulation of Gb3 and significant increases of cell surface area, the landmarks of FD-associated cardiomyopathy."

Human stem-cell-derived GLA-null cardiomyocytes recapitulated Gb3 accumulation and hypertrophic cellular features of Fabry cardiomyopathy.

PMID:30965672 SUPPORT In Vitro

"This caused impairment of autophagic flux and protein turnover, resulting in an increase of reactive oxygen species and apoptosis."

The same cardiomyocyte model directly supports the autophagy-ROS-apoptosis mechanism in the cardiac branch.

Atrial cardiomyocyte electrophysiological remodeling

Fabry atrial cardiomyocyte models show altered action-potential behavior, calcium handling, and contraction, and in silico atrial models translate these cellular changes into early P-wave morphology changes and increased atrial fibrillation vulnerability.

atrial cardiomyocyte CL:0002129

cardiac muscle cell action potential GO:0086001 ↕ DYSREGULATED

cardiac atrium UBERON:0002081

Experimental models

GLA p.N215S iPSC-derived atrial cardiomyocyte arrhythmia model IPSC DERIVED MODEL The model assays action-potential, calcium-handling, and contraction changes in Fabry atrial cardiomyocytes.

Computational models

Bi-atrial in silico Fabry arrhythmia model PHYSIOLOGICAL In silico bi-atrial electrophysiology modeling The model translates cellular action-potential and calcium-handling changes into atrial ECG and arrhythmia outputs.

Downstream

Early atrial ECG changes Atrial electrical remodeling manifests clinically as early P-wave and PQ-interval changes.

Cardiac arrhythmia Atrial electrophysiological remodeling contributes to atrial fibrillation and other arrhythmia risk.

Show evidence (2 references)

PMID:40557493 SUPPORT In Vitro

"Atrial GLA p.N215S iPSC-CMs demonstrated a more positive diastolic membrane potential, faster action potential upstroke velocity, greater incidence of delayed afterdepolarizations, greater contraction force, and alterations in calcium handling compared with wild-type iPSC-CMs."

Genome-edited atrial iPSC-cardiomyocytes directly support the atrial electrophysiological and calcium-handling remodeling node.

PMID:40557493 SUPPORT Computational

"Simulations with these changes in the in silico models resulted in similar P-wave morphology changes to those seen in early FD cardiomyopathy and increased atrial fibrillation vulnerability."

Computational atrial modeling links the cellular remodeling state to clinical ECG morphology and arrhythmia vulnerability.

Vascular endothelial glycosphingolipid storage and dysfunction

Gb3/lyso-Gb3 accumulation in endothelial and vascular cells leads to adhesion-molecule upregulation, reduced nitric oxide availability, and vascular remodeling. This branch links multisystem storage to cerebrovascular events and cochleo-vestibular manifestations.

endothelial cell CL:0000115 smooth muscle cell CL:0000192

leukocyte adhesion to endothelial cells GO:0061756

blood vessel UBERON:0001981

Downstream

Stroke Vascular and endothelial dysfunction contribute to cerebrovascular events.

Transient ischemic attack Fabry vasculopathy contributes to transient cerebral ischemic events.

Hearing impairment Vascular and nervous-system involvement can contribute to cochleo-vestibular manifestations.

Tinnitus Auditory-system glycosphingolipid storage and vasculopathy contribute to cochleo-vestibular symptoms including tinnitus.

Show evidence (2 references)

PMID:39408658 PARTIAL Computational

"are the accumulation of sphingolipids and subsequent inflammatory events, mainly at the endothelial level. The outcomes include different nervous system manifestations as well as multiple organ damage."

Computational systems-biology evidence supports endothelial-level inflammatory vascular injury in Fabry disease.

PMID:36334424 SUPPORT Other

"Accumulation of GL3 in the kidney, heart, vasculature, neurons, skin, gastrointestinal tract and auditory system correlates to cellular damage and irreversible organ damage"

The review includes vasculature among tissue compartments where GL3 accumulation correlates with damage.

Peripheral small-fiber and autonomic glycosphingolipid storage

Glycosphingolipid accumulation in peripheral sensory and autonomic pathways contributes to small-fiber dysfunction, neuropathic pain, impaired sweating, heat intolerance, and gastrointestinal symptoms.

sensory neuron CL:0000101 autonomic neuron CL:0000107

sweat secretion GO:0160269 ↓ DECREASED

peripheral nervous system UBERON:0000010

Downstream

Acroparesthesia Sensory-neuron dysfunction contributes to distal paresthesias and neuropathic pain crises.

Neuropathic pain Small-fiber dysfunction produces chronic or episodic neuropathic pain and Fabry pain crises.

Hypohidrosis Autonomic small-fiber dysfunction reduces sweating.

Heat intolerance Reduced sweat secretion and autonomic dysfunction impair heat tolerance and can worsen Fabry pain crises.

Abdominal pain Autonomic and gastrointestinal involvement can produce abdominal pain as part of the Fabry gastrointestinal symptom cluster.

Nausea and vomiting Gastrointestinal autonomic involvement contributes to nausea and vomiting in Fabry disease.

Show evidence (2 references)

PMID:36334424 SUPPORT Other

"Accumulation of GL3 in the kidney, heart, vasculature, neurons, skin, gastrointestinal tract and auditory system correlates to cellular damage and irreversible organ damage"

The review includes neurons among GL3-affected compartments and links damage to downstream clinical manifestations.

PMID:31939530 SUPPORT Other

"The onset of symptoms occurs during childhood, with acroparesthesia, heat intolerance, and gastrointestinal symptoms, such as nausea, vomiting, abdominal pain, and neuropathic pain"

The clinical review supports the neuronal pain branch through early acroparesthesia and neuropathic pain.

Ocular glycosphingolipid deposition

Glycosphingolipid deposition in ocular tissues produces the ocular branch of Fabry disease, including whorl-like cornea verticillata, corneal opacity, and lenticular opacity/cataract detected on eye examination.

corneal epithelial cell CL:0000076

corneal epithelium UBERON:0001772 lens of camera-type eye UBERON:0000965

Downstream

Cornea verticillata Ocular glycosphingolipid deposition produces whorl-like corneal deposits.

Corneal opacity Ocular glycosphingolipid deposition can contribute to corneal opacity.

Cataract Lenticular glycosphingolipid involvement contributes to cataract/lens opacity in Fabry disease.

Show evidence (2 references)

PMID:31939530 SUPPORT Other

"Gb3 accumulates in lysosomes of different types of cells of the heart, kidneys, skin, eyes, central nervous system, and gastrointestinal system"

The review includes ocular tissues among compartments affected by Gb3 lysosomal accumulation.

PMID:28613767 SUPPORT Other

"Ocular involvement includes corneal and lenticular abnormalities"

StatPearls directly supports corneal and lenticular ocular involvement in Fabry disease.

Cutaneous vascular glycosphingolipid storage

GL3 accumulation in skin and cutaneous microvasculature contributes to angiokeratomas and other microvascular skin findings, separating the cutaneous branch from renal, cardiac, and neural manifestations.

endothelial cell CL:0000115

skin of body UBERON:0002097

Downstream

Angiokeratomas Cutaneous microvascular storage and dilation contribute to angiokeratoma formation.

Show evidence (2 references)

PMID:36334424 SUPPORT Other

"Accumulation of GL3 in the kidney, heart, vasculature, neurons, skin, gastrointestinal tract and auditory system correlates to cellular damage and irreversible organ damage"

The review includes skin and vasculature among compartments where GL3 accumulation correlates with tissue damage.

PMID:28613767 SUPPORT Other

"microvascular skin lesions, eg, angiokeratomas"

StatPearls directly supports angiokeratomas as microvascular skin lesions in Fabry disease.

Endoplasmic reticulum stress and unfolded protein response

Misfolded α-Gal A variants trigger endoplasmic reticulum stress and activate the unfolded protein response (UPR). Persistent UPR activation causes apoptosis and inflammatory signaling through NF-κB and MAPK pathways, contributing to cell death and tissue injury.

response to unfolded protein GO:0006986 NF-kappaB signaling pathway GO:0007249

Downstream

Innate immune activation and inflammation UPR activation causes pro-inflammatory cytokine release and contributes to inflammatory status.

Show evidence (1 reference)

PMID:39978321 PARTIAL Other

"Missense variants in the coding sequence of the GLA gene would generate the misfolding of the altered protein alpha-galactosidase A. Emergence of misfolded proteins may generate stress of the endoplasmic reticulum, leading to induction of the unfolded protein response (UPR)"

Supports ER stress/UPR induction from misfolded GLA variants, but does not fully establish all downstream pathway details stated.

Mitochondrial dysfunction and oxidative stress

Fabry podocyte models show mitochondrial abnormalities and oxidative-stress pathway activation downstream of GLA deficiency. This captures a renal cellular stress mechanism rather than a whole-disease terminal phenotype.

reactive oxygen species metabolic process GO:0072593 regulation of mitochondrial membrane potential GO:0051881

Show evidence (2 references)

PMID:39100494 SUPPORT In Vitro

"Functional analysis of differentially expressed genes showed their involvement in various pathways related to oxidative stress"

Fabry GLA-edited podocyte transcriptomics supports oxidative-stress pathway involvement.

PMID:39100494 SUPPORT In Vitro

"The complex pathogenesis of FD involves lysosomal dysfunction, altered autophagy, and mitochondrial abnormalities."

Fabry podocyte-model evidence supports mitochondrial abnormalities as part of the disease mechanism.

Autophagy impairment

Lysosomal Gb3 accumulation in Fabry podocytes impairs autophagic flux, leading to accumulation of damaged proteins and organelles. Persistent podocyte injury despite enzyme replacement therapy is mediated in part by α-synuclein accumulation, implicating lysosomal toxicity as a disease driver beyond Gb3 storage.

podocyte CL:0000653

SNCA hgnc:11138

autophagy GO:0006914 ↓ DECREASED

Downstream

Proteinuria Fabry podocyte lysosomal dysfunction contributes to podocyte injury and proteinuria.

Chronic kidney disease Persistent podocyte injury and lysosomal dysfunction contribute to Fabry nephropathy progression.

Show evidence (1 reference)

PMID:37014703 PARTIAL In Vitro

"Genetic and pharmacological inhibition of SNCA improved lysosomal structure and function in Fabry podocytes, exceeding the benefits of ERT"

Shows that α-synuclein accumulation impairs lysosomal function and autophagy in Fabry podocytes, and that SNCA is a key driver of injury beyond Gb3 accumulation

Innate immune activation and inflammation

Gb3/lyso-Gb3 accumulation and unfolded-protein stress activate innate inflammatory programs, including complement activation and monocyte/macrophage/dendritic-cell cytokine release. This node captures the shared inflammatory mediator state before its consequences are interpreted in renal, vascular, and profibrotic tissue contexts.

complement activation GO:0006956 inflammatory response GO:0006954

Downstream

Renal glycosphingolipid storage and podocyte injury Kidney-associated cytokine production and inflammation contribute to the renal injury branch.

Vascular endothelial glycosphingolipid storage and dysfunction Chronic inflammatory signaling propagates vascular and endothelial dysfunction.

Fibrosis and extracellular matrix remodeling Inflammatory cytokines including TGF-beta promote profibrotic tissue remodeling.

Show evidence (3 references)

PMID:39978321 SUPPORT Other

"It has been demonstrated that intralysosomal accumulation of Gb3 and LysoGb3 triggers an inflammatory response."

This review supports the upstream link from Fabry substrate accumulation to an inflammatory response.

PMID:38304433 SUPPORT Human Clinical

"we demonstrate strong activation of the complement system in 17 classical male FD patients with either missense or nonsense mutations before and after ERT as evidenced by high C3a and C5a serum levels"

Demonstrates that complement system is strongly activated in Fabry disease patients, supporting the role of innate immune activation in pathogenesis

PMID:38932991 PARTIAL Other

"Inflammation is emerging as an important aspect of the pathogenesis of Fabry disease. This is thought to be predominantly mediated by the innate immune response, with growing evidence pointing towards the potential involvement of adaptive immune mechanisms"

Confirms inflammation as a key pathogenic mechanism in Fabry disease, with emphasis on innate immune response

Fibrosis and extracellular matrix remodeling

TGF-β-driven profibrotic signaling leads to extracellular matrix deposition in kidney and heart. This fibrotic process becomes partially independent of Gb3 substrate levels and contributes to progressive organ dysfunction through epithelial-to-mesenchymal transition and myofibroblast activation.

TGFB1 hgnc:11766

extracellular matrix organization GO:0030198 transforming growth factor beta signaling pathway GO:0007179

Downstream

Chronic kidney disease Renal fibrosis contributes to progressive kidney dysfunction.

Left ventricular hypertrophy Cardiac fibrosis and remodeling accompany hypertrophic Fabry cardiomyopathy.

Cardiac arrhythmia Myocardial fibrosis creates an arrhythmogenic substrate.

Show evidence (2 references)

PMID:38304433 PARTIAL Human Clinical

"we found increased IL-6, IL-10 and TGF-ß1 serum levels in FD patients"

Supports elevated profibrotic cytokine signaling (TGF-β1), but not the full extracellular matrix remodeling cascade described.

PMID:33602475 SUPPORT Other

"Cardiovascular involvement usually manifests as left ventricular hypertrophy, myocardial fibrosis, heart failure, and arrhythmias"

Cardiac review evidence links myocardial fibrosis with the major cardiac manifestations in Fabry disease.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

19

Cardiovascular 4

Angiokeratomas VERY_FREQUENT Angiokeratoma HP:0001014

Show evidence (2 references)

PMID:31939530 SUPPORT Other

"Subsequently, symptoms related to progressive impairment appear, such as angiokeratomas, cornea verticillata, left ventricular hypertrophy, myocardial fibrosis, proteinuria, and renal insufficiency"

Identifies angiokeratomas as a characteristic progressive clinical manifestation of Fabry disease

ORPHA:324 SUPPORT Other

"HP:0001014 | Angiokeratoma | Very frequent (99-80%)"

Orphanet phenotype data confirms angiokeratoma as a very frequent manifestation of Fabry disease.

Left ventricular hypertrophy OCCASIONAL Left ventricular hypertrophy HP:0001712

Show evidence (3 references)

PMID:33602475 SUPPORT Other

"Cardiovascular involvement usually manifests as left ventricular hypertrophy, myocardial fibrosis, heart failure, and arrhythmias, which limit quality of life and represent the most common causes of death"

Confirms that left ventricular hypertrophy is a major cardiac manifestation of Fabry disease

ORPHA:324 SUPPORT Other

"HP:0001712 | Left ventricular hypertrophy | Occasional (29-5%)"

Orphanet phenotype data records left ventricular hypertrophy as an occasional manifestation.

PMID:38749654 SUPPORT Human Clinical

"LVH at treatment initiation was a strong predictor of LVMI progression and adverse events on ERT."

Long-term Swiss cohort evidence links baseline LVH with subsequent left-ventricular-mass progression and adverse Fabry events during ERT.

Cardiac arrhythmia OCCASIONAL Arrhythmia HP:0011675

Show evidence (2 references)

PMID:33602475 SUPPORT Other

"Cardiovascular involvement usually manifests as left ventricular hypertrophy, myocardial fibrosis, heart failure, and arrhythmias"

Cardiac review evidence directly identifies arrhythmias as a Fabry cardiac manifestation.

ORPHA:324 SUPPORT Other

"HP:0011675 | Arrhythmia | Occasional (29-5%)"

Orphanet phenotype data confirms arrhythmia as an occasional manifestation.

Stroke OCCASIONAL stroke HP:0001297

Show evidence (2 references)

PMID:32723516 SUPPORT Other

"Symptoms and organ involvements of classical Fabry disease are acral pain crisis, cornea verticillata, hypertrophic cardiomyopathy, stroke and chronic kidney disease with proteinuria."

Clinical-practice review evidence lists stroke among classical Fabry disease organ involvements.

ORPHA:324 SUPPORT Other

"HP:0001297 | Stroke | Occasional (29-5%)"

Orphanet phenotype data confirms stroke as an occasional manifestation.

Digestive 1

Nausea and vomiting FREQUENT Nausea and vomiting HP:0002017

Show evidence (1 reference)

ORPHA:324 SUPPORT Other

"HP:0002017 | Nausea and vomiting | Frequent (79-30%)"

Orphanet phenotype data records nausea and vomiting as a frequent manifestation of Fabry disease.

Ear 2

Hearing impairment VERY_FREQUENT Hearing impairment HP:0000365

Show evidence (1 reference)

ORPHA:324 SUPPORT Other

"HP:0000365 | Hearing impairment | Very frequent (99-80%)"

Orphanet phenotype data records hearing impairment as a very frequent manifestation.

Tinnitus FREQUENT Tinnitus HP:0000360

Show evidence (1 reference)

ORPHA:324 SUPPORT Other

"HP:0000360 | Tinnitus | Frequent (79-30%)"

Orphanet phenotype data records tinnitus as a frequent manifestation of Fabry disease.

Eye 2

Corneal opacity VERY_FREQUENT Corneal opacity HP:0007957

Show evidence (1 reference)

ORPHA:324 SUPPORT Other

"HP:0007957 | Corneal opacity | Very frequent (99-80%)"

Orphanet phenotype data records corneal opacity as a very frequent manifestation.

Cataract FREQUENT Cataract HP:0000518

Show evidence (2 references)

ORPHA:324 SUPPORT Other

"HP:0000518 | Cataract | Frequent (79-30%)"

Orphanet phenotype data records cataract as a frequent manifestation of Fabry disease.

PMID:20301469 SUPPORT Human Clinical

"characteristic corneal and lenticular opacities"

GeneReviews describes lenticular opacities as characteristic ocular features of classic Fabry disease.

Genitourinary 2

Proteinuria FREQUENT proteinuria HP:0000093

Show evidence (2 references)

PMID:39100494 PARTIAL In Vitro

"This study focuses on genome-wide expression analysis in an FD human podocyte model to gain insights into the underlying mechanisms of podocyte dysfunction"

Supports podocyte dysfunction mechanisms, but does not directly report clinical proteinuria frequency.

ORPHA:324 SUPPORT Other

"HP:0000093 | Proteinuria | Frequent (79-30%)"

Orphanet phenotype data confirms proteinuria as a frequent manifestation.

Chronic kidney disease FREQUENT Chronic kidney disease HP:0012622

Show evidence (2 references)

PMID:31939530 SUPPORT Other

"proteinuria, and renal insufficiency. The latter being the main cause of death in FD."

Identifies progressive renal failure as the primary cause of death in Fabry disease

ORPHA:324 PARTIAL Other

"HP:0000083 | Renal insufficiency | Very frequent (99-80%)"

Orphanet rates the broader term renal insufficiency (HP:0000083) as very frequent, which is consistent with but not a direct match for the more specific chronic kidney disease (HP:0012622).

Integument 1

Hypohidrosis VERY_FREQUENT Hypohidrosis HP:0000966

Show evidence (1 reference)

ORPHA:324 SUPPORT Other

"HP:0000966 | Hypohidrosis | Very frequent (99-80%)"

Orphanet phenotype data records hypohidrosis as a very frequent manifestation of Fabry disease.

Metabolism 1

Heat intolerance FREQUENT Heat intolerance HP:0002046

Show evidence (1 reference)

ORPHA:324 SUPPORT Other

"HP:0002046 | Heat intolerance | Frequent (79-30%)"

Orphanet phenotype data records heat intolerance as a frequent manifestation of Fabry disease.

Constitutional 2

Neuropathic pain VERY_FREQUENT Pain HP:0012531

Show evidence (1 reference)

PMID:21290706 SUPPORT Human Clinical

"FOS has confirmed a very high frequency of neuropathic pain (76% males, 64% females), beginning in childhood or adolescence."

FOS registry data (688 patients) establish neuropathic pain as a very frequent manifestation across both sexes.

Abdominal pain VERY_FREQUENT Abdominal pain HP:0002027

Show evidence (1 reference)

ORPHA:324 SUPPORT Other

"HP:0002027 | Abdominal pain | Very frequent (99-80%)"

Orphanet phenotype data records abdominal pain as a very frequent manifestation of Fabry disease.

Other 4

Acroparesthesia FREQUENT Acroparesthesia HP:0031006

Show evidence (2 references)

PMID:31939530 SUPPORT Other

"The onset of symptoms occurs during childhood, with acroparesthesia, heat intolerance, and gastrointestinal symptoms, such as nausea, vomiting, abdominal pain, and neuropathic pain"

Establishes acroparesthesia and neuropathic pain as early clinical manifestations in Fabry disease

ORPHA:324 SUPPORT Other

"HP:0031006 | Acroparesthesia | Frequent (79-30%)"

Orphanet phenotype data confirms acroparesthesia as a frequent manifestation.

Early atrial ECG changes Abnormal EKG HP:0003115

Show evidence (1 reference)

PMID:40557493 SUPPORT Human Clinical

"ECG analysis demonstrated P-wave duration and PQ interval shortening in FD adults before the onset of cardiomyopathy."

Human ECG analysis in Fabry adults supports early atrial electrical changes before clinical cardiomyopathy.

Transient ischemic attack OCCASIONAL Transient ischemic attack HP:0002326

Show evidence (2 references)

ORPHA:324 PARTIAL Other

"HP:0002326 | Transient ischemic attack | Very frequent (99-80%)"

Orphanet supports TIA as a Fabry manifestation but gives a higher frequency band than registry data.

PMID:21290706 SUPPORT Human Clinical

"Thus, 13.2% (15.1% males, 11.5% females) have suffered an ischaemic stroke or transient ischaemic attack, usually at an early age."

FOS registry data place combined stroke/TIA events in the 5-29% band, supporting the occasional frequency assignment.

Cornea verticillata FREQUENT Cornea verticillata HP:0500008

Show evidence (1 reference)

ORPHA:324 SUPPORT Other

"HP:0500008 | Cornea verticillata | Frequent (79-30%)"

Orphanet phenotype data records cornea verticillata as a frequent manifestation.

🧬

Genetic Associations

2

GLA gene mutations (X-linked recessive)

Gene: GLA hgnc:4296

X-linked recessive

Show evidence (3 references)

PMID:39100494 SUPPORT In Vitro

"Fabry disease (FD) is an X-linked lysosomal disease caused by an enzyme deficiency of alpha-galactosidase A (α-gal A)"

Confirms that Fabry disease is X-linked and caused by deficiency of alpha-galactosidase A enzyme

PMID:39609713 SUPPORT Human Clinical

"Genetic testing is the gold standard for precise diagnosis of FD, however conventional genetic testing could miss deep intronic variants and large deletions or duplications"

Establishes genetic testing as diagnostic gold standard and highlights need for comprehensive sequencing approaches to detect all variant types

ORPHA:324 SUPPORT Other

"GLA | galactosidase alpha | hgnc:4296 | Disease-causing germline mutation(s) in"

Orphanet gene-disease association confirms GLA as the causative gene for Fabry disease.

GLA (Pathogenic Variants)

Gene: GLA hgnc:4296

Show evidence (1 reference)

CGGV:assertion_eb4bb6f4-89de-4586-af6b-3f218b8cb4dc-2019-01-23T170000.000Z SUPPORT Other

ClinGen classifies the GLA-Fabry disease gene-disease relationship as definitive with X-linked inheritance.

💊

Medical Actions

5

Enzyme replacement therapy

Action: enzyme replacement therapy Ontology label: enzyme replacement or supplementation therapy MAXO:0000933

Recombinant α-galactosidase A (agalsidase alfa/beta and pegunigalsidase alfa) restores enzyme activity and reduces Gb3 accumulation. Early initiation improves outcomes, but renal injury and cardiac hypertrophy can still progress despite long-term therapy.

Mechanism Target:

INHIBITS Lysosomal Gb3 and lyso-Gb3 accumulation — Enzyme replacement reduces intracellular Gb3 accumulation caused by deficient alpha-galactosidase A.

Show evidence (1 reference)

PMID:37014703 SUPPORT Human Clinical

"long-term use of ERT reduced Gb3 accumulation in podocytes"

Serial human kidney biopsy evidence supports reduced podocyte Gb3 accumulation with ERT.

Target Phenotypes: Proteinuria HP:0000093 Chronic kidney disease HP:0012622

Show evidence (2 references)

PMID:37014703 PARTIAL Human Clinical

"long-term use of ERT reduced Gb3 accumulation in podocytes but did not reverse podocyte injury"

Shows that ERT reduces substrate accumulation but cannot fully reverse organ damage in Fabry nephropathy

PMID:38749654 PARTIAL Human Clinical

"Over a median follow-up of >10 years under ERT, 36% of the patients still had LVMI cardiac progression, and 32%, predominantly older men, experienced major AFD-related events."

Long-term cohort evidence supports residual cardiac progression despite ERT, reinforcing that substrate-directed therapy does not fully prevent downstream organ damage.

Pharmacological chaperone therapy

Action: Pharmacotherapy NCIT:C15986

Agent: migalastat CHEBI:135923

Migalastat stabilizes GLA mutant variants and improves lysosomal trafficking. Useful for approximately 35-50% of patients with amenable mutations.

Mechanism Target:

RESTORES Decreased alpha-galactosidase A activity — Migalastat stabilizes amenable alpha-galactosidase A variants to improve lysosomal enzyme function.

Show evidence (1 reference)

PMID:40310476 SUPPORT Other

"if a responding ('amenable') α-galactosidase A mutation is present, oral pharmacological chaperone therapy (migalastat 123 mg, every other day)"

Treatment review evidence supports migalastat therapy for amenable alpha-galactosidase A mutations.

Show evidence (1 reference)

PMID:40310476 SUPPORT Other

"if a responding ('amenable') α-galactosidase A mutation is present, oral pharmacological chaperone therapy (migalastat 123 mg, every other day)"

Confirms migalastat is an approved oral chaperone therapy for amenable GLA mutations

Investigational substrate reduction therapy

Action: substrate reduction therapy MAXO:0020025

Glucosylceramide synthase inhibition is an investigational substrate-reduction strategy for Fabry disease that aims to reduce glycosphingolipid substrate supply. In Fabry iPSC-derived cardiomyocytes, substrate reduction therapy prevented accumulation and cleared lysosomal GL-3, linking the cardiac non-animal model to a candidate therapeutic mechanism.

Mechanism Target:

INHIBITS Cardiac glycosphingolipid storage and myocardial remodeling — Glucosylceramide synthase inhibition reduces substrate supply and cleared lysosomal GL-3 in Fabry iPSC-derived cardiomyocytes.

Show evidence (1 reference)

PMID:24850378 SUPPORT In Vitro

"Using this human in vitro model, we demonstrated that substrate reduction therapy via glucosylceramide synthase inhibition was able to prevent accumulation and to clear lysosomal GL-3 in cardiomyocytes."

The iPSC-cardiomyocyte model directly supports inhibition of the cardiac glycosphingolipid storage mechanism by substrate reduction therapy.

Show evidence (1 reference)

PMID:24850378 PARTIAL In Vitro

"Using this human in vitro model, we demonstrated that substrate reduction therapy via glucosylceramide synthase inhibition was able to prevent accumulation and to clear lysosomal GL-3 in cardiomyocytes."

Human iPSC-derived Fabry cardiomyocyte evidence supports substrate reduction as an investigational mechanism for clearing cardiac GL-3, but does not establish clinical efficacy.

Gene therapy

Action: gene therapy MAXO:0001001

AAV and lentiviral-based therapies deliver functional GLA gene for sustained enzyme expression. Shows promise for achieving durable Gb3 clearance and reduced need for repeated infusions.

Mechanism Target:

RESTORES Decreased alpha-galactosidase A activity — Gene therapy aims to restore functional GLA expression upstream of Gb3 accumulation.

Show evidence (1 reference)

PMID:40310476 PARTIAL Other

"Future therapeutic options may include substrate reduction therapy, gene therapy, messenger RNA therapy, and/or vesicle-packaged enzyme replacement therapy"

Treatment review evidence supports gene therapy as an emerging option aimed at the upstream enzyme defect.

Show evidence (1 reference)

PMID:40310476 PARTIAL Other

"Future therapeutic options may include substrate reduction therapy, gene therapy, messenger RNA therapy, and/or vesicle-packaged enzyme replacement therapy"

Supports gene therapy as a future option, but not established clinical efficacy outcomes.

Supportive care

Action: supportive care MAXO:0000950

Management of complications including pain control, renal protection with ACE inhibitors, cardiac monitoring, and stroke prevention. Pain management and cardiovascular monitoring are essential for quality of life.

Target Phenotypes: Pain HP:0012531 Arrhythmia HP:0011675

Show evidence (1 reference)

PMID:35652398 SUPPORT Other

"A multidisciplinary symptomatic treatment is recommended for FD patients, personalized according to disease manifestations and their severity."

Narrative review evidence supports personalized multidisciplinary symptomatic treatment for Fabry disease manifestations.

🔬

Biochemical Markers

2

Lyso-Gb3 (Increased)

Context: Diagnostic and therapeutic biomarker closely associated with disease severity and organ damage

Pathograph Readouts

Readout Of Lysosomal Gb3 and lyso-Gb3 accumulation Positive Monitoring

Increased lyso-Gb3 reflects the upstream sphingolipid substrate accumulation caused by alpha-galactosidase A deficiency.

Show evidence (3 references)

PMID:32183665 SUPPORT Other

"Measurement of the biomarkers Gb3 and Lyso Gb3 in biological specimens may facilitate diagnosis."

Treatment review evidence directly supports Lyso-Gb3 as a Fabry biomarker.

PMID:20716442 SUPPORT Human Clinical

"Increased urinary excretion of lyso-Gb(3) of Fabry patients correlated well with a number of indicators of disease severity."

This Fabry patient study supports lyso-Gb3 as a disease-associated biomarker correlated with severity indicators.

PMID:37207471 PARTIAL Other

"Disease-specific biomarkers are useful in the diagnosis of Fabry disease; non-disease-specific biomarkers may be useful to assess organ damage"

Supports biomarker use in Fabry disease broadly, but does not specifically name lyso-Gb3 in the quoted text.

Renal Globotriaosylceramide Inclusions (Increased)

Context: Renal GL-3 accumulation in podocytes and other kidney cells; can be assessed in biopsy as a tissue biomarker of Fabry disease and treatment response.

Pathograph Readouts

Readout Of Renal glycosphingolipid storage and podocyte injury Positive Pharmacodynamic

Renal GL-3 inclusions are a tissue-level readout of the kidney/podocyte storage branch and can decrease when enzyme replacement clears GL-3.

FDA-SE-adult-noncancer-024 FDA

Complete/near complete clearance of GL-3 inclusions in biopsied renal peritubular capillaries (using the Fabrazyme Scoring System)

Traditional Validated Surrogate Endpoint

Patients with confirmed Fabry disease

FDA-SE-adult-noncancer-025 FDA

Reduction of GL-3 inclusions in biopsied renal peritubular capillaries (using the BLISS methodology)

Accelerated Reasonably Likely Surrogate Endpoint

Patients with confirmed Fabry disease and amenable GLA gene variants

FDA-SE-pediatric-noncancer-019 FDA

Complete/near complete clearance of GL-3 inclusions in biopsied renal peritubular capillaries (using the Fabrazyme Scoring System)

Traditional Validated Surrogate Endpoint

Patients with confirmed Fabry disease

Show evidence (2 references)

PMID:27129690 SUPPORT Human Clinical

"Despite normal renal function and urinalysis, renal biopsy showed abnormal structure, with marked accumulation of GL-3 in podocytes, partial effacement of foot processes and irregularly reduced expression of nephrin in the slit diaphragm."

This biopsy-confirmed Fabry case supports renal GL-3 accumulation as a tissue biochemical marker even before routine renal labs become abnormal.

PMID:36334424 SUPPORT Human Clinical

"Treatment with agalsidase beta is effective in substantially clearing GL3 in a range of cells from the tissues affected by FD."

This review supports tissue GL-3 clearance as a treatment-responsive biochemical readout in Fabry disease.

🔀

Differential Diagnoses

5

Conditions with similar clinical presentations that must be differentiated from Fabry disease:

Hypertrophic Cardiomyopathy (HCM) MONDO:0005045

Overlapping Features HCM is the most common cardiac differential diagnosis for Fabry disease, as both conditions present with left ventricular hypertrophy, cardiomyocyte dysfunction, and arrhythmias. Both can cause sudden cardiac death and progressive heart failure. The cardiac phenotype of Fabry disease (apical involvement, LGE pattern, reduced ejection fraction) overlaps significantly with HCM. Systemic manifestations including neuropathic pain, renal disease, and skin lesions are distinguishing features of Fabry disease absent in HCM.

Distinguishing Features

Prominent basal inferolateral late gadolinium enhancement (LGE) pattern (~50% of Fabry patients)
Acroparesthesia and pain crises (absent in HCM)
Angiokeratomas and cornea verticillata (pathognomonic for Fabry disease)
Progressive renal disease with proteinuria and decline in GFR (rare in HCM)
X-linked inheritance pattern (HCM typically autosomal dominant)
Elevated lyso-Gb3 biomarker (diagnostic for Fabry disease)
Prominent papillary muscles are characteristic of Fabry disease

Show evidence (1 reference)

PMID:33922740 PARTIAL Other

"Hypertrophic cardiomyopathy (HCM) is the main cardiac manifestation of FD"

Establishes HCM as the primary cardiac differential diagnosis for Fabry disease

Cardiac Amyloidosis MONDO:0019065

Overlapping Features Cardiac amyloidosis presents with heart failure, arrhythmias, and LGE patterns similar to Fabry disease. Both conditions can cause concentric or apical hypertrophy, conduction abnormalities, and restrictive physiology. Systolic dysfunction may occur in both. The apical sparing pattern seen on imaging can occur in both amyloidosis and Fabry disease, making differentiation challenging without additional diagnostic markers.

Distinguishing Features

Extracardiac systemic manifestations (neuropathic pain, angiokeratomas, renal disease) are typical of Fabry disease but absent in cardiac amyloidosis
Distinctive cornea verticillata, a whorl-like corneal opacity on slit-lamp examination, is characteristic of Fabry disease
Young age of symptom onset is characteristic of Fabry disease (often in childhood); cardiac amyloidosis is more common in elderly
Male predominance with severe phenotype indicates X-linked inheritance typical of Fabry disease
Elevated lyso-Gb3 biomarker is diagnostic for Fabry disease
Skin or conjunctival biopsy showing amyloid (amyloidosis) versus genetic testing for GLA mutations (Fabry disease) provides definitive diagnosis

Show evidence (1 reference)

PMID:33922740 PARTIAL Other

"An apical sparing pattern on longitudinal strain has also been described in FD, similarly to amyloidosis"

Identifies cardiac amyloidosis as an important differential diagnosis based on overlapping imaging patterns

Myocarditis Not Yet Curated MONDO:0004496

Overlapping Features Myocarditis frequently occurs in Fabry disease (reported in 56% of patients) and can also present as an independent disorder. Both can cause acute or subacute cardiac dysfunction, ventricular dysfunction, arrhythmias, and myocardial inflammation on imaging. Myocarditis in Fabry disease results from chronic Gb3 accumulation in cardiomyocytes, while primary myocarditis is typically triggered by viral infections, autoimmune mechanisms, or drug reactions. The distinction is critical for treatment planning.

Distinguishing Features

Myocarditis in Fabry disease is chronic and progressive (from lysosomal substrate accumulation), whereas primary myocarditis is acute/subacute
Extracardiac features including neuropathic pain, angiokeratomas, renal disease, and cornea verticillata are absent in isolated myocarditis
Elevated lyso-Gb3 biomarker is diagnostic for Fabry disease
Family history showing X-linked inheritance pattern indicates Fabry disease, whereas primary myocarditis typically presents sporadically
Left ventricular hypertrophy pattern is characteristic of Fabry disease, while acute myocarditis presents with dilated cardiomyopathy
Prodromal viral illness preceding acute myocarditis is typically absent in Fabry disease

Show evidence (1 reference)

PMID:33922740 PARTIAL Other

"Endomyocardial biopsies have shown myocarditis in 56% of FD patients"

Establishes the high prevalence of myocardial inflammation in Fabry disease and importance of differential diagnosis

Chagas Disease MONDO:0001444

Overlapping Features Chagas disease, caused by Trypanosoma cruzi, can present with cardiac manifestations including cardiomyopathy, arrhythmias, and sudden cardiac death, overlapping with Fabry disease cardiac phenotypes. Both can cause left ventricular dysfunction and conduction abnormalities. Chronic Chagas disease produces cardiomyopathy with LGE patterns that can mimic Fabry disease. However, systemic manifestations differ significantly.

Distinguishing Features

Acroparesthesia and pain crises are characteristic of Fabry disease but not seen in Chagas disease
Angiokeratomas and cornea verticillata are pathognomonic for Fabry disease
Renal involvement with progressive proteinuria and chronic kidney disease is typical of Fabry disease but absent in Chagas disease
Geographic/epidemiological risk differs (Chagas disease endemic to Central/South America; Fabry disease worldwide with X-linked inheritance)
Gastrointestinal involvement (megaesophagus, megacolon) is typical of Chagas disease but not seen in Fabry disease
Serological testing for Trypanosoma cruzi antibodies versus genetic testing for GLA mutations provides definitive diagnosis

Show evidence (1 reference)

PMID:33922740 PARTIAL Other

"this LGE pattern is not exclusive of FD and may also be found in myocarditis, Chagas disease, and sarcoidosis [52]."

Highlights the imaging overlap between Fabry disease and Chagas disease as cardiac differentials

Sarcoidosis MONDO:0019338

Overlapping Features Sarcoidosis is a multisystem granulomatous disorder that can involve heart (cardiac sarcoidosis), kidneys, nervous system, and skin, creating potential overlap with Fabry disease systemic manifestations. Both can cause cardiomyopathy, arrhythmias, conduction abnormalities, renal disease, and neuropathy. Cardiac sarcoidosis with LGE on imaging can superficially resemble Fabry disease cardiomyopathy. Neurological involvement (stroke, neuropathy) occurs in both conditions.

Distinguishing Features

Acroparesthesia with pain crises is characteristic of Fabry disease, whereas sarcoidosis causes other neuropathy types
Angiokeratomas and cornea verticillata are pathognomonic for Fabry disease and absent in sarcoidosis
Pulmonary involvement with hilar lymphadenopathy is typical of sarcoidosis but absent in Fabry disease
Cutaneous manifestations differ (angiokeratomas in Fabry disease versus erythema nodosum or lupus pernio in sarcoidosis)
Calcium metabolism abnormalities (hypercalcemia, hypercalciuria) are typical of sarcoidosis but absent in Fabry disease
Elevated lyso-Gb3 biomarker is diagnostic for Fabry disease, while elevated ACE and serum calcium suggest sarcoidosis
Skin or conjunctival biopsy showing granulomas versus genetic testing for GLA mutations provides definitive diagnosis

Show evidence (1 reference)

PMID:33922740 PARTIAL Other

"this LGE pattern is not exclusive of FD and may also be found in myocarditis, Chagas disease, and sarcoidosis [52]."

Establishes sarcoidosis as a multisystem differential diagnosis for Fabry disease with overlapping imaging patterns

🧫

Experimental Models

5

Fabry patient iPSC-derived cardiomyocyte GL-3 clearance model IPSC_DERIVED_MODEL

Human Fabry patient iPSC-derived cardiomyocyte model that recapitulates lysosomal GL-3 accumulation in cardiac cells and supports testing tissue-specific substrate-reduction responses outside the renal biopsy compartment.

Organism

human NCBITaxon:9606

Tissue

heart UBERON:0000948

Cell source

Fabry patient-derived induced pluripotent stem cells

Culture

iPSC-derived cardiomyocyte culture

Publication

PMID:24850378

Pathograph links

Cardiac glycosphingolipid storage and myocardial remodeling The model recapitulates cardiac-cell GL-3 accumulation and can assay GL-3 clearance after substrate-reduction therapy.

Show evidence (1 reference)

PMID:24850378 SUPPORT In Vitro

"We generated induced pluripotent stem cells (iPSC) from Fabry patients and differentiated them into cardiomyocytes. In these cells, GL-3 accumulates in the lysosomes over time, resulting in phenotypic changes similar to those found in cardiac tissue from Fabry patients."

The paper directly supports patient iPSC-derived cardiomyocytes as a cardiac Fabry storage model.

Findings

Substrate-reduction therapy cleared lysosomal GL-3 in Fabry iPSC-derived cardiomyocytes.

"Using this human in vitro model, we demonstrated that substrate reduction therapy via glucosylceramide synthase inhibition was able to prevent accumulation and to clear lysosomal GL-3 in cardiomyocytes."

Show evidence (1 reference)

PMID:24850378 SUPPORT In Vitro

"This new in vitro model recapitulates essential features of cardiomyocytes from patients with Fabry disease and therefore provides a useful and relevant tool for further investigations of new therapy."

The study supports this iPSC-cardiomyocyte system as a disease-relevant non-animal model for testing Fabry cardiac therapeutic response.

Fabry patient iPSC-derived cardiomyocyte GLA modRNA rescue model IPSC_DERIVED_MODEL

Patient-derived iPSC-cardiomyocyte model used to test lipid-nanoparticle delivery of GLA-encoding modified mRNA, measuring GB3 reduction and lysosomal-protein rescue in cardiac cells.

Organism

human NCBITaxon:9606

Tissue

heart UBERON:0000948

Cell source

iPSCs derived from Fabry-affected individuals

Culture

iPSC-derived cardiomyocyte culture with lipid nanoparticle-modRNA treatment

Publication

PMID:37607539

Pathograph links

Decreased alpha-galactosidase A activity The model assays restoration of alpha-galactosidase A activity after GLA modRNA treatment.

Show evidence (1 reference)

PMID:37607539 SUPPORT In Vitro

"Importantly, a significant reduction of GB3 levels was observed in GLA modRNA-treated cardiomyocytes, demonstrating that α-GAL enzymatic activity was restored."

GB3 reduction after GLA modRNA treatment supports restoration of the upstream enzyme activity in cardiomyocytes.

Cardiac glycosphingolipid storage and myocardial remodeling Fabry iPSC-cardiomyocytes accumulate GB3, providing a cardiac substrate readout for the disease branch.

Show evidence (1 reference)

PMID:37607539 SUPPORT In Vitro

"Consistent with the clinical phenotype, cardiomyocytes from iPSCs derived from Fabry-affected individuals showed accumulation of the glycosphingolipid Globotriaosylceramide (GB3), which is an α-galactosidase substrate."

The model directly supports cardiac-cell GB3 accumulation in Fabry-derived iPSC-cardiomyocytes.

Findings

GLA modRNA treatment reduced GB3 in Fabry iPSC-derived cardiomyocytes.

"Importantly, a significant reduction of GB3 levels was observed in GLA modRNA-treated cardiomyocytes, demonstrating that α-GAL enzymatic activity was restored."

Show evidence (1 reference)

PMID:37607539 SUPPORT In Vitro

"Together, our results validate the utility of iPSC-derived cardiomyocytes from affected individuals as a model to study disease processes in Fabry disease and the therapeutic potential of GLA modRNA treatment to reduce GB3 accumulation in the heart."

The paper explicitly validates Fabry iPSC-derived cardiomyocytes as a cardiac non-animal model and treatment-response system.

Female Fabry iPSC-cardiomyocyte high-content drug-screening model IPSC_DERIVED_MODEL

Female Fabry patient iPSC-cardiomyocyte model exploiting X-chromosome inactivation to produce GLA-deficient disease clones and normal-activity isogenic controls, with automated Gb3 staining for high-content drug screening.

Organism

human NCBITaxon:9606

Tissue

heart UBERON:0000948

Cell source

iPSCs from a female Fabry patient

Culture

iPSC-derived cardiomyocyte culture with automated Gb3 imaging

Publication

PMID:30048710

Pathograph links

Cardiac glycosphingolipid storage and myocardial remodeling The model measures Gb3 accumulation and molecular cardiomyopathic change in Fabry iPSC-derived cardiomyocytes.

Show evidence (1 reference)

PMID:30048710 SUPPORT In Vitro

"Gb3 accumulation was observed in iPSC-derived cardiomyocytes (iPS-CMs) from GLA activity-deficient iPSCs by mass-spectrometry and immunofluorescent staining."

The study directly supports Gb3 accumulation in GLA-deficient Fabry iPSC-derived cardiomyocytes.

Findings

Patient iPSC clones provided disease and isogenic-control cardiomyocyte models.

"Each iPSC clone from the female patient showed either deficient or normal GLA activity, which could be used as a Fabry disease model or its isogenic control, respectively."

The system supports automated high-content Gb3 drug screening.

"We also established an algorithm for selecting proper Gb3 staining that could be used for high-content analysis-based drug screening."

Show evidence (1 reference)

PMID:30048710 SUPPORT In Vitro

"We generated a Fabry cardiomyopathy model and a drug screening system by using iPS-CMs from a female Fabry patient."

The paper supports this model as a patient-derived iPSC-cardiomyocyte drug-screening system for Fabry cardiomyopathy.

GLA-null hESC-derived cardiomyocyte autophagy and ROS model CELL_LINE

CRISPR/Cas9 GLA-knockout human embryonic stem cell-derived cardiomyocyte model used to study cardiomyocyte hypertrophy, vesicle trafficking, autophagic flux, mitochondrial ROS production, and cell death.

Organism

human NCBITaxon:9606

Tissue

heart UBERON:0000948

Cell source

CRISPR/Cas9-edited human embryonic stem cells

Culture

hESC-derived cardiomyocyte culture with proteomics and cellular stress assays

Publication

PMID:30965672

Pathograph links

Cardiomyocyte autophagy impairment and oxidative stress The model assays GLA-null cardiomyocyte autophagic flux, ROS production, apoptosis, necrosis, and hypertrophic changes.

Show evidence (1 reference)

PMID:30965672 SUPPORT In Vitro

"GLA-null CMs were characterized by autophagy impairment and active mitochondrial ROS production that caused apoptosis and necrosis."

The GLA-null cardiomyocyte model directly supports the cardiac autophagy and oxidative-stress mechanism.

Cardiac glycosphingolipid storage and myocardial remodeling GLA-null cardiomyocytes accumulate Gb3 and show hypertrophic cellular features.

Show evidence (1 reference)

PMID:30965672 SUPPORT In Vitro

"cardiomyocytes differentiated from these hESCs (GLA-null CMs) were characterized by the accumulation of Gb3 and significant increases of cell surface area, the landmarks of FD-associated cardiomyopathy."

The model captures cardiac Gb3 accumulation and hypertrophic changes downstream of GLA loss.

Findings

GLA-null stem-cell-derived cardiomyocytes model Fabry hypertrophic cardiomyopathy.

"we established a FD model which can be used as a promising tool to study human hypertrophic cardiomyopathy in a physiologically and pathologically relevant manner"

Show evidence (1 reference)

PMID:30965672 SUPPORT In Vitro

"To summarize, in the present study we show that CRISPR/Cas9-mediated GLA knockout of hESC-derived CMs can serve as an in vitro FD model for studying hypertrophic cardiomyopathy."

The paper supports this non-animal cardiomyocyte system as a mechanistic model for Fabry cardiac disease.

GLA p.N215S iPSC-derived atrial cardiomyocyte arrhythmia model IPSC_DERIVED_MODEL

Genome-edited iPSC-derived atrial cardiomyocyte model carrying the GLA p.N215S variant, used to measure Gb3 accumulation, atrial action-potential changes, calcium handling, contraction, and arrhythmia-linked cellular changes.

Organism

human NCBITaxon:9606

Tissue

cardiac atrium UBERON:0002081

Cell source

CRISPR/Cas9 genome-edited induced pluripotent stem cells

Culture

iPSC-derived atrial cardiomyocyte culture with electrophysiology, calcium handling, and contraction assays

Publication

PMID:40557493

Pathograph links

Atrial cardiomyocyte electrophysiological remodeling The model assays action-potential, calcium-handling, and contraction changes in Fabry atrial cardiomyocytes.

Show evidence (1 reference)

PMID:40557493 SUPPORT In Vitro

"Atrial GLA p.N215S iPSC-CMs demonstrated a more positive diastolic membrane potential, faster action potential upstroke velocity, greater incidence of delayed afterdepolarizations, greater contraction force, and alterations in calcium handling compared with wild-type iPSC-CMs."

The atrial iPSC-cardiomyocyte model directly supports electrophysiological remodeling in the cardiac branch.

Cardiac glycosphingolipid storage and myocardial remodeling The atrial model validates upstream Fabry enzyme deficiency and substrate accumulation in cardiac cells.

Show evidence (1 reference)

PMID:40557493 SUPPORT In Vitro

"GLA p.N215S iPSC-CMs were deficient in α-Gal A and exhibited globotriaosylceramide accumulation."

The model recapitulates the upstream cardiac storage state before measuring atrial electrophysiological effects.

Show evidence (1 reference)

PMID:40557493 SUPPORT In Vitro

"Cellular contractile and electrophysiological function were examined in a novel atrial cellular FD model developed and imputed into in silico atrial models to provide insight into mechanisms of arrhythmia."

The paper supports this atrial iPSC-cardiomyocyte system as a cellular non-animal model for Fabry arrhythmia mechanisms.

🧮

Computational Models

1

Bi-atrial in silico Fabry arrhythmia model In silico bi-atrial electrophysiology modeling PHYSIOLOGICAL

Physiological bi-atrial simulation model parameterized with GLA p.N215S iPSC-derived atrial cardiomyocyte changes to evaluate P-wave morphology and atrial fibrillation vulnerability in early Fabry cardiac disease.

PMID:40557493

Variable	Model ID	Unit	Ontology Mappings	Phenotype Thresholds
P-wave morphology Simulated ECG morphology output linked to early Fabry cardiomyopathy.
Atrial fibrillation vulnerability Simulated arrhythmia susceptibility output from atrial cellular remodeling.

Pathograph links

Atrial cardiomyocyte electrophysiological remodeling The model translates cellular action-potential and calcium-handling changes into atrial ECG and arrhythmia outputs.

Show evidence (1 reference)

PMID:40557493 SUPPORT Computational

"Bi-atrial in silico models were developed with cellular changes as in GLA p.N215S iPSC-CMs."

The computational model was parameterized from Fabry atrial iPSC-cardiomyocyte cellular changes.

Findings

Simulated atrial-cell changes reproduced early Fabry P-wave morphology changes and increased atrial fibrillation vulnerability.

"Simulations with these changes in the in silico models resulted in similar P-wave morphology changes to those seen in early FD cardiomyopathy and increased atrial fibrillation vulnerability."

Show evidence (1 reference)

PMID:40557493 SUPPORT Computational

"Simulations with these changes in the in silico models resulted in similar P-wave morphology changes to those seen in early FD cardiomyopathy and increased atrial fibrillation vulnerability."

The paper supports a computational model linking cellular Fabry atrial remodeling to early ECG and arrhythmia-risk outputs.

{ }

Source YAML

click to show

name: Fabry disease
creation_date: '2026-01-08T17:12:45Z'
updated_date: '2026-05-21T16:39:58Z'
category: Mendelian
disease_term:
  preferred_term: Fabry disease
  term:
    id: MONDO:0010526
    label: Fabry disease
parents:
- "Lysosomal storage diseases"
- "X-linked genetic disorders"

has_subtypes:
- name: Classic
  display_name: Classic Fabry disease
  classification: clinical_phenotype
  description: >
    Classic Fabry disease is the early-onset, multisystem phenotype associated with absent or severely reduced
    alpha-galactosidase A activity.
  evidence:
  - reference: PMID:35926321
    reference_title: "An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In classic Fabry disease, α-galactosidase A (α-Gal A) activity is absent or severely reduced and disease manifestations have an early onset that can affect multiple organs."
    explanation: Expert consensus defines the classic Fabry phenotype as early-onset, multisystem disease with absent or severely reduced enzyme activity.
- name: Late-onset cardiac
  display_name: Late-onset cardiac Fabry disease
  classification: clinical_phenotype
  description: >
    Late-onset cardiac Fabry disease preserves residual alpha-galactosidase A activity and presents predominantly with
    cardiac involvement rather than the full early-onset multisystem classic phenotype.
  evidence:
  - reference: PMID:35926321
    reference_title: "An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In contrast, in later-onset Fabry disease, patients have residual α-Gal A activity and clinical features are primarily confined to the heart."
    explanation: Expert consensus distinguishes later-onset Fabry disease as a phenotype with residual enzyme activity and predominantly cardiac clinical features.

mappings:
  icd10cm_mappings:
  - term:
      id: ICD10CM:E75.2
      label: Other sphingolipidosis
    mapping_predicate: skos:narrowMatch
    mapping_source: ORPHA:324
    mapping_justification: Orphanet lists ICD-10 E75.2 as a narrower cross-reference for Fabry disease.
    consistency:
    - reference: ORPHA:324
      consistent: CONSISTENT
      notes: "ICD-10:E75.2 | Narrower"
  icd11f_mappings:
  - term:
      id: icd11f:66996647
      label: Fabry disease
    mapping_predicate: skos:exactMatch
    mapping_source: ORPHA:324
    mapping_justification: Orphanet lists ICD-11 5C56.01 as an exact cross-reference for Fabry disease; the local ICD-11 Foundation ontology represents this as icd11f:66996647.
    consistency:
    - reference: ORPHA:324
      consistent: CONSISTENT
      notes: "ICD-11:5C56.01 | Exact"
  mondo_mappings:
  - term:
      id: MONDO:0010526
      label: Fabry disease
    mapping_predicate: skos:exactMatch
    mapping_source: ORPHA:324
    mapping_justification: Orphanet lists MONDO:0010526 as an exact cross-reference for Fabry disease.
    consistency:
    - reference: ORPHA:324
      consistent: CONSISTENT
      notes: "MONDO:0010526 | Exact"
definitions:
- name: Orphanet disease definition
  definition_type: CASE_DEFINITION
  description: >
    Orphanet defines Fabry disease as a rare genetic, multisystemic lysosomal
    disease with cutaneous, neurological, renal, cardiovascular,
    cochleo-vestibular, and cerebrovascular manifestations.
  evidence:
  - reference: ORPHA:324
    reference_title: "Fabry disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "A rare genetic, multisystemic lysosomal disease characterized by specific cutaneous (angiokeratoma), neurological (pain), renal (proteinuria, chronic kidney failure), cardiovascular (cardiomyopathy, arrhythmia), cochleo-vestibular and cerebrovascular manifestations (transient ischemic attacks, strokes)."
    explanation: Orphanet's definition supports the multisystem lysosomal storage disease framing of this entry.

external_assertions:
- name: Orphanet Fabry disease record
  source: Orphanet
  assertion_type: Structured disease record
  external_id: ORPHA:324
  url: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324
  description: >
    Orphanet structured record for Fabry disease, including curated
    cross-references to MONDO, ICD-10, ICD-11, OMIM, MeSH, MedDRA, and UMLS
    identifiers.
  evidence:
  - reference: ORPHA:324
    reference_title: "Fabry disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MONDO:0010526 | Exact"
    explanation: The Orphanet cross-reference table exactly maps ORPHA:324 to MONDO:0010526.
  - reference: ORPHA:324
    reference_title: "Fabry disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ICD-10:E75.2 | Narrower"
    explanation: The Orphanet cross-reference table maps ORPHA:324 to ICD-10 E75.2 as a narrower match.
  - reference: ORPHA:324
    reference_title: "Fabry disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ICD-11:5C56.01 | Exact"
    explanation: The Orphanet cross-reference table exactly maps ORPHA:324 to ICD-11 5C56.01.
  - reference: ORPHA:324
    reference_title: "Fabry disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "UMLS:C0002986 | Exact"
    explanation: The Orphanet cross-reference table exactly maps ORPHA:324 to UMLS C0002986.
- name: StatPearls Fabry disease review
  source: NCBI Bookshelf
  assertion_type: Clinical review
  external_id: NBK435996
  url: https://www.ncbi.nlm.nih.gov/books/NBK435996/
  description: >
    StatPearls clinical review of Fabry disease, updated January 31, 2026,
    covering pathophysiology, clinical manifestations, evaluation, treatment,
    complications, and interprofessional care.
  evidence:
  - reference: PMID:28613767
    reference_title: "Fabry Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Fabry disease represents an X-linked, multisystem lysosomal storage disorder caused by defective function of the enzyme alpha-galactosidase A (α-Gal A)."
    explanation: The StatPearls review supports the clinical overview framing of Fabry disease as an X-linked multisystem lysosomal storage disorder caused by deficient alpha-galactosidase A function.

inheritance:
- name: X-linked recessive inheritance
  inheritance_term:
    preferred_term: X-linked recessive inheritance
    term:
      id: HP:0001419
      label: X-linked recessive inheritance
  evidence:
  - reference: ORPHA:324
    reference_title: "Fabry disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "X-linked recessive"
    explanation: Orphanet records X-linked recessive inheritance for Fabry disease.
- name: X-linked dominant inheritance
  inheritance_term:
    preferred_term: X-linked dominant inheritance
    term:
      id: HP:0001423
      label: X-linked dominant inheritance
  evidence:
  - reference: ORPHA:324
    reference_title: "Fabry disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "X-linked dominant"
    explanation: Orphanet records X-linked dominant inheritance for Fabry disease, reflecting that heterozygous females can develop significant organ damage.

description: >
  Fabry disease is an X-linked lysosomal storage disorder caused by pathogenic variants in GLA that reduce or abolish
  α-galactosidase A activity. Enzyme deficiency causes lysosomal accumulation of glycosphingolipids, principally
  globotriaosylceramide (Gb3) and its deacylated derivative globotriaosylsphingosine (lyso-Gb3). This shared biochemical
  lesion is expressed through tissue-specific branches in kidney, heart, vasculature, nervous system, ocular tissues,
  and skin, where local cell types and stress responses determine the clinical manifestations.

prevalence:
- population: Global clinically recognized populations
  percentage: 1 in 100,000
  notes: >-
    Traditional clinically recognized Fabry disease incidence is about 1 in
    100,000, but this likely underestimates true prevalence because late-onset
    and heterozygous cases are frequently missed outside screening programs.
  evidence:
  - reference: PMID:21092187
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "FD is pan-ethnic and the reported annual incidence of 1 in 100,000 may underestimate the true prevalence of the disease."
    explanation: This review provides the conventional global clinical incidence estimate and explicitly notes underascertainment.
  - reference: PMID:19621417
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Newborn screening identified a surprisingly high frequency of Taiwanese males with Fabry disease (approximately 1 in 1,250), 86% having the IVS4+919G>A mutation previously found in later-onset cardiac phenotype patients."
    explanation: This newborn-screening study supports the point that traditional clinical incidence underestimates Fabry prevalence in screened populations.
- population: Taiwanese male newborns
  percentage: 1 in 1,250
  notes: >-
    Newborn screening in Taiwan detected a much higher frequency than
    traditional clinical estimates, driven largely by the later-onset IVS4
    founder splice variant.
  evidence:
  - reference: PMID:19621417
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Newborn screening identified a surprisingly high frequency of Taiwanese males with Fabry disease (approximately 1 in 1,250), 86% having the IVS4+919G>A mutation previously found in later-onset cardiac phenotype patients."
    explanation: This pilot newborn-screening study directly reports the screened prevalence among Taiwanese male newborns.
  - reference: PMID:21092187
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "FD is pan-ethnic and the reported annual incidence of 1 in 100,000 may underestimate the true prevalence of the disease."
    explanation: The review contextualizes the Taiwan screening estimate as substantially higher than older clinically recognized incidence estimates.
- population: Europe (Orphanet point prevalence)
  percentage: 0.01-0.05
  notes: Orphanet reports a European point-prevalence class of 1-5 per 10,000.
  evidence:
  - reference: ORPHA:324
    reference_title: "Fabry disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-5 / 10 000 | Europe | Point prevalence | ORPHANET"
    explanation: The Orphanet epidemiology table provides a European point-prevalence class for Fabry disease.
- population: Worldwide (Orphanet prevalence at birth)
  percentage: 0.0001-0.0009
  notes: Orphanet reports a worldwide prevalence-at-birth class of 1-9 per 1,000,000.
  evidence:
  - reference: ORPHA:324
    reference_title: "Fabry disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-9 / 1 000 000 | Worldwide | Prevalence at birth | ORPHANET"
    explanation: The Orphanet epidemiology table provides a worldwide prevalence-at-birth class for Fabry disease.

progression:
- phase: Onset
  age_range: Childhood to Adulthood
  evidence:
  - reference: ORPHA:324
    reference_title: "Fabry disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Childhood"
    explanation: Orphanet records childhood as an age-of-onset category for Fabry disease.
  - reference: ORPHA:324
    reference_title: "Fabry disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Adolescent"
    explanation: Orphanet records adolescent as an age-of-onset category for Fabry disease.
  - reference: ORPHA:324
    reference_title: "Fabry disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Adult"
    explanation: Orphanet records adult as an age-of-onset category for Fabry disease.

mechanistic_hypotheses:
- hypothesis_group_id: canonical_gla_deficiency_gb3_lysosomal_storage_model
  hypothesis_label: Canonical α-Galactosidase A / Gb3 Lysosomal Storage Model
  status: CANONICAL
  description: >-
    Fabry disease is an X-linked lysosomal storage disorder caused by loss-of-function variants in GLA
    on Xq22.1 encoding the lysosomal enzyme α-galactosidase A (α-Gal A). Loss of α-Gal A catalytic
    activity prevents lysosomal hydrolysis of globotriaosylceramide (Gb3) and related
    glycosphingolipids, leading to progressive accumulation in lysosomes of vascular endothelium,
    podocytes, cardiomyocytes, dorsal root ganglion neurons, and other cell types. Substrate
    accumulation causes endothelial dysfunction, microvascular ischemia, cardiomyopathy, progressive
    renal failure, small-fiber neuropathy, and stroke. Enzyme replacement therapy (agalsidase
    alfa/beta), pharmacological chaperone therapy (migalastat for amenable mutations), and substrate
    reduction trials all corroborate the α-Gal A deficiency / Gb3 accumulation axis as the canonical
    pathogenic mechanism.
  notes: >-
    Retained as CANONICAL but flagged as
    "mechanistically incomplete as a storage-only model." The
    2026 falcon hypothesis-search report
    (kb/hypotheses/Fabry_Disease/canonical_gla_deficiency_gb3_lysosomal_storage_model;
    openscientist timed out at 3600s) confirms α-Gal A restoration →
    reduced Gb3/lyso-Gb3 burden across tissues via enzyme
    replacement (agalsidase alfa/beta, pegunigalsidase alfa),
    pharmacological chaperone (migalastat for amenable mutations),
    substrate reduction, and gene therapy — with EM reduction of
    storage inclusions in preclinical AAV-GLA models. However, the
    storage model is qualified by four refinements: (1) downstream
    programs — inflammation, oxidative stress / NO dysregulation,
    ER stress / unfolded protein response ('agalopathy'),
    autophagy-lysosomal dysfunction, fibrosis — can persist
    despite biochemical normalization and may become partially
    self-sustaining, limiting reversibility in advanced disease;
    (2) lyso-Gb3 (globotriaosylsphingosine) is not only a
    pharmacodynamic biomarker but a likely bioactive mediator that
    propagates pathology even when total Gb3 is reduced;
    (3) tissue-specific responses differ markedly — vascular
    endothelium clears Gb3 readily with ERT while podocytes and
    cardiomyocytes show only partial clearance, explaining
    persistent nephropathy/cardiomyopathy on long-term therapy;
    (4) inflammation/innate immune activation in Fabry
    cardiomyopathy and nephropathy reframes the canonical
    storage-only model as a storage + cytokine/oxidative-axis
    disorder requiring combined therapeutic strategies.
  evidence:
  - reference: PMID:28613767
    reference_title: "Fabry Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Fabry disease represents an X-linked, multisystem lysosomal storage disorder caused by defective function of the enzyme alpha-galactosidase A (α-Gal A)."
    explanation: >
      Canonical mechanism reference used as the seed for the
      hypothesis-search deep-research run.
pathophysiology:
- name: Decreased alpha-galactosidase A activity
  conforms_to: "lysosomal_substrate_accumulation#Lysosomal Hydrolase or Cofactor Deficiency"
  description: >
    Pathogenic GLA variants reduce or abolish α-galactosidase A activity, impairing lysosomal catabolism of neutral
    glycosphingolipids. This is the upstream enzymatic lesion that explains both the biochemical substrate burden and
    the genotype-dependent response to chaperone or gene-restorative therapies.
  evidence:
  - reference: PMID:28613767
    reference_title: "Fabry Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Fabry disease represents an X-linked, multisystem lysosomal storage disorder caused by defective function of the enzyme alpha-galactosidase A (α-Gal A)."
    explanation: StatPearls directly supports deficient alpha-galactosidase A function as the proximal biochemical cause of Fabry disease.
  - reference: PMID:33602475
    reference_title: "Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Fabry disease (FD) is a rare X-linked inherited lysosomal storage disorder caused by deficient α-galactosidase A activity"
    explanation: Cardiac review evidence independently frames deficient alpha-galactosidase A activity as the cause of Fabry disease.
  molecular_functions:
  - preferred_term: alpha-galactosidase activity
    term:
      id: GO:0004557
      label: alpha-galactosidase activity
  biological_processes:
  - preferred_term: glycolipid catabolic process
    term:
      id: GO:0019377
      label: glycolipid catabolic process
  genes:
  - preferred_term: GLA
    term:
      id: hgnc:4296
      label: GLA
  downstream:
  - target: Lysosomal Gb3 and lyso-Gb3 accumulation
    description: Reduced alpha-galactosidase A activity prevents normal lysosomal clearance of Gb3 and related glycosphingolipids.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:36334424
      reference_title: "Clinical relevance of globotriaosylceramide accumulation in Fabry disease and the effect of agalsidase beta in affected tissues."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Fabry disease (FD) is a rare lysosomal storage disorder, characterized by a reduction in α-galactosidase A enzyme activity and the progressive accumulation of globotriaosylceramide (GL3) and its metabolites in the cells of various organs.
      explanation: Review evidence directly links reduced alpha-galactosidase A activity to progressive GL3 and metabolite accumulation.
  - target: Endoplasmic reticulum stress and unfolded protein response
    description: Misfolded alpha-galactosidase A variants can trigger ER stress and UPR activation.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - misfolded alpha-galactosidase A variants
    - endoplasmic-reticulum protein quality-control stress
    evidence:
    - reference: PMID:39978321
      reference_title: "The Inflammatory Pathogenetic Pathways of Fabry Nephropathy and Agalopathy: <italic>GLA</italic> Variant Induction of Endoplasmic Reticulum Stress."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Missense variants in the coding sequence of the GLA gene would generate the misfolding of the altered protein alpha-galactosidase A. Emergence of misfolded proteins may generate stress of the endoplasmic reticulum, leading to induction of the unfolded protein response (UPR)
      explanation: This review supports the mechanistic path from GLA missense variants through alpha-galactosidase A misfolding to ER stress and UPR activation.
- name: Lysosomal Gb3 and lyso-Gb3 accumulation
  conforms_to: "lysosomal_substrate_accumulation#Lysosomal Substrate Accumulation"
  description: >
    Deficient α-galactosidase A activity causes progressive lysosomal accumulation of globotriaosylceramide (Gb3/GL-3)
    and related metabolites including lyso-Gb3. This node captures the shared biochemical storage lesion before it is
    specialized into organ and cell-type contexts.
  evidence:
  - reference: PMID:31939530
    reference_title: "Fabry disease: genetics, pathology, and treatment."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Mutations in the GLA gene lead to the progressive accumulation of globotriaosylceramide (Gb3)."
    explanation: The review directly connects GLA mutation to progressive Gb3 accumulation.
  - reference: PMID:36334424
    reference_title: "Clinical relevance of globotriaosylceramide accumulation in Fabry disease and the effect of agalsidase beta in affected tissues."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Fabry disease (FD) is a rare lysosomal storage disorder, characterized by a reduction in α-galactosidase A enzyme activity and the progressive accumulation of globotriaosylceramide (GL3) and its metabolites in the cells of various organs."
    explanation: This review supports the shared biochemical step from enzyme reduction to GL3/metabolite accumulation across organs.
  chemical_entities:
  - preferred_term: globotriaosylceramide
    term:
      id: CHEBI:18313
      label: alpha-D-galactosyl-(1->4)-beta-D-galactosyl-(1->4)-beta-D-glucosylceramide
  biological_processes:
  - preferred_term: glycosphingolipid metabolic process
    term:
      id: GO:0006687
      label: glycosphingolipid metabolic process
  cellular_components:
  - preferred_term: lysosome
    term:
      id: GO:0005764
      label: lysosome
  downstream:
  - target: Lyso-Gb3
    description: Impaired alpha-galactosidase A activity produces accumulation of Gb3 and its deacylated biomarker lyso-Gb3.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20716442
      reference_title: "How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "BACKGROUND: Fabry disease is characterized by accumulation of glycosphingolipids, such as globotriaosylceramide (Gb(3)), in many tissues and body fluids. A novel plasma biomarker, globotriaosylsphingosine (lyso-Gb(3)), is increased in patients with the disease."
      explanation: Fabry patient biomarker evidence directly links glycosphingolipid accumulation with increased lyso-Gb3 in the disease.
  - target: Tissue-specific glycosphingolipid storage
    description: The shared lysosomal storage lesion occurs in multiple organ systems and must be interpreted in local tissue contexts.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:36334424
      reference_title: "Clinical relevance of globotriaosylceramide accumulation in Fabry disease and the effect of agalsidase beta in affected tissues."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Accumulation of GL3 in the kidney, heart, vasculature, neurons, skin, gastrointestinal tract and auditory system correlates to cellular damage and irreversible organ damage
      explanation: The review supports branching from shared GL3 accumulation into organ-specific storage and tissue damage.
  - target: Innate immune activation and inflammation
    description: Gb3 and lyso-Gb3 accumulation promotes inflammatory mediator production.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Gb3 and lyso-Gb3 sensing by innate immune cells
    - cytokine release
    evidence:
    - reference: PMID:39978321
      reference_title: "The Inflammatory Pathogenetic Pathways of Fabry Nephropathy and Agalopathy: <italic>GLA</italic> Variant Induction of Endoplasmic Reticulum Stress."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: It has been demonstrated that intralysosomal accumulation of Gb3 and LysoGb3 triggers an inflammatory response.
      explanation: The review directly supports inflammatory activation downstream of intralysosomal Gb3 and LysoGb3 accumulation.
- name: Tissue-specific glycosphingolipid storage
  description: >
    The same lysosomal substrate burden occurs across kidney, heart, blood vessels, neurons, skin, ocular tissues, and
    other affected compartments. This branch point represents the generic multisystem storage state before downstream
    damage is specialized by organ location, cell type, and local stress-response biology.
  evidence:
  - reference: PMID:36334424
    reference_title: "Clinical relevance of globotriaosylceramide accumulation in Fabry disease and the effect of agalsidase beta in affected tissues."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Accumulation of GL3 in the kidney, heart, vasculature, neurons, skin, gastrointestinal tract and auditory system correlates to cellular damage and irreversible organ damage"
    explanation: This review directly supports a multisystem branch point in which the same storage substrate is present in several affected organ and cell compartments.
  - reference: PMID:31939530
    reference_title: "Fabry disease: genetics, pathology, and treatment."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Gb3 accumulates in lysosomes of different types of cells of the heart, kidneys, skin, eyes, central nervous system, and gastrointestinal system"
    explanation: The review supports tissue-specific branching from a shared lysosomal storage lesion.
  downstream:
  - target: Renal glycosphingolipid storage and podocyte injury
    description: Kidney and podocyte substrate accumulation defines the renal branch and is the context for renal GL-3 tissue readouts.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:27129690
      reference_title: "Significant improvement in Fabry disease podocytopathy after 3 years of treatment with agalsidase beta."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Despite normal renal function and urinalysis, renal biopsy showed abnormal structure, with marked accumulation of GL-3 in podocytes, partial effacement of foot processes and irregularly reduced expression of nephrin in the slit diaphragm.
      explanation: Human renal biopsy evidence places GL-3 accumulation specifically in podocytes and links it to podocyte structural injury.
  - target: Cardiac glycosphingolipid storage and myocardial remodeling
    description: Cardiac substrate accumulation drives the branch leading to hypertrophic and fibrotic Fabry cardiomyopathy.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:33602475
      reference_title: "Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Fabry disease (FD) is a rare X-linked inherited lysosomal storage disorder caused by deficient α-galactosidase A activity that leads to an accumulation of globotriasylceramide (Gb3) in affected tissues, including the heart.
      explanation: The cardiac review supports heart-specific Gb3 accumulation as a Fabry disease tissue branch.
  - target: Vascular endothelial glycosphingolipid storage and dysfunction
    description: Vascular and endothelial substrate accumulation defines the branch leading to cerebrovascular and cochleo-vestibular manifestations.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:36334424
      reference_title: "Clinical relevance of globotriaosylceramide accumulation in Fabry disease and the effect of agalsidase beta in affected tissues."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Accumulation of GL3 in the kidney, heart, vasculature, neurons, skin, gastrointestinal tract and auditory system correlates to cellular damage and irreversible organ damage
      explanation: The review includes vasculature among GL3-affected compartments where storage correlates with cellular and organ damage.
  - target: Peripheral small-fiber and autonomic glycosphingolipid storage
    description: Neuronal and autonomic substrate accumulation defines the pain, sweating, heat-intolerance, and gastrointestinal branches.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:36334424
      reference_title: "Clinical relevance of globotriaosylceramide accumulation in Fabry disease and the effect of agalsidase beta in affected tissues."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Accumulation of GL3 in the kidney, heart, vasculature, neurons, skin, gastrointestinal tract and auditory system correlates to cellular damage and irreversible organ damage
      explanation: The review includes neurons and gastrointestinal tract among GL3-affected compartments, supporting the peripheral/autonomic branch.
  - target: Ocular glycosphingolipid deposition
    description: Ocular substrate deposition defines the corneal and lenticular opacity branch.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31939530
      reference_title: "Fabry disease: genetics, pathology, and treatment."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Gb3 accumulates in lysosomes of different types of cells of the heart, kidneys, skin, eyes, central nervous system, and gastrointestinal system
      explanation: The review includes the eyes among tissues with lysosomal Gb3 accumulation, supporting the ocular branch.
  - target: Cutaneous vascular glycosphingolipid storage
    description: Cutaneous vascular substrate accumulation defines the angiokeratoma branch.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:36334424
      reference_title: "Clinical relevance of globotriaosylceramide accumulation in Fabry disease and the effect of agalsidase beta in affected tissues."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Accumulation of GL3 in the kidney, heart, vasculature, neurons, skin, gastrointestinal tract and auditory system correlates to cellular damage and irreversible organ damage
      explanation: The review includes skin and vasculature among GL3-affected tissues, supporting the cutaneous vascular storage branch.
- name: Renal glycosphingolipid storage and podocyte injury
  description: >
    GL-3 accumulation in kidney cells, especially podocytes, injures the glomerular filtration barrier. Podocyte storage
    connects the shared Fabry substrate burden to renal GL-3 biopsy readouts, proteinuria, and progressive chronic kidney
    disease.
  evidence:
  - reference: PMID:27129690
    reference_title: "Significant improvement in Fabry disease podocytopathy after 3 years of treatment with agalsidase beta."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "renal biopsy showed abnormal structure, with marked accumulation of GL-3 in podocytes, partial effacement of foot processes and irregularly reduced expression of nephrin in the slit diaphragm."
    explanation: Human biopsy evidence directly supports renal podocyte GL-3 accumulation and podocyte structural injury.
  - reference: PMID:36334424
    reference_title: "Clinical relevance of globotriaosylceramide accumulation in Fabry disease and the effect of agalsidase beta in affected tissues."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Damage leads to renal dysfunction and end-stage renal disease"
    explanation: The GL3 clinical relevance review links storage-associated tissue damage to renal dysfunction.
  cell_types:
  - preferred_term: podocyte
    term:
      id: CL:0000653
      label: podocyte
  locations:
  - preferred_term: kidney
    term:
      id: UBERON:0002113
      label: kidney
  downstream:
  - target: Autophagy impairment
    description: Fabry podocyte injury includes lysosomal and autophagy dysfunction.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - lysosomal dysfunction in GLA-edited podocytes
    - podocyte cellular stress response
    evidence:
    - reference: PMID:39100494
      reference_title: "Genome-wide expression analysis in a Fabry disease human podocyte cell line."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: The complex pathogenesis of FD involves lysosomal dysfunction, altered autophagy, and mitochondrial abnormalities.
      explanation: Fabry podocyte-model evidence links the renal cellular disease context to altered autophagy.
  - target: Mitochondrial dysfunction and oxidative stress
    description: Fabry podocyte models show oxidative-stress and mitochondrial-abnormality pathways downstream of GLA deficiency.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - GLA-edited podocyte stress-response changes
    - mitochondrial abnormalities
    evidence:
    - reference: PMID:39100494
      reference_title: "Genome-wide expression analysis in a Fabry disease human podocyte cell line."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Functional analysis of differentially expressed genes showed their involvement in various pathways related to oxidative stress, inflammation, fatty acid metabolism, collagen and extracellular matrix homeostasis, kidney injury, apoptosis, autophagy, and cellular stress response.
      explanation: Transcriptomic analysis of Fabry podocytes supports oxidative-stress and cellular-stress pathways downstream of podocyte dysfunction.
  - target: Proteinuria
    description: Podocyte injury damages the filtration barrier and contributes to proteinuria.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - podocyte foot-process injury
    - slit-diaphragm dysfunction
    - glomerular filtration barrier injury
    evidence:
    - reference: PMID:28613767
      reference_title: "Fabry Disease."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Ocular involvement includes corneal and lenticular abnormalities, while progressive renal involvement leads to proteinuria and eventual end-stage renal disease.
      explanation: The clinical review supports proteinuria as a consequence of progressive renal involvement in Fabry disease.
  - target: Chronic kidney disease
    description: Persistent renal cellular injury contributes to Fabry nephropathy progression.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - progressive renal cellular injury
    - glomerular and interstitial damage
    evidence:
    - reference: PMID:36334424
      reference_title: "Clinical relevance of globotriaosylceramide accumulation in Fabry disease and the effect of agalsidase beta in affected tissues."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Damage leads to renal dysfunction and end-stage renal disease
      explanation: The GL3 clinical-relevance review links storage-associated renal damage to renal dysfunction and end-stage renal disease.
  - target: Renal Globotriaosylceramide Inclusions
    description: Renal podocyte GL-3 storage can be observed as biopsy-level renal globotriaosylceramide inclusions.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:27129690
      reference_title: "Significant improvement in Fabry disease podocytopathy after 3 years of treatment with agalsidase beta."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Despite normal renal function and urinalysis, renal biopsy showed abnormal structure, with marked accumulation of GL-3 in podocytes, partial effacement of foot processes and irregularly reduced expression of nephrin in the slit diaphragm.
      explanation: Human biopsy evidence supports renal GL-3 inclusions as a direct tissue readout of the renal podocyte storage branch.
- name: Cardiac glycosphingolipid storage and myocardial remodeling
  description: >
    Gb3 accumulation in cardiac tissue contributes to Fabry cardiomyopathy, with cardiomyocyte hypertrophy, myocardial
    fibrosis, heart failure risk, and arrhythmogenic remodeling. This branch separates cardiac outcome biology from the
    renal substrate-clearance surrogate.
  evidence:
  - reference: PMID:33602475
    reference_title: "Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "globotriasylceramide (Gb3) in affected tissues, including the heart."
    explanation: Cardiac review evidence directly supports heart involvement in the Fabry substrate-accumulation branch.
  - reference: PMID:33602475
    reference_title: "Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Cardiovascular involvement usually manifests as left ventricular hypertrophy, myocardial fibrosis, heart failure, and arrhythmias"
    explanation: The review supports the cardiac branch leading to hypertrophy, fibrosis, heart failure, and arrhythmias.
  cell_types:
  - preferred_term: cardiomyocyte
    term:
      id: CL:0000746
      label: cardiac muscle cell
  locations:
  - preferred_term: heart
    term:
      id: UBERON:0000948
      label: heart
  downstream:
  - target: Fibrosis and extracellular matrix remodeling
    description: Cardiac storage and injury promote myocardial fibrosis and remodeling.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - cardiac glycosphingolipid storage
    - myocardial inflammation and remodeling
    evidence:
    - reference: PMID:33602475
      reference_title: "Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Cardiovascular involvement usually manifests as left ventricular hypertrophy, myocardial fibrosis, heart failure, and arrhythmias, which limit quality of life and represent the most common causes of death
      explanation: The cardiac review links Fabry cardiac involvement with myocardial fibrosis and remodeling-related outcomes.
  - target: Cardiomyocyte autophagy impairment and oxidative stress
    description: Cardiomyocyte storage models show autophagy impairment, ROS production, cell death, and hypertrophic changes.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - cardiomyocyte Gb3 accumulation
    - autophagic-flux impairment
    - mitochondrial ROS production
    evidence:
    - reference: PMID:30965672
      reference_title: "Generation of GLA-Knockout Human Embryonic Stem Cell Lines to Model Autophagic Dysfunction and Exosome Secretion in Fabry Disease-Associated Hypertrophic Cardiomyopathy."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: This caused impairment of autophagic flux and protein turnover, resulting in an increase of reactive oxygen species and apoptosis.
      explanation: GLA-null human stem-cell-derived cardiomyocyte evidence supports autophagy impairment and ROS production downstream of the cardiac disease model.
  - target: Atrial cardiomyocyte electrophysiological remodeling
    description: Atrial cardiomyocyte storage models show electrophysiological and calcium-handling changes linked to arrhythmia risk.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - atrial cardiomyocyte alpha-galactosidase A deficiency
    - atrial globotriaosylceramide accumulation
    evidence:
    - reference: PMID:40557493
      reference_title: "Early Atrial Remodeling Drives Arrhythmia in Fabry Disease."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: GLA p.N215S iPSC-CMs were deficient in α-Gal A and exhibited globotriaosylceramide accumulation. Atrial GLA p.N215S iPSC-CMs demonstrated a more positive diastolic membrane potential, faster action potential upstroke velocity, greater incidence of delayed afterdepolarizations, greater contraction force, and alterations in calcium handling compared with wild-type iPSC-CMs.
      explanation: The atrial iPSC-cardiomyocyte model connects Fabry enzyme deficiency and globotriaosylceramide accumulation to atrial electrophysiological remodeling.
- name: Cardiomyocyte autophagy impairment and oxidative stress
  description: >
    In cardiac pluripotent-stem-cell models of Fabry disease, GLA deficiency and Gb3 accumulation impair autophagic flux
    and protein turnover, increase mitochondrial reactive oxygen species, and promote apoptosis/necrosis and hypertrophic
    cellular features. This node captures a cardiac intracellular mechanism that is not measured by the renal GL-3
    surrogate.
  evidence:
  - reference: PMID:30965672
    reference_title: "Generation of GLA-Knockout Human Embryonic Stem Cell Lines to Model Autophagic Dysfunction and Exosome Secretion in Fabry Disease-Associated Hypertrophic Cardiomyopathy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "cardiomyocytes differentiated from these hESCs (GLA-null CMs) were characterized by the accumulation of Gb3 and significant increases of cell surface area, the landmarks of FD-associated cardiomyopathy."
    explanation: Human stem-cell-derived GLA-null cardiomyocytes recapitulated Gb3 accumulation and hypertrophic cellular features of Fabry cardiomyopathy.
  - reference: PMID:30965672
    reference_title: "Generation of GLA-Knockout Human Embryonic Stem Cell Lines to Model Autophagic Dysfunction and Exosome Secretion in Fabry Disease-Associated Hypertrophic Cardiomyopathy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "This caused impairment of autophagic flux and protein turnover, resulting in an increase of reactive oxygen species and apoptosis."
    explanation: The same cardiomyocyte model directly supports the autophagy-ROS-apoptosis mechanism in the cardiac branch.
  cell_types:
  - preferred_term: cardiomyocyte
    term:
      id: CL:0000746
      label: cardiac muscle cell
  locations:
  - preferred_term: heart
    term:
      id: UBERON:0000948
      label: heart
  biological_processes:
  - preferred_term: autophagy
    term:
      id: GO:0006914
      label: autophagy
    modifier: DYSREGULATED
  - preferred_term: reactive oxygen species metabolic process
    term:
      id: GO:0072593
      label: reactive oxygen species metabolic process
    modifier: INCREASED
  - preferred_term: apoptotic process
    term:
      id: GO:0006915
      label: apoptotic process
    modifier: INCREASED
  downstream:
  - target: Left ventricular hypertrophy
    description: Cardiomyocyte hypertrophic changes contribute to the LVH branch of Fabry cardiomyopathy.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - impaired cardiomyocyte autophagic flux
    - mitochondrial ROS production
    - hypertrophic cardiomyocyte remodeling
    evidence:
    - reference: PMID:30965672
      reference_title: "Generation of GLA-Knockout Human Embryonic Stem Cell Lines to Model Autophagic Dysfunction and Exosome Secretion in Fabry Disease-Associated Hypertrophic Cardiomyopathy."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: cardiomyocytes differentiated from these hESCs (GLA-null CMs) were characterized by the accumulation of Gb3 and significant increases of cell surface area, the landmarks of FD-associated cardiomyopathy.
      explanation: The GLA-null cardiomyocyte model supports hypertrophic cellular remodeling in the same model that shows autophagy and ROS abnormalities.
- name: Atrial cardiomyocyte electrophysiological remodeling
  description: >
    Fabry atrial cardiomyocyte models show altered action-potential behavior, calcium handling, and contraction, and
    in silico atrial models translate these cellular changes into early P-wave morphology changes and increased atrial
    fibrillation vulnerability.
  evidence:
  - reference: PMID:40557493
    reference_title: "Early Atrial Remodeling Drives Arrhythmia in Fabry Disease."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Atrial GLA p.N215S iPSC-CMs demonstrated a more positive diastolic membrane potential, faster action potential upstroke velocity, greater incidence of delayed afterdepolarizations, greater contraction force, and alterations in calcium handling compared with wild-type iPSC-CMs."
    explanation: Genome-edited atrial iPSC-cardiomyocytes directly support the atrial electrophysiological and calcium-handling remodeling node.
  - reference: PMID:40557493
    reference_title: "Early Atrial Remodeling Drives Arrhythmia in Fabry Disease."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "Simulations with these changes in the in silico models resulted in similar P-wave morphology changes to those seen in early FD cardiomyopathy and increased atrial fibrillation vulnerability."
    explanation: Computational atrial modeling links the cellular remodeling state to clinical ECG morphology and arrhythmia vulnerability.
  cell_types:
  - preferred_term: atrial cardiomyocyte
    term:
      id: CL:0002129
      label: regular atrial cardiac myocyte
  locations:
  - preferred_term: cardiac atrium
    term:
      id: UBERON:0002081
      label: cardiac atrium
  biological_processes:
  - preferred_term: cardiac muscle cell action potential
    term:
      id: GO:0086001
      label: cardiac muscle cell action potential
    modifier: DYSREGULATED
  downstream:
  - target: Early atrial ECG changes
    description: Atrial electrical remodeling manifests clinically as early P-wave and PQ-interval changes.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:40557493
      reference_title: "Early Atrial Remodeling Drives Arrhythmia in Fabry Disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: ECG analysis demonstrated P-wave duration and PQ interval shortening in FD adults before the onset of cardiomyopathy.
      explanation: Human ECG analysis supports early atrial conduction changes as a downstream manifestation of Fabry atrial remodeling.
  - target: Cardiac arrhythmia
    description: Atrial electrophysiological remodeling contributes to atrial fibrillation and other arrhythmia risk.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - altered atrial action-potential behavior
    - abnormal calcium handling
    - atrial fibrillation vulnerability
    evidence:
    - reference: PMID:40557493
      reference_title: "Early Atrial Remodeling Drives Arrhythmia in Fabry Disease."
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: Simulations with these changes in the in silico models resulted in similar P-wave morphology changes to those seen in early FD cardiomyopathy and increased atrial fibrillation vulnerability.
      explanation: Computational atrial modeling links the observed Fabry atrial-cell changes to increased atrial fibrillation vulnerability.
- name: Vascular endothelial glycosphingolipid storage and dysfunction
  description: >
    Gb3/lyso-Gb3 accumulation in endothelial and vascular cells leads to adhesion-molecule upregulation, reduced nitric
    oxide availability, and vascular remodeling. This branch links multisystem storage to cerebrovascular events and
    cochleo-vestibular manifestations.
  evidence:
  - reference: PMID:39408658
    reference_title: "In Silico Modeling of Fabry Disease Pathophysiology for the Identification of Early Cellular Damage Biomarker Candidates."
    supports: PARTIAL
    evidence_source: COMPUTATIONAL
    snippet: "are the accumulation of sphingolipids and subsequent inflammatory events, mainly at the endothelial level. The outcomes include different nervous system manifestations as well as multiple organ damage."
    explanation: Computational systems-biology evidence supports endothelial-level inflammatory vascular injury in Fabry disease.
  - reference: PMID:36334424
    reference_title: "Clinical relevance of globotriaosylceramide accumulation in Fabry disease and the effect of agalsidase beta in affected tissues."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Accumulation of GL3 in the kidney, heart, vasculature, neurons, skin, gastrointestinal tract and auditory system correlates to cellular damage and irreversible organ damage"
    explanation: The review includes vasculature among tissue compartments where GL3 accumulation correlates with damage.
  cell_types:
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  - preferred_term: smooth muscle cell
    term:
      id: CL:0000192
      label: smooth muscle cell
  locations:
  - preferred_term: blood vessel
    term:
      id: UBERON:0001981
      label: blood vessel
  biological_processes:
  - preferred_term: leukocyte adhesion to endothelial cells
    term:
      id: GO:0061756
      label: leukocyte adhesion to vascular endothelial cell
  downstream:
  - target: Stroke
    description: Vascular and endothelial dysfunction contribute to cerebrovascular events.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - vascular GL3-associated cellular damage
    - endothelial dysfunction
    - cerebrovascular ischemia
    evidence:
    - reference: PMID:36334424
      reference_title: "Clinical relevance of globotriaosylceramide accumulation in Fabry disease and the effect of agalsidase beta in affected tissues."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Damage leads to renal dysfunction and end-stage renal disease; myocardial hypertrophy with heart failure and arrhythmias; ischemic stroke; neuropathic pain; skin lesions; intestinal ischemia and dysmotility; and hearing loss.
      explanation: The GL3 clinical-relevance review links tissue damage downstream of GL3 accumulation to ischemic stroke.
  - target: Transient ischemic attack
    description: Fabry vasculopathy contributes to transient cerebral ischemic events.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Fabry vasculopathy
    - cerebrovascular ischemia
    evidence:
    - reference: PMID:21290706
      reference_title: "Nervous system manifestations of Fabry disease: data from FOS – the Fabry Outcome Survey."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Thus, 13.2% (15.1% males, 11.5% females) have suffered an ischaemic stroke or transient ischaemic attack, usually at an early age.
      explanation: Fabry Outcome Survey data support stroke or TIA as clinical downstream events of the nervous-system and vascular branch.
  - target: Hearing impairment
    description: Vascular and nervous-system involvement can contribute to cochleo-vestibular manifestations.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - auditory-system GL3 accumulation
    - vascular and neural injury
    evidence:
    - reference: PMID:36334424
      reference_title: "Clinical relevance of globotriaosylceramide accumulation in Fabry disease and the effect of agalsidase beta in affected tissues."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Damage leads to renal dysfunction and end-stage renal disease; myocardial hypertrophy with heart failure and arrhythmias; ischemic stroke; neuropathic pain; skin lesions; intestinal ischemia and dysmotility; and hearing loss.
      explanation: The review links GL3-associated tissue damage to hearing loss, supporting the cochleo-vestibular branch.
  - target: Tinnitus
    description: Auditory-system glycosphingolipid storage and vasculopathy contribute to cochleo-vestibular symptoms including tinnitus.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - auditory system glycosphingolipid accumulation
    - vascular dysfunction
    evidence:
    - reference: ORPHA:324
      reference_title: "Fabry disease (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0000360 | Tinnitus | Frequent (79-30%)"
      explanation: Orphanet records tinnitus as a frequent Fabry disease phenotype.

- name: Peripheral small-fiber and autonomic glycosphingolipid storage
  description: >
    Glycosphingolipid accumulation in peripheral sensory and autonomic pathways contributes to small-fiber dysfunction,
    neuropathic pain, impaired sweating, heat intolerance, and gastrointestinal symptoms.
  evidence:
  - reference: PMID:36334424
    reference_title: "Clinical relevance of globotriaosylceramide accumulation in Fabry disease and the effect of agalsidase beta in affected tissues."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Accumulation of GL3 in the kidney, heart, vasculature, neurons, skin, gastrointestinal tract and auditory system correlates to cellular damage and irreversible organ damage"
    explanation: The review includes neurons among GL3-affected compartments and links damage to downstream clinical manifestations.
  - reference: PMID:31939530
    reference_title: "Fabry disease: genetics, pathology, and treatment."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The onset of symptoms occurs during childhood, with acroparesthesia, heat intolerance, and gastrointestinal symptoms, such as nausea, vomiting, abdominal pain, and neuropathic pain"
    explanation: The clinical review supports the neuronal pain branch through early acroparesthesia and neuropathic pain.
  cell_types:
  - preferred_term: sensory neuron
    term:
      id: CL:0000101
      label: sensory neuron
  - preferred_term: autonomic neuron
    term:
      id: CL:0000107
      label: autonomic neuron
  locations:
  - preferred_term: peripheral nervous system
    term:
      id: UBERON:0000010
      label: peripheral nervous system
  biological_processes:
  - preferred_term: sweat secretion
    term:
      id: GO:0160269
      label: sweat secretion
    modifier: DECREASED
  downstream:
  - target: Acroparesthesia
    description: Sensory-neuron dysfunction contributes to distal paresthesias and neuropathic pain crises.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - neuronal glycosphingolipid storage
    - small-fiber dysfunction
    evidence:
    - reference: PMID:31939530
      reference_title: "Fabry disease: genetics, pathology, and treatment."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: The onset of symptoms occurs during childhood, with acroparesthesia, heat intolerance, and gastrointestinal symptoms, such as nausea, vomiting, abdominal pain, and neuropathic pain
      explanation: The review places acroparesthesia in the early neurological and autonomic symptom cluster downstream of Fabry storage.
  - target: Neuropathic pain
    description: Small-fiber dysfunction produces chronic or episodic neuropathic pain and Fabry pain crises.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - small-fiber dysfunction
    - neuronal glycosphingolipid storage
    evidence:
    - reference: PMID:21290706
      reference_title: "Nervous system manifestations of Fabry disease: data from FOS – the Fabry Outcome Survey."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "FOS has confirmed a very high frequency of neuropathic pain (76% males, 64% females), beginning in childhood or adolescence."
      explanation: Fabry Outcome Survey data directly support neuropathic pain as a frequent nervous-system manifestation.
  - target: Hypohidrosis
    description: Autonomic small-fiber dysfunction reduces sweating.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - autonomic small-fiber dysfunction
    - reduced sweat secretion
    evidence:
    - reference: ORPHA:324
      reference_title: "Fabry disease (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0000966 | Hypohidrosis | Very frequent (99-80%)"
      explanation: Orphanet records hypohidrosis as a very frequent Fabry disease phenotype.
  - target: Heat intolerance
    description: Reduced sweat secretion and autonomic dysfunction impair heat tolerance and can worsen Fabry pain crises.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - autonomic small-fiber dysfunction
    - reduced sweat secretion
    evidence:
    - reference: PMID:31939530
      reference_title: "Fabry disease: genetics, pathology, and treatment."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "The onset of symptoms occurs during childhood, with acroparesthesia, heat intolerance, and gastrointestinal symptoms, such as nausea, vomiting, abdominal pain, and neuropathic pain"
      explanation: The review lists heat intolerance with early Fabry acroparesthesia and neuropathic/gastrointestinal symptoms.
  - target: Abdominal pain
    description: Autonomic and gastrointestinal involvement can produce abdominal pain as part of the Fabry gastrointestinal symptom cluster.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - autonomic dysfunction
    - gastrointestinal glycosphingolipid involvement
    evidence:
    - reference: PMID:31939530
      reference_title: "Fabry disease: genetics, pathology, and treatment."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "The onset of symptoms occurs during childhood, with acroparesthesia, heat intolerance, and gastrointestinal symptoms, such as nausea, vomiting, abdominal pain, and neuropathic pain"
      explanation: The review lists abdominal pain among early gastrointestinal symptoms in Fabry disease.
  - target: Nausea and vomiting
    description: Gastrointestinal autonomic involvement contributes to nausea and vomiting in Fabry disease.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - autonomic dysfunction
    - gastrointestinal glycosphingolipid involvement
    evidence:
    - reference: PMID:31939530
      reference_title: "Fabry disease: genetics, pathology, and treatment."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "The onset of symptoms occurs during childhood, with acroparesthesia, heat intolerance, and gastrointestinal symptoms, such as nausea, vomiting, abdominal pain, and neuropathic pain"
      explanation: The review lists nausea and vomiting among early gastrointestinal symptoms in Fabry disease.

- name: Ocular glycosphingolipid deposition
  description: >
    Glycosphingolipid deposition in ocular tissues produces the ocular branch of Fabry disease, including whorl-like
    cornea verticillata, corneal opacity, and lenticular opacity/cataract detected on eye examination.
  evidence:
  - reference: PMID:31939530
    reference_title: "Fabry disease: genetics, pathology, and treatment."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Gb3 accumulates in lysosomes of different types of cells of the heart, kidneys, skin, eyes, central nervous system, and gastrointestinal system"
    explanation: The review includes ocular tissues among compartments affected by Gb3 lysosomal accumulation.
  - reference: PMID:28613767
    reference_title: "Fabry Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Ocular involvement includes corneal and lenticular abnormalities"
    explanation: StatPearls directly supports corneal and lenticular ocular involvement in Fabry disease.
  cell_types:
  - preferred_term: corneal epithelial cell
    term:
      id: CL:0000076
      label: squamous epithelial cell
  locations:
  - preferred_term: corneal epithelium
    term:
      id: UBERON:0001772
      label: corneal epithelium
  - preferred_term: lens of camera-type eye
    term:
      id: UBERON:0000965
      label: lens of camera-type eye
  downstream:
  - target: Cornea verticillata
    description: Ocular glycosphingolipid deposition produces whorl-like corneal deposits.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31939530
      reference_title: "Fabry disease: genetics, pathology, and treatment."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Subsequently, symptoms related to progressive impairment appear, such as angiokeratomas, cornea verticillata, left ventricular hypertrophy, myocardial fibrosis, proteinuria, and renal insufficiency
      explanation: The review lists cornea verticillata among Fabry manifestations that follow progressive tissue impairment.
  - target: Corneal opacity
    description: Ocular glycosphingolipid deposition can contribute to corneal opacity.
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:324
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0007957 | Corneal opacity | Very frequent (99-80%)
      explanation: Orphanet records corneal opacity as a very frequent Fabry disease manifestation, supporting this ocular downstream target.
  - target: Cataract
    description: Lenticular glycosphingolipid involvement contributes to cataract/lens opacity in Fabry disease.
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:324
      reference_title: "Fabry disease (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0000518 | Cataract | Frequent (79-30%)
      explanation: Orphanet records cataract as a frequent Fabry disease manifestation, supporting this lenticular ocular downstream target.
- name: Cutaneous vascular glycosphingolipid storage
  description: >
    GL3 accumulation in skin and cutaneous microvasculature contributes to angiokeratomas and other microvascular skin
    findings, separating the cutaneous branch from renal, cardiac, and neural manifestations.
  evidence:
  - reference: PMID:36334424
    reference_title: "Clinical relevance of globotriaosylceramide accumulation in Fabry disease and the effect of agalsidase beta in affected tissues."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Accumulation of GL3 in the kidney, heart, vasculature, neurons, skin, gastrointestinal tract and auditory system correlates to cellular damage and irreversible organ damage"
    explanation: The review includes skin and vasculature among compartments where GL3 accumulation correlates with tissue damage.
  - reference: PMID:28613767
    reference_title: "Fabry Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "microvascular skin lesions, eg, angiokeratomas"
    explanation: StatPearls directly supports angiokeratomas as microvascular skin lesions in Fabry disease.
  cell_types:
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  locations:
  - preferred_term: skin of body
    term:
      id: UBERON:0002097
      label: skin of body
  downstream:
  - target: Angiokeratomas
    description: Cutaneous microvascular storage and dilation contribute to angiokeratoma formation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:28613767
      reference_title: "Fabry Disease."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Common presenting features include severe episodic pain in the extremities consistent with acroparesthesia, microvascular skin lesions, eg, angiokeratomas, and abnormalities of sweating that may manifest as anhidrosis, hypohidrosis, or hyperhidrosis.
      explanation: StatPearls identifies angiokeratomas as microvascular skin lesions, supporting the edge from cutaneous vascular storage to angiokeratomas.
- name: Endoplasmic reticulum stress and unfolded protein response
  description: >
    Misfolded α-Gal A variants trigger endoplasmic reticulum stress and activate the unfolded protein response (UPR).
    Persistent UPR activation causes apoptosis and inflammatory signaling through NF-κB and MAPK pathways, contributing
    to cell death and tissue injury.
  evidence:
  - reference: PMID:39978321
    reference_title: "The Inflammatory Pathogenetic Pathways of Fabry Nephropathy and Agalopathy: <italic>GLA</italic> Variant Induction of Endoplasmic Reticulum Stress."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: "Missense variants in the coding sequence of the GLA gene would generate the misfolding of the altered protein alpha-galactosidase A. Emergence of misfolded proteins may generate stress of the endoplasmic reticulum, leading to induction of the unfolded protein response (UPR)"
    explanation: "Supports ER stress/UPR induction from misfolded GLA variants, but does not fully establish all downstream pathway details stated."
  biological_processes:
  - preferred_term: response to unfolded protein
    term:
      id: GO:0006986
      label: response to unfolded protein
  - preferred_term: NF-kappaB signaling pathway
    term:
      id: GO:0007249
      label: canonical NF-kappaB signal transduction
  downstream:
  - target: Innate immune activation and inflammation
    description: UPR activation causes pro-inflammatory cytokine release and contributes to inflammatory status.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:39978321
      reference_title: "The Inflammatory Pathogenetic Pathways of Fabry Nephropathy and Agalopathy: <italic>GLA</italic> Variant Induction of Endoplasmic Reticulum Stress."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: The UPR causes the release of pro-inflammatory cytokines and contributes to inflammatory status.
      explanation: The review directly supports pro-inflammatory cytokine release downstream of UPR activation.
- name: Mitochondrial dysfunction and oxidative stress
  description: >
    Fabry podocyte models show mitochondrial abnormalities and oxidative-stress pathway activation downstream of GLA
    deficiency. This captures a renal cellular stress mechanism rather than a whole-disease terminal phenotype.
  evidence:
  - reference: PMID:39100494
    reference_title: "Genome-wide expression analysis in a Fabry disease human podocyte cell line."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Functional analysis of differentially expressed genes showed their involvement in various pathways related to oxidative stress"
    explanation: Fabry GLA-edited podocyte transcriptomics supports oxidative-stress pathway involvement.
  - reference: PMID:39100494
    reference_title: "Genome-wide expression analysis in a Fabry disease human podocyte cell line."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The complex pathogenesis of FD involves lysosomal dysfunction, altered autophagy, and mitochondrial abnormalities."
    explanation: Fabry podocyte-model evidence supports mitochondrial abnormalities as part of the disease mechanism.
  biological_processes:
  - preferred_term: reactive oxygen species metabolic process
    term:
      id: GO:0072593
      label: reactive oxygen species metabolic process
  - preferred_term: regulation of mitochondrial membrane potential
    term:
      id: GO:0051881
      label: regulation of mitochondrial membrane potential

- name: Autophagy impairment
  description: >
    Lysosomal Gb3 accumulation in Fabry podocytes impairs autophagic flux, leading to accumulation of damaged proteins and organelles.
    Persistent podocyte injury despite enzyme replacement therapy is mediated in part by α-synuclein accumulation,
    implicating lysosomal toxicity as a disease driver beyond Gb3 storage.
  evidence:
  - reference: PMID:37014703
    reference_title: "Accumulation of α-synuclein mediates podocyte injury in Fabry nephropathy."
    supports: PARTIAL
    evidence_source: IN_VITRO
    snippet: "Genetic and pharmacological inhibition of SNCA improved lysosomal structure and function in Fabry podocytes, exceeding the benefits of ERT"
    explanation: "Shows that α-synuclein accumulation impairs lysosomal function and autophagy in Fabry podocytes, and that SNCA is a key driver of injury beyond Gb3 accumulation"
  cell_types:
  - preferred_term: podocyte
    term:
      id: CL:0000653
      label: podocyte
  biological_processes:
  - preferred_term: autophagy
    term:
      id: GO:0006914
      label: autophagy
    modifier: DECREASED
  genes:
  - preferred_term: SNCA
    term:
      id: hgnc:11138
      label: SNCA
  downstream:
  - target: Proteinuria
    description: Fabry podocyte lysosomal dysfunction contributes to podocyte injury and proteinuria.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - lysosomal dysfunction in podocytes
    - podocyte injury
    - glomerular filtration barrier injury
    evidence:
    - reference: PMID:39100494
      reference_title: "Genome-wide expression analysis in a Fabry disease human podocyte cell line."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Functional analysis of differentially expressed genes showed their involvement in various pathways related to oxidative stress, inflammation, fatty acid metabolism, collagen and extracellular matrix homeostasis, kidney injury, apoptosis, autophagy, and cellular stress response.
      explanation: Fabry podocyte transcriptomics links autophagy-related cellular stress with kidney-injury pathways that can lead to proteinuria.
  - target: Chronic kidney disease
    description: Persistent podocyte injury and lysosomal dysfunction contribute to Fabry nephropathy progression.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - persistent podocyte lysosomal dysfunction
    - podocyte injury
    - progressive kidney injury
    evidence:
    - reference: PMID:37014703
      reference_title: "Accumulation of α-synuclein mediates podocyte injury in Fabry nephropathy."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: Current therapies for Fabry disease are based on reversing intracellular accumulation of globotriaosylceramide (Gb3) by enzyme replacement therapy (ERT) or chaperone-mediated stabilization of the defective enzyme, thereby alleviating lysosomal dysfunction. However, their effect in the reversal of end-organ damage, like kidney injury and chronic kidney disease, remains unclear.
      explanation: Human-biopsy study framing supports persistent lysosomal/podocyte injury as a contributor to kidney injury and chronic kidney disease, though it does not isolate autophagy alone.
- name: Innate immune activation and inflammation
  description: >
    Gb3/lyso-Gb3 accumulation and unfolded-protein stress activate innate inflammatory programs, including complement
    activation and monocyte/macrophage/dendritic-cell cytokine release. This node captures the shared inflammatory
    mediator state before its consequences are interpreted in renal, vascular, and profibrotic tissue contexts.
  evidence:
  - reference: PMID:39978321
    reference_title: "The Inflammatory Pathogenetic Pathways of Fabry Nephropathy and Agalopathy: <italic>GLA</italic> Variant Induction of Endoplasmic Reticulum Stress."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "It has been demonstrated that intralysosomal accumulation of Gb3 and LysoGb3 triggers an inflammatory response."
    explanation: This review supports the upstream link from Fabry substrate accumulation to an inflammatory response.
  - reference: PMID:38304433
    reference_title: "Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we demonstrate strong activation of the complement system in 17 classical male FD patients with either missense or nonsense mutations before and after ERT as evidenced by high C3a and C5a serum levels"
    explanation: "Demonstrates that complement system is strongly activated in Fabry disease patients, supporting the role of innate immune activation in pathogenesis"
  - reference: PMID:38932991
    reference_title: "Inflammation in Fabry disease: stages, molecular pathways, and therapeutic implications."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: "Inflammation is emerging as an important aspect of the pathogenesis of Fabry disease. This is thought to be predominantly mediated by the innate immune response, with growing evidence pointing towards the potential involvement of adaptive immune mechanisms"
    explanation: "Confirms inflammation as a key pathogenic mechanism in Fabry disease, with emphasis on innate immune response"
  biological_processes:
  - preferred_term: complement activation
    term:
      id: GO:0006956
      label: complement activation
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  downstream:
  - target: Renal glycosphingolipid storage and podocyte injury
    description: Kidney-associated cytokine production and inflammation contribute to the renal injury branch.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - pro-inflammatory cytokine signaling
    - podocyte stress-response activation
    evidence:
    - reference: PMID:39100494
      reference_title: "Genome-wide expression analysis in a Fabry disease human podocyte cell line."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Functional analysis of differentially expressed genes showed their involvement in various pathways related to oxidative stress, inflammation, fatty acid metabolism, collagen and extracellular matrix homeostasis, kidney injury, apoptosis, autophagy, and cellular stress response.
      explanation: Fabry podocyte transcriptomics supports inflammatory and kidney-injury pathways within the renal branch.
  - target: Vascular endothelial glycosphingolipid storage and dysfunction
    description: Chronic inflammatory signaling propagates vascular and endothelial dysfunction.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - endothelial inflammatory events
    - adhesion-molecule and cytokine signaling
    evidence:
    - reference: PMID:39408658
      reference_title: "In Silico Modeling of Fabry Disease Pathophysiology for the Identification of Early Cellular Damage Biomarker Candidates."
      supports: PARTIAL
      evidence_source: COMPUTATIONAL
      snippet: are the accumulation of sphingolipids and subsequent inflammatory events, mainly at the endothelial level. The outcomes include different nervous system manifestations as well as multiple organ damage.
      explanation: Computational systems-biology evidence supports inflammatory events at the endothelial level as part of Fabry vascular injury.
  - target: Fibrosis and extracellular matrix remodeling
    description: Inflammatory cytokines including TGF-beta promote profibrotic tissue remodeling.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - pro-inflammatory cytokine release
    - TGF-beta signaling
    - profibrotic remodeling
    evidence:
    - reference: PMID:39978321
      reference_title: "The Inflammatory Pathogenetic Pathways of Fabry Nephropathy and Agalopathy: <italic>GLA</italic> Variant Induction of Endoplasmic Reticulum Stress."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: These processes determine the activation of inflammation processes associated with chronic inflammation and tissue fibrosis.
      explanation: The inflammatory-pathways review links chronic inflammatory activation to tissue fibrosis.
- name: Fibrosis and extracellular matrix remodeling
  description: >
    TGF-β-driven profibrotic signaling leads to extracellular matrix deposition in kidney and heart. This fibrotic process
    becomes partially independent of Gb3 substrate levels and contributes to progressive organ dysfunction through epithelial-to-mesenchymal
    transition and myofibroblast activation.
  evidence:
  - reference: PMID:38304433
    reference_title: "Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "we found increased IL-6, IL-10 and TGF-ß1 serum levels in FD patients"
    explanation: "Supports elevated profibrotic cytokine signaling (TGF-β1), but not the full extracellular matrix remodeling cascade described."
  - reference: PMID:33602475
    reference_title: "Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Cardiovascular involvement usually manifests as left ventricular hypertrophy, myocardial fibrosis, heart failure, and arrhythmias"
    explanation: Cardiac review evidence links myocardial fibrosis with the major cardiac manifestations in Fabry disease.
  biological_processes:
  - preferred_term: extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
  - preferred_term: transforming growth factor beta signaling pathway
    term:
      id: GO:0007179
      label: transforming growth factor beta receptor signaling pathway
  genes:
  - preferred_term: TGFB1
    term:
      id: hgnc:11766
      label: TGFB1
  downstream:
  - target: Chronic kidney disease
    description: Renal fibrosis contributes to progressive kidney dysfunction.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - renal sclerosis and fibrosis
    - progressive renal dysfunction
    evidence:
    - reference: PMID:36334424
      reference_title: "Clinical relevance of globotriaosylceramide accumulation in Fabry disease and the effect of agalsidase beta in affected tissues."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Accumulation of GL3 in the kidney, heart, vasculature, neurons, skin, gastrointestinal tract and auditory system correlates to cellular damage and irreversible organ damage, as a result of sclerosis, fibrosis, apoptosis, inflammation, and endothelial dysfunction. Damage leads to renal dysfunction and end-stage renal disease
      explanation: The review links fibrosis and other GL3-associated damage mechanisms to renal dysfunction and end-stage renal disease.
  - target: Left ventricular hypertrophy
    description: Cardiac fibrosis and remodeling accompany hypertrophic Fabry cardiomyopathy.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - myocardial remodeling
    - hypertrophic cardiomyopathy progression
    evidence:
    - reference: PMID:33602475
      reference_title: "Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Cardiovascular involvement usually manifests as left ventricular hypertrophy, myocardial fibrosis, heart failure, and arrhythmias, which limit quality of life and represent the most common causes of death
      explanation: The cardiac review places left ventricular hypertrophy and myocardial fibrosis together in Fabry cardiac involvement.
  - target: Cardiac arrhythmia
    description: Myocardial fibrosis creates an arrhythmogenic substrate.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - myocardial fibrosis
    - arrhythmogenic substrate formation
    evidence:
    - reference: PMID:33602475
      reference_title: "Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Cardiovascular involvement usually manifests as left ventricular hypertrophy, myocardial fibrosis, heart failure, and arrhythmias
      explanation: The cardiac review supports arrhythmias as a downstream manifestation in the myocardial fibrosis/remodeling branch.
phenotypes:
- name: Acroparesthesia
  category: Neurological
  description: >
    Tingling, burning, or painful paresthesias affecting the extremities, particularly hands and feet, often the earliest clinical manifestation.
    Pain crises can be disabling. Pathophysiology involves neuronal sensitization from lyso-Gb3 effects and lysosomal dysfunction.
  frequency: FREQUENT
  evidence:
  - reference: PMID:31939530
    reference_title: "Fabry disease: genetics, pathology, and treatment."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The onset of symptoms occurs during childhood, with acroparesthesia, heat intolerance, and gastrointestinal symptoms, such as nausea, vomiting, abdominal pain, and neuropathic pain"
    explanation: "Establishes acroparesthesia and neuropathic pain as early clinical manifestations in Fabry disease"
  - reference: ORPHA:324
    reference_title: "Fabry disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0031006 | Acroparesthesia | Frequent (79-30%)"
    explanation: Orphanet phenotype data confirms acroparesthesia as a frequent manifestation.
  phenotype_term:
    preferred_term: Acroparesthesia
    term:
      id: HP:0031006
      label: Acroparesthesia

- name: Neuropathic pain
  category: Neurological
  description: >
    Episodic or chronic neuropathic pain including Fabry crises (burning extremity pain often triggered by fever or exertion)
    affecting a majority of patients, beginning in childhood or adolescence.
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:21290706
    reference_title: "Nervous system manifestations of Fabry disease: data from FOS – the Fabry Outcome Survey."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "FOS has confirmed a very high frequency of neuropathic pain (76% males, 64% females), beginning in childhood or adolescence."
    explanation: FOS registry data (688 patients) establish neuropathic pain as a very frequent manifestation across both sexes.
  phenotype_term:
    preferred_term: Neuropathic pain
    term:
      id: HP:0012531
      label: Pain

- name: Hypohidrosis
  category: Autonomic
  description: >
    Reduced or absent sweating resulting from autonomic nerve fiber dysfunction due to glycosphingolipid accumulation.
    Often presents in childhood and contributes to heat intolerance.
  frequency: VERY_FREQUENT
  evidence:
  - reference: ORPHA:324
    reference_title: "Fabry disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000966 | Hypohidrosis | Very frequent (99-80%)"
    explanation: Orphanet phenotype data records hypohidrosis as a very frequent manifestation of Fabry disease.
  phenotype_term:
    preferred_term: Hypohidrosis
    term:
      id: HP:0000966
      label: Hypohidrosis

- name: Heat intolerance
  category: Autonomic
  description: >
    Intolerance to high ambient temperatures resulting from hypohidrosis and autonomic dysfunction. Frequently triggers
    or worsens Fabry pain crises.
  frequency: FREQUENT
  evidence:
  - reference: ORPHA:324
    reference_title: "Fabry disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002046 | Heat intolerance | Frequent (79-30%)"
    explanation: Orphanet phenotype data records heat intolerance as a frequent manifestation of Fabry disease.
  phenotype_term:
    preferred_term: Heat intolerance
    term:
      id: HP:0002046
      label: Heat intolerance

- name: Abdominal pain
  category: Gastrointestinal
  description: >
    Episodic or chronic abdominal pain resulting from gastrointestinal autonomic dysfunction and ischemia from
    glycosphingolipid accumulation in gut vasculature and nerves.
  frequency: VERY_FREQUENT
  evidence:
  - reference: ORPHA:324
    reference_title: "Fabry disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002027 | Abdominal pain | Very frequent (99-80%)"
    explanation: Orphanet phenotype data records abdominal pain as a very frequent manifestation of Fabry disease.
  phenotype_term:
    preferred_term: Abdominal pain
    term:
      id: HP:0002027
      label: Abdominal pain

- name: Nausea and vomiting
  category: Gastrointestinal
  description: >
    Recurrent nausea and vomiting are gastrointestinal manifestations of Fabry disease and accompany the broader
    autonomic and gastrointestinal symptom burden.
  frequency: FREQUENT
  evidence:
  - reference: ORPHA:324
    reference_title: "Fabry disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002017 | Nausea and vomiting | Frequent (79-30%)"
    explanation: Orphanet phenotype data records nausea and vomiting as a frequent manifestation of Fabry disease.
  phenotype_term:
    preferred_term: Nausea and vomiting
    term:
      id: HP:0002017
      label: Nausea and vomiting

- name: Angiokeratomas
  category: Cutaneous
  description: >
    Small, dark red skin lesions that cluster in the lower trunk and genital region. These are pathognomonic cutaneous
    manifestations of Fabry disease resulting from vascular dilatation with epidermal hyperkeratosis.
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:31939530
    reference_title: "Fabry disease: genetics, pathology, and treatment."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Subsequently, symptoms related to progressive impairment appear, such as angiokeratomas, cornea verticillata, left ventricular hypertrophy, myocardial fibrosis, proteinuria, and renal insufficiency"
    explanation: "Identifies angiokeratomas as a characteristic progressive clinical manifestation of Fabry disease"
  - reference: ORPHA:324
    reference_title: "Fabry disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001014 | Angiokeratoma | Very frequent (99-80%)"
    explanation: Orphanet phenotype data confirms angiokeratoma as a very frequent manifestation of Fabry disease.
  phenotype_term:
    preferred_term: Angiokeratoma
    term:
      id: HP:0001014
      label: Angiokeratoma

- name: Proteinuria
  category: Renal
  description: >
    Urinary protein excretion, often the earliest sign of Fabry nephropathy. Progresses from microalbuminuria to overt
    proteinuria. Results from podocyte injury due to Gb3/lyso-Gb3 accumulation, autophagy impairment, and inflammatory signaling.
  frequency: FREQUENT
  evidence:
  - reference: PMID:39100494
    reference_title: "Genome-wide expression analysis in a Fabry disease human podocyte cell line."
    supports: PARTIAL
    evidence_source: IN_VITRO
    snippet: "This study focuses on genome-wide expression analysis in an FD human podocyte model to gain insights into the underlying mechanisms of podocyte dysfunction"
    explanation: "Supports podocyte dysfunction mechanisms, but does not directly report clinical proteinuria frequency."
  - reference: ORPHA:324
    reference_title: "Fabry disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000093 | Proteinuria | Frequent (79-30%)"
    explanation: Orphanet phenotype data confirms proteinuria as a frequent manifestation.
  phenotype_term:
    preferred_term: Proteinuria
    term:
      id: HP:0000093
      label: proteinuria

- name: Chronic kidney disease
  category: Renal
  description: >
    Progressive renal dysfunction leading to end-stage renal disease. Driven by podocyte loss, glomerulosclerosis,
    tubulointerstitial fibrosis, and persistent inflammation.
  frequency: FREQUENT
  evidence:
  - reference: PMID:31939530
    reference_title: "Fabry disease: genetics, pathology, and treatment."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "proteinuria, and renal insufficiency. The latter being the main cause of death in FD."
    explanation: "Identifies progressive renal failure as the primary cause of death in Fabry disease"
  - reference: ORPHA:324
    reference_title: "Fabry disease (Orphanet structured-database record)"
    supports: PARTIAL
    evidence_source: OTHER
    snippet: "HP:0000083 | Renal insufficiency | Very frequent (99-80%)"
    explanation: Orphanet rates the broader term renal insufficiency (HP:0000083) as very frequent, which is consistent with but not a direct match for the more specific chronic kidney disease (HP:0012622).
  phenotype_term:
    preferred_term: Chronic kidney disease
    term:
      id: HP:0012622
      label: Chronic kidney disease

- name: Left ventricular hypertrophy
  category: Cardiac
  description: >
    Concentric hypertrophy of the left ventricle resulting from cardiomyocyte lipid accumulation, oxidative stress,
    inflammation, and fibrosis. Increases arrhythmia risk and may progress to heart failure.
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:33602475
    reference_title: "Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Cardiovascular involvement usually manifests as left ventricular hypertrophy, myocardial fibrosis, heart failure, and arrhythmias, which limit quality of life and represent the most common causes of death"
    explanation: "Confirms that left ventricular hypertrophy is a major cardiac manifestation of Fabry disease"
  - reference: ORPHA:324
    reference_title: "Fabry disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001712 | Left ventricular hypertrophy | Occasional (29-5%)"
    explanation: Orphanet phenotype data records left ventricular hypertrophy as an occasional manifestation.
  - reference: PMID:38749654
    reference_title: "Fabry disease: development and progression of left ventricular hypertrophy despite long-term enzyme replacement therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "LVH at treatment initiation was a strong predictor of LVMI progression and adverse events on ERT."
    explanation: Long-term Swiss cohort evidence links baseline LVH with subsequent left-ventricular-mass progression and adverse Fabry events during ERT.
  phenotype_term:
    preferred_term: Left ventricular hypertrophy
    term:
      id: HP:0001712
      label: Left ventricular hypertrophy

- name: Cardiac arrhythmia
  category: Cardiac
  description: >
    Atrial fibrillation and ventricular arrhythmias result from cardiomyocyte hypertrophy, fibrosis, and inflammatory
    remodeling that create arrhythmogenic substrate.
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:33602475
    reference_title: "Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Cardiovascular involvement usually manifests as left ventricular hypertrophy, myocardial fibrosis, heart failure, and arrhythmias"
    explanation: Cardiac review evidence directly identifies arrhythmias as a Fabry cardiac manifestation.
  - reference: ORPHA:324
    reference_title: "Fabry disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0011675 | Arrhythmia | Occasional (29-5%)"
    explanation: Orphanet phenotype data confirms arrhythmia as an occasional manifestation.
  phenotype_term:
    preferred_term: Arrhythmia
    term:
      id: HP:0011675
      label: Arrhythmia

- name: Early atrial ECG changes
  category: Cardiac
  description: >
    Shortened P-wave duration and PQ interval can appear in Fabry disease before overt cardiomyopathy, indicating early
    atrial conduction remodeling.
  evidence:
  - reference: PMID:40557493
    reference_title: "Early Atrial Remodeling Drives Arrhythmia in Fabry Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ECG analysis demonstrated P-wave duration and PQ interval shortening in FD adults before the onset of cardiomyopathy."
    explanation: Human ECG analysis in Fabry adults supports early atrial electrical changes before clinical cardiomyopathy.
  phenotype_term:
    preferred_term: Early atrial ECG changes
    term:
      id: HP:0003115
      label: Abnormal EKG

- name: Stroke
  category: Neurological
  description: >
    Increased risk of ischemic stroke and transient ischemic attacks due to cerebrovascular dysfunction from endothelial
    dysfunction, microvascular remodeling, and pro-thrombotic state.
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:32723516
    reference_title: "When and How to Diagnose Fabry Disease in Clinical Practice."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Symptoms and organ involvements of classical Fabry disease are acral pain crisis, cornea verticillata, hypertrophic cardiomyopathy, stroke and chronic kidney disease with proteinuria."
    explanation: Clinical-practice review evidence lists stroke among classical Fabry disease organ involvements.
  - reference: ORPHA:324
    reference_title: "Fabry disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001297 | Stroke | Occasional (29-5%)"
    explanation: Orphanet phenotype data confirms stroke as an occasional manifestation.
  phenotype_term:
    preferred_term: Stroke
    term:
      id: HP:0001297
      label: stroke

- name: Transient ischemic attack
  category: Neurological
  description: >
    Transient episodes of focal neurological deficit due to cerebrovascular dysfunction. Often precedes
    completed stroke and reflects the underlying vasculopathy of Fabry disease.
  frequency: OCCASIONAL
  evidence:
  - reference: ORPHA:324
    reference_title: "Fabry disease (Orphanet structured-database record)"
    supports: PARTIAL
    evidence_source: OTHER
    snippet: "HP:0002326 | Transient ischemic attack | Very frequent (99-80%)"
    explanation: Orphanet supports TIA as a Fabry manifestation but gives a higher frequency band than registry data.
  - reference: PMID:21290706
    reference_title: "Nervous system manifestations of Fabry disease: data from FOS – the Fabry Outcome Survey."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thus, 13.2% (15.1% males, 11.5% females) have suffered an ischaemic stroke or transient ischaemic attack, usually at an early age."
    explanation: FOS registry data place combined stroke/TIA events in the 5-29% band, supporting the occasional frequency assignment.
  phenotype_term:
    preferred_term: Transient ischemic attack
    term:
      id: HP:0002326
      label: Transient ischemic attack

- name: Hearing impairment
  category: Neurological
  description: >
    Progressive sensorineural hearing loss, often high-frequency, resulting from cochlear vascular
    dysfunction and neuronal damage from glycosphingolipid accumulation.
  frequency: VERY_FREQUENT
  evidence:
  - reference: ORPHA:324
    reference_title: "Fabry disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000365 | Hearing impairment | Very frequent (99-80%)"
    explanation: Orphanet phenotype data records hearing impairment as a very frequent manifestation.
  phenotype_term:
    preferred_term: Hearing impairment
    term:
      id: HP:0000365
      label: Hearing impairment

- name: Tinnitus
  category: Auditory
  description: >
    Ringing or buzzing perception in the ears that accompanies Fabry cochleo-vestibular involvement and can occur with
    hearing impairment.
  frequency: FREQUENT
  evidence:
  - reference: ORPHA:324
    reference_title: "Fabry disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000360 | Tinnitus | Frequent (79-30%)"
    explanation: Orphanet phenotype data records tinnitus as a frequent manifestation of Fabry disease.
  phenotype_term:
    preferred_term: Tinnitus
    term:
      id: HP:0000360
      label: Tinnitus

- name: Cornea verticillata
  category: Ophthalmological
  description: >
    Whorl-like corneal deposits (cornea verticillata) resulting from glycosphingolipid accumulation
    in corneal epithelium. Pathognomonic for Fabry disease and detectable on slit-lamp examination.
  frequency: FREQUENT
  evidence:
  - reference: ORPHA:324
    reference_title: "Fabry disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0500008 | Cornea verticillata | Frequent (79-30%)"
    explanation: Orphanet phenotype data records cornea verticillata as a frequent manifestation.
  phenotype_term:
    preferred_term: Cornea verticillata
    term:
      id: HP:0500008
      label: Cornea verticillata

- name: Corneal opacity
  category: Ophthalmological
  description: >
    Corneal opacification from glycosphingolipid deposition in the cornea. Fabry corneal
    opacities are usually detected on slit-lamp examination and generally do not impair vision.
  frequency: VERY_FREQUENT
  evidence:
  - reference: ORPHA:324
    reference_title: "Fabry disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0007957 | Corneal opacity | Very frequent (99-80%)"
    explanation: Orphanet phenotype data records corneal opacity as a very frequent manifestation.
  phenotype_term:
    preferred_term: Corneal opacity
    term:
      id: HP:0007957
      label: Corneal opacity

- name: Cataract
  category: Ophthalmological
  description: >
    Lens opacity/cataract is a frequent ocular manifestation of Fabry disease and is anatomically distinct from corneal opacity.
  frequency: FREQUENT
  evidence:
  - reference: ORPHA:324
    reference_title: "Fabry disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000518 | Cataract | Frequent (79-30%)"
    explanation: Orphanet phenotype data records cataract as a frequent manifestation of Fabry disease.
  - reference: PMID:20301469
    reference_title: "Fabry Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "characteristic corneal and lenticular opacities"
    explanation: GeneReviews describes lenticular opacities as characteristic ocular features of classic Fabry disease.
  phenotype_term:
    preferred_term: Cataract
    term:
      id: HP:0000518
      label: Cataract

biochemical:
- name: Lyso-Gb3
  presence: Increased
  context: Diagnostic and therapeutic biomarker closely associated with disease severity and organ damage
  readouts:
  - target: Lysosomal Gb3 and lyso-Gb3 accumulation
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: MONITORING
    interpretation: >-
      Increased lyso-Gb3 reflects the upstream sphingolipid substrate
      accumulation caused by alpha-galactosidase A deficiency.
  biomarker_term:
    preferred_term: globotriaosylsphingosine measurement
    term:
      id: NCIT:C209601
      label: Globotriaosylsphingosine Measurement
  synonyms:
  - globotriaosylsphingosine
  evidence:
  - reference: PMID:32183665
    reference_title: "Treatment of Anderson-Fabry Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Measurement of the biomarkers Gb3 and Lyso Gb3 in biological specimens may facilitate diagnosis."
    explanation: Treatment review evidence directly supports Lyso-Gb3 as a Fabry biomarker.
  - reference: PMID:20716442
    reference_title: "How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Increased urinary excretion of lyso-Gb(3) of Fabry patients correlated
      well with a number of indicators of disease severity.
    explanation: >-
      This Fabry patient study supports lyso-Gb3 as a disease-associated
      biomarker correlated with severity indicators.
  - reference: PMID:37207471
    reference_title: "An expert consensus on the recommendations for the use of biomarkers in Fabry disease."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: "Disease-specific biomarkers are useful in the diagnosis of Fabry disease; non-disease-specific biomarkers may be useful to assess organ damage"
    explanation: "Supports biomarker use in Fabry disease broadly, but does not specifically name lyso-Gb3 in the quoted text."
- name: Renal Globotriaosylceramide Inclusions
  presence: Increased
  context: >-
    Renal GL-3 accumulation in podocytes and other kidney cells; can be assessed
    in biopsy as a tissue biomarker of Fabry disease and treatment response.
  readouts:
  - target: Renal glycosphingolipid storage and podocyte injury
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: PHARMACODYNAMIC
    regulatory_endpoint_refs:
    - FDA-SE-adult-noncancer-024
    - FDA-SE-adult-noncancer-025
    - FDA-SE-pediatric-noncancer-019
    interpretation: >-
      Renal GL-3 inclusions are a tissue-level readout of the kidney/podocyte
      storage branch and can decrease when enzyme replacement clears GL-3.
  biomarker_term:
    preferred_term: globotriaosylceramide measurement
    term:
      id: NCIT:C209593
      label: Globotriaosylceramide Measurement
  synonyms:
  - renal GL-3
  - kidney globotriaosylceramide
  evidence:
  - reference: PMID:27129690
    reference_title: "Significant improvement in Fabry disease podocytopathy after 3 years of treatment with agalsidase beta."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Despite normal renal function and urinalysis, renal biopsy showed abnormal
      structure, with marked accumulation of GL-3 in podocytes, partial
      effacement of foot processes and irregularly reduced expression of nephrin
      in the slit diaphragm.
    explanation: >-
      This biopsy-confirmed Fabry case supports renal GL-3 accumulation as a
      tissue biochemical marker even before routine renal labs become abnormal.
  - reference: PMID:36334424
    reference_title: "Clinical relevance of globotriaosylceramide accumulation in Fabry disease and the effect of agalsidase beta in affected tissues."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Treatment with agalsidase beta is effective in substantially clearing GL3
      in a range of cells from the tissues affected by FD.
    explanation: >-
      This review supports tissue GL-3 clearance as a treatment-responsive
      biochemical readout in Fabry disease.

genetic:
- name: GLA gene mutations
  gene_term:
    preferred_term: GLA
    term:
      id: hgnc:4296
      label: GLA
  presence: Pathogenic
  association: X-linked recessive
  notes: >
    Loss-of-function mutations in GLA cause deficiency of α-galactosidase A. Disease shows X-linked inheritance with
    hemizygous males severely affected and heterozygous females showing variable phenotypes due to X-inactivation.
    Genetic testing is the gold standard for diagnosis and can identify a wide spectrum of variants including point mutations,
    insertions, deletions, and deep intronic variants. Long-read sequencing approaches enable comprehensive variant detection.
  evidence:
  - reference: PMID:39100494
    reference_title: "Genome-wide expression analysis in a Fabry disease human podocyte cell line."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Fabry disease (FD) is an X-linked lysosomal disease caused by an enzyme deficiency of alpha-galactosidase A (α-gal A)"
    explanation: "Confirms that Fabry disease is X-linked and caused by deficiency of alpha-galactosidase A enzyme"
  - reference: PMID:39609713
    reference_title: "Long-read sequencing enables comprehensive molecular genetic diagnosis of Fabry disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genetic testing is the gold standard for precise diagnosis of FD, however conventional genetic testing could miss deep intronic variants and large deletions or duplications"
    explanation: "Establishes genetic testing as diagnostic gold standard and highlights need for comprehensive sequencing approaches to detect all variant types"
  - reference: ORPHA:324
    reference_title: "Fabry disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "GLA | galactosidase alpha | hgnc:4296 | Disease-causing germline mutation(s) in"
    explanation: Orphanet gene-disease association confirms GLA as the causative gene for Fabry disease.
  inheritance:
  - name: X-linked recessive
    description: Males are hemizygous and severely affected; females are heterozygous carriers with variable presentation. In males, diagnosis is based on enzyme activity testing showing very low or absent α-galactosidase A activity in classical forms (near zero) or reduced activity (under 30%) in late-onset forms.
    evidence:
    - reference: PMID:31939530
      reference_title: "Fabry disease: genetics, pathology, and treatment."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Fabry disease (FD) is a recessive monogenic inheritance disease linked to chromosome X, secondary to mutations in the GLA gene"
      explanation: "Confirms X-linked recessive inheritance pattern of Fabry disease"
    - reference: PMID:32723516
      reference_title: "When and How to Diagnose Fabry Disease in Clinical Practice."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "In male, diagnosis is made with alpha-galactosidase A enzyme activity dosage in leukocyte, that is very low or null in classical forms and under 30 percent in late-onset forms"
      explanation: "Describes enzyme activity testing thresholds for diagnosis in males based on disease form severity"

- name: GLA
  gene_term:
    preferred_term: GLA
    term:
      id: hgnc:4296
      label: GLA
  association: Pathogenic Variants
  evidence:
  - reference: CGGV:assertion_eb4bb6f4-89de-4586-af6b-3f218b8cb4dc-2019-01-23T170000.000Z
    reference_title: "GLA / Fabry disease (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "GLA | HGNC:4296 | Fabry disease | MONDO:0010526 | XL | Definitive"
    explanation: ClinGen classifies the GLA-Fabry disease gene-disease relationship as definitive with X-linked inheritance.
treatments:
- name: Enzyme replacement therapy
  description: >
    Recombinant α-galactosidase A (agalsidase alfa/beta and pegunigalsidase alfa) restores enzyme activity and reduces Gb3
    accumulation. Early initiation improves outcomes, but renal injury and cardiac hypertrophy can still progress despite
    long-term therapy.
  evidence:
  - reference: PMID:37014703
    reference_title: "Accumulation of α-synuclein mediates podocyte injury in Fabry nephropathy."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "long-term use of ERT reduced Gb3 accumulation in podocytes but did not reverse podocyte injury"
    explanation: "Shows that ERT reduces substrate accumulation but cannot fully reverse organ damage in Fabry nephropathy"
  - reference: PMID:38749654
    reference_title: "Fabry disease: development and progression of left ventricular hypertrophy despite long-term enzyme replacement therapy."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Over a median follow-up of >10 years under ERT, 36% of the patients still had LVMI cardiac progression, and 32%, predominantly older men, experienced major AFD-related events."
    explanation: Long-term cohort evidence supports residual cardiac progression despite ERT, reinforcing that substrate-directed therapy does not fully prevent downstream organ damage.
  treatment_term:
    preferred_term: enzyme replacement therapy
    term:
      id: MAXO:0000933
      label: enzyme replacement or supplementation therapy
  target_phenotypes:
  - preferred_term: Proteinuria
    term:
      id: HP:0000093
      label: proteinuria
  - preferred_term: Chronic kidney disease
    term:
      id: HP:0012622
      label: Chronic kidney disease
  target_mechanisms:
  - target: Lysosomal Gb3 and lyso-Gb3 accumulation
    treatment_effect: INHIBITS
    description: Enzyme replacement reduces intracellular Gb3 accumulation caused by deficient alpha-galactosidase A.
    evidence:
    - reference: PMID:37014703
      reference_title: "Accumulation of α-synuclein mediates podocyte injury in Fabry nephropathy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "long-term use of ERT reduced Gb3 accumulation in podocytes"
      explanation: Serial human kidney biopsy evidence supports reduced podocyte Gb3 accumulation with ERT.

- name: Pharmacological chaperone therapy
  description: >
    Migalastat stabilizes GLA mutant variants and improves lysosomal trafficking. Useful for approximately 35-50% of patients
    with amenable mutations.
  evidence:
  - reference: PMID:40310476
    reference_title: "Progress and Challenges in the Treatment of Fabry Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "if a responding ('amenable') α-galactosidase A mutation is present, oral pharmacological chaperone therapy (migalastat 123 mg, every other day)"
    explanation: "Confirms migalastat is an approved oral chaperone therapy for amenable GLA mutations"
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: migalastat
      term:
        id: CHEBI:135923
        label: migalastat
  target_mechanisms:
  - target: Decreased alpha-galactosidase A activity
    treatment_effect: RESTORES
    description: Migalastat stabilizes amenable alpha-galactosidase A variants to improve lysosomal enzyme function.
    evidence:
    - reference: PMID:40310476
      reference_title: "Progress and Challenges in the Treatment of Fabry Disease."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "if a responding ('amenable') α-galactosidase A mutation is present, oral pharmacological chaperone therapy (migalastat 123 mg, every other day)"
      explanation: Treatment review evidence supports migalastat therapy for amenable alpha-galactosidase A mutations.

- name: Investigational substrate reduction therapy
  description: >
    Glucosylceramide synthase inhibition is an investigational substrate-reduction strategy for Fabry disease that aims to
    reduce glycosphingolipid substrate supply. In Fabry iPSC-derived cardiomyocytes, substrate reduction therapy prevented
    accumulation and cleared lysosomal GL-3, linking the cardiac non-animal model to a candidate therapeutic mechanism.
  evidence:
  - reference: PMID:24850378
    reference_title: "Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease."
    supports: PARTIAL
    evidence_source: IN_VITRO
    snippet: "Using this human in vitro model, we demonstrated that substrate reduction therapy via glucosylceramide synthase inhibition was able to prevent accumulation and to clear lysosomal GL-3 in cardiomyocytes."
    explanation: Human iPSC-derived Fabry cardiomyocyte evidence supports substrate reduction as an investigational mechanism for clearing cardiac GL-3, but does not establish clinical efficacy.
  treatment_term:
    preferred_term: substrate reduction therapy
    term:
      id: MAXO:0020025
      label: substrate reduction therapy
  target_mechanisms:
  - target: Cardiac glycosphingolipid storage and myocardial remodeling
    treatment_effect: INHIBITS
    description: Glucosylceramide synthase inhibition reduces substrate supply and cleared lysosomal GL-3 in Fabry iPSC-derived cardiomyocytes.
    evidence:
    - reference: PMID:24850378
      reference_title: "Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Using this human in vitro model, we demonstrated that substrate reduction therapy via glucosylceramide synthase inhibition was able to prevent accumulation and to clear lysosomal GL-3 in cardiomyocytes."
      explanation: The iPSC-cardiomyocyte model directly supports inhibition of the cardiac glycosphingolipid storage mechanism by substrate reduction therapy.

- name: Gene therapy
  description: >
    AAV and lentiviral-based therapies deliver functional GLA gene for sustained enzyme expression. Shows promise for achieving
    durable Gb3 clearance and reduced need for repeated infusions.
  evidence:
  - reference: PMID:40310476
    reference_title: "Progress and Challenges in the Treatment of Fabry Disease."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: "Future therapeutic options may include substrate reduction therapy, gene therapy, messenger RNA therapy, and/or vesicle-packaged enzyme replacement therapy"
    explanation: "Supports gene therapy as a future option, but not established clinical efficacy outcomes."
  treatment_term:
    preferred_term: gene therapy
    term:
      id: MAXO:0001001
      label: gene therapy
  target_mechanisms:
  - target: Decreased alpha-galactosidase A activity
    treatment_effect: RESTORES
    description: Gene therapy aims to restore functional GLA expression upstream of Gb3 accumulation.
    evidence:
    - reference: PMID:40310476
      reference_title: "Progress and Challenges in the Treatment of Fabry Disease."
      supports: PARTIAL
      evidence_source: OTHER
      snippet: "Future therapeutic options may include substrate reduction therapy, gene therapy, messenger RNA therapy, and/or vesicle-packaged enzyme replacement therapy"
      explanation: Treatment review evidence supports gene therapy as an emerging option aimed at the upstream enzyme defect.

- name: Supportive care
  description: >
    Management of complications including pain control, renal protection with ACE inhibitors, cardiac monitoring, and stroke prevention.
    Pain management and cardiovascular monitoring are essential for quality of life.
  evidence:
  - reference: PMID:35652398
    reference_title: "Fabry Disease: Current and Novel Therapeutic Strategies. A Narrative Review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "A multidisciplinary symptomatic treatment is recommended for FD patients, personalized according to disease manifestations and their severity."
    explanation: Narrative review evidence supports personalized multidisciplinary symptomatic treatment for Fabry disease manifestations.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  target_phenotypes:
  - preferred_term: Pain
    term:
      id: HP:0012531
      label: Pain
  - preferred_term: Arrhythmia
    term:
      id: HP:0011675
      label: Arrhythmia

experimental_models:
- name: Fabry patient iPSC-derived cardiomyocyte GL-3 clearance model
  description: >
    Human Fabry patient iPSC-derived cardiomyocyte model that recapitulates lysosomal GL-3 accumulation in cardiac
    cells and supports testing tissue-specific substrate-reduction responses outside the renal biopsy compartment.
  experimental_model_type: IPSC_DERIVED_MODEL
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  tissue_term:
    preferred_term: heart
    term:
      id: UBERON:0000948
      label: heart
  cell_types:
  - preferred_term: cardiomyocyte
    term:
      id: CL:0000746
      label: cardiac muscle cell
  conditions:
  - Fabry disease
  - substrate reduction therapy
  cell_source: Fabry patient-derived induced pluripotent stem cells
  culture_system: iPSC-derived cardiomyocyte culture
  publication: PMID:24850378
  modeled_mechanisms:
  - target: Cardiac glycosphingolipid storage and myocardial remodeling
    description: The model recapitulates cardiac-cell GL-3 accumulation and can assay GL-3 clearance after substrate-reduction therapy.
    evidence:
    - reference: PMID:24850378
      reference_title: "Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "We generated induced pluripotent stem cells (iPSC) from Fabry patients and differentiated them into cardiomyocytes. In these cells, GL-3 accumulates in the lysosomes over time, resulting in phenotypic changes similar to those found in cardiac tissue from Fabry patients."
      explanation: The paper directly supports patient iPSC-derived cardiomyocytes as a cardiac Fabry storage model.
  findings:
  - statement: Substrate-reduction therapy cleared lysosomal GL-3 in Fabry iPSC-derived cardiomyocytes.
    supporting_text: "Using this human in vitro model, we demonstrated that substrate reduction therapy via glucosylceramide synthase inhibition was able to prevent accumulation and to clear lysosomal GL-3 in cardiomyocytes."
  evidence:
  - reference: PMID:24850378
    reference_title: "Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "This new in vitro model recapitulates essential features of cardiomyocytes from patients with Fabry disease and therefore provides a useful and relevant tool for further investigations of new therapy."
    explanation: The study supports this iPSC-cardiomyocyte system as a disease-relevant non-animal model for testing Fabry cardiac therapeutic response.

- name: Fabry patient iPSC-derived cardiomyocyte GLA modRNA rescue model
  description: >
    Patient-derived iPSC-cardiomyocyte model used to test lipid-nanoparticle delivery of GLA-encoding modified mRNA,
    measuring GB3 reduction and lysosomal-protein rescue in cardiac cells.
  experimental_model_type: IPSC_DERIVED_MODEL
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  tissue_term:
    preferred_term: heart
    term:
      id: UBERON:0000948
      label: heart
  cell_types:
  - preferred_term: cardiomyocyte
    term:
      id: CL:0000746
      label: cardiac muscle cell
  conditions:
  - Fabry disease
  - GLA modified mRNA treatment
  cell_source: iPSCs derived from Fabry-affected individuals
  culture_system: iPSC-derived cardiomyocyte culture with lipid nanoparticle-modRNA treatment
  publication: PMID:37607539
  modeled_mechanisms:
  - target: Decreased alpha-galactosidase A activity
    description: The model assays restoration of alpha-galactosidase A activity after GLA modRNA treatment.
    evidence:
    - reference: PMID:37607539
      reference_title: "GLA-modified RNA treatment lowers GB3 levels in iPSC-derived cardiomyocytes from Fabry-affected individuals."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Importantly, a significant reduction of GB3 levels was observed in GLA modRNA-treated cardiomyocytes, demonstrating that α-GAL enzymatic activity was restored."
      explanation: GB3 reduction after GLA modRNA treatment supports restoration of the upstream enzyme activity in cardiomyocytes.
  - target: Cardiac glycosphingolipid storage and myocardial remodeling
    description: Fabry iPSC-cardiomyocytes accumulate GB3, providing a cardiac substrate readout for the disease branch.
    evidence:
    - reference: PMID:37607539
      reference_title: "GLA-modified RNA treatment lowers GB3 levels in iPSC-derived cardiomyocytes from Fabry-affected individuals."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Consistent with the clinical phenotype, cardiomyocytes from iPSCs derived from Fabry-affected individuals showed accumulation of the glycosphingolipid Globotriaosylceramide (GB3), which is an α-galactosidase substrate."
      explanation: The model directly supports cardiac-cell GB3 accumulation in Fabry-derived iPSC-cardiomyocytes.
  findings:
  - statement: GLA modRNA treatment reduced GB3 in Fabry iPSC-derived cardiomyocytes.
    supporting_text: "Importantly, a significant reduction of GB3 levels was observed in GLA modRNA-treated cardiomyocytes, demonstrating that α-GAL enzymatic activity was restored."
  evidence:
  - reference: PMID:37607539
    reference_title: "GLA-modified RNA treatment lowers GB3 levels in iPSC-derived cardiomyocytes from Fabry-affected individuals."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Together, our results validate the utility of iPSC-derived cardiomyocytes from affected individuals as a model to study disease processes in Fabry disease and the therapeutic potential of GLA modRNA treatment to reduce GB3 accumulation in the heart."
    explanation: The paper explicitly validates Fabry iPSC-derived cardiomyocytes as a cardiac non-animal model and treatment-response system.

- name: Female Fabry iPSC-cardiomyocyte high-content drug-screening model
  description: >
    Female Fabry patient iPSC-cardiomyocyte model exploiting X-chromosome inactivation to produce GLA-deficient disease
    clones and normal-activity isogenic controls, with automated Gb3 staining for high-content drug screening.
  experimental_model_type: IPSC_DERIVED_MODEL
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  tissue_term:
    preferred_term: heart
    term:
      id: UBERON:0000948
      label: heart
  cell_types:
  - preferred_term: cardiomyocyte
    term:
      id: CL:0000746
      label: cardiac muscle cell
  conditions:
  - Fabry cardiomyopathy
  - high-content drug screening
  cell_source: iPSCs from a female Fabry patient
  culture_system: iPSC-derived cardiomyocyte culture with automated Gb3 imaging
  publication: PMID:30048710
  modeled_mechanisms:
  - target: Cardiac glycosphingolipid storage and myocardial remodeling
    description: The model measures Gb3 accumulation and molecular cardiomyopathic change in Fabry iPSC-derived cardiomyocytes.
    evidence:
    - reference: PMID:30048710
      reference_title: "Generation of Fabry cardiomyopathy model for drug screening using induced pluripotent stem cell-derived cardiomyocytes from a female Fabry patient."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Gb3 accumulation was observed in iPSC-derived cardiomyocytes (iPS-CMs) from GLA activity-deficient iPSCs by mass-spectrometry and immunofluorescent staining."
      explanation: The study directly supports Gb3 accumulation in GLA-deficient Fabry iPSC-derived cardiomyocytes.
  findings:
  - statement: Patient iPSC clones provided disease and isogenic-control cardiomyocyte models.
    supporting_text: "Each iPSC clone from the female patient showed either deficient or normal GLA activity, which could be used as a Fabry disease model or its isogenic control, respectively."
  - statement: The system supports automated high-content Gb3 drug screening.
    supporting_text: "We also established an algorithm for selecting proper Gb3 staining that could be used for high-content analysis-based drug screening."
  evidence:
  - reference: PMID:30048710
    reference_title: "Generation of Fabry cardiomyopathy model for drug screening using induced pluripotent stem cell-derived cardiomyocytes from a female Fabry patient."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We generated a Fabry cardiomyopathy model and a drug screening system by using iPS-CMs from a female Fabry patient."
    explanation: The paper supports this model as a patient-derived iPSC-cardiomyocyte drug-screening system for Fabry cardiomyopathy.

- name: GLA-null hESC-derived cardiomyocyte autophagy and ROS model
  description: >
    CRISPR/Cas9 GLA-knockout human embryonic stem cell-derived cardiomyocyte model used to study cardiomyocyte
    hypertrophy, vesicle trafficking, autophagic flux, mitochondrial ROS production, and cell death.
  experimental_model_type: CELL_LINE
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  tissue_term:
    preferred_term: heart
    term:
      id: UBERON:0000948
      label: heart
  cell_types:
  - preferred_term: cardiomyocyte
    term:
      id: CL:0000746
      label: cardiac muscle cell
  conditions:
  - GLA knockout
  - Fabry-associated hypertrophic cardiomyopathy
  cell_source: CRISPR/Cas9-edited human embryonic stem cells
  culture_system: hESC-derived cardiomyocyte culture with proteomics and cellular stress assays
  publication: PMID:30965672
  modeled_mechanisms:
  - target: Cardiomyocyte autophagy impairment and oxidative stress
    description: The model assays GLA-null cardiomyocyte autophagic flux, ROS production, apoptosis, necrosis, and hypertrophic changes.
    evidence:
    - reference: PMID:30965672
      reference_title: "Generation of GLA-Knockout Human Embryonic Stem Cell Lines to Model Autophagic Dysfunction and Exosome Secretion in Fabry Disease-Associated Hypertrophic Cardiomyopathy."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "GLA-null CMs were characterized by autophagy impairment and active mitochondrial ROS production that caused apoptosis and necrosis."
      explanation: The GLA-null cardiomyocyte model directly supports the cardiac autophagy and oxidative-stress mechanism.
  - target: Cardiac glycosphingolipid storage and myocardial remodeling
    description: GLA-null cardiomyocytes accumulate Gb3 and show hypertrophic cellular features.
    evidence:
    - reference: PMID:30965672
      reference_title: "Generation of GLA-Knockout Human Embryonic Stem Cell Lines to Model Autophagic Dysfunction and Exosome Secretion in Fabry Disease-Associated Hypertrophic Cardiomyopathy."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "cardiomyocytes differentiated from these hESCs (GLA-null CMs) were characterized by the accumulation of Gb3 and significant increases of cell surface area, the landmarks of FD-associated cardiomyopathy."
      explanation: The model captures cardiac Gb3 accumulation and hypertrophic changes downstream of GLA loss.
  findings:
  - statement: GLA-null stem-cell-derived cardiomyocytes model Fabry hypertrophic cardiomyopathy.
    supporting_text: "we established a FD model which can be used as a promising tool to study human hypertrophic cardiomyopathy in a physiologically and pathologically relevant manner"
  evidence:
  - reference: PMID:30965672
    reference_title: "Generation of GLA-Knockout Human Embryonic Stem Cell Lines to Model Autophagic Dysfunction and Exosome Secretion in Fabry Disease-Associated Hypertrophic Cardiomyopathy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "To summarize, in the present study we show that CRISPR/Cas9-mediated GLA knockout of hESC-derived CMs can serve as an in vitro FD model for studying hypertrophic cardiomyopathy."
    explanation: The paper supports this non-animal cardiomyocyte system as a mechanistic model for Fabry cardiac disease.

- name: GLA p.N215S iPSC-derived atrial cardiomyocyte arrhythmia model
  description: >
    Genome-edited iPSC-derived atrial cardiomyocyte model carrying the GLA p.N215S variant, used to measure Gb3
    accumulation, atrial action-potential changes, calcium handling, contraction, and arrhythmia-linked cellular changes.
  experimental_model_type: IPSC_DERIVED_MODEL
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  tissue_term:
    preferred_term: cardiac atrium
    term:
      id: UBERON:0002081
      label: cardiac atrium
  cell_types:
  - preferred_term: atrial cardiomyocyte
    term:
      id: CL:0002129
      label: regular atrial cardiac myocyte
  conditions:
  - GLA p.N215S variant
  - atrial arrhythmia vulnerability
  cell_source: CRISPR/Cas9 genome-edited induced pluripotent stem cells
  culture_system: iPSC-derived atrial cardiomyocyte culture with electrophysiology, calcium handling, and contraction assays
  publication: PMID:40557493
  modeled_mechanisms:
  - target: Atrial cardiomyocyte electrophysiological remodeling
    description: The model assays action-potential, calcium-handling, and contraction changes in Fabry atrial cardiomyocytes.
    evidence:
    - reference: PMID:40557493
      reference_title: "Early Atrial Remodeling Drives Arrhythmia in Fabry Disease."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Atrial GLA p.N215S iPSC-CMs demonstrated a more positive diastolic membrane potential, faster action potential upstroke velocity, greater incidence of delayed afterdepolarizations, greater contraction force, and alterations in calcium handling compared with wild-type iPSC-CMs."
      explanation: The atrial iPSC-cardiomyocyte model directly supports electrophysiological remodeling in the cardiac branch.
  - target: Cardiac glycosphingolipid storage and myocardial remodeling
    description: The atrial model validates upstream Fabry enzyme deficiency and substrate accumulation in cardiac cells.
    evidence:
    - reference: PMID:40557493
      reference_title: "Early Atrial Remodeling Drives Arrhythmia in Fabry Disease."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "GLA p.N215S iPSC-CMs were deficient in α-Gal A and exhibited globotriaosylceramide accumulation."
      explanation: The model recapitulates the upstream cardiac storage state before measuring atrial electrophysiological effects.
  evidence:
  - reference: PMID:40557493
    reference_title: "Early Atrial Remodeling Drives Arrhythmia in Fabry Disease."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Cellular contractile and electrophysiological function were examined in a novel atrial cellular FD model developed and imputed into in silico atrial models to provide insight into mechanisms of arrhythmia."
    explanation: The paper supports this atrial iPSC-cardiomyocyte system as a cellular non-animal model for Fabry arrhythmia mechanisms.

computational_models:
- name: Bi-atrial in silico Fabry arrhythmia model
  description: >
    Physiological bi-atrial simulation model parameterized with GLA p.N215S iPSC-derived atrial cardiomyocyte changes to
    evaluate P-wave morphology and atrial fibrillation vulnerability in early Fabry cardiac disease.
  model_type: PHYSIOLOGICAL
  model_software: In silico bi-atrial electrophysiology modeling
  publication: PMID:40557493
  variables:
  - name: P-wave morphology
    description: Simulated ECG morphology output linked to early Fabry cardiomyopathy.
  - name: Atrial fibrillation vulnerability
    description: Simulated arrhythmia susceptibility output from atrial cellular remodeling.
  modeled_mechanisms:
  - target: Atrial cardiomyocyte electrophysiological remodeling
    description: The model translates cellular action-potential and calcium-handling changes into atrial ECG and arrhythmia outputs.
    evidence:
    - reference: PMID:40557493
      reference_title: "Early Atrial Remodeling Drives Arrhythmia in Fabry Disease."
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: "Bi-atrial in silico models were developed with cellular changes as in GLA p.N215S iPSC-CMs."
      explanation: The computational model was parameterized from Fabry atrial iPSC-cardiomyocyte cellular changes.
  findings:
  - statement: Simulated atrial-cell changes reproduced early Fabry P-wave morphology changes and increased atrial fibrillation vulnerability.
    supporting_text: "Simulations with these changes in the in silico models resulted in similar P-wave morphology changes to those seen in early FD cardiomyopathy and increased atrial fibrillation vulnerability."
  evidence:
  - reference: PMID:40557493
    reference_title: "Early Atrial Remodeling Drives Arrhythmia in Fabry Disease."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "Simulations with these changes in the in silico models resulted in similar P-wave morphology changes to those seen in early FD cardiomyopathy and increased atrial fibrillation vulnerability."
    explanation: The paper supports a computational model linking cellular Fabry atrial remodeling to early ECG and arrhythmia-risk outputs.

references:
- reference: PMID:20301469
  title: Fabry Disease.
  tags:
  - GeneReviews
  findings: []
notes: >
  Early diagnosis and treatment initiation are critical for improving outcomes. Progressive organ damage despite enzyme replacement
  therapy suggests ongoing pathogenic mechanisms beyond lipid substrate, including persistent inflammation, oxidative stress, fibrosis,
  and α-synuclein-mediated lysosomal toxicity. Multi-targeted therapeutic approaches may be needed to address these diverse mechanisms.
differential_diagnoses:
- name: Hypertrophic Cardiomyopathy (HCM)
  disease_term:
    preferred_term: Hypertrophic Cardiomyopathy
    term:
      id: MONDO:0005045
      label: hypertrophic cardiomyopathy
  description: >
    HCM is the most common cardiac differential diagnosis for Fabry disease, as both conditions present with left ventricular hypertrophy,
    cardiomyocyte dysfunction, and arrhythmias. Both can cause sudden cardiac death and progressive heart failure. The cardiac phenotype
    of Fabry disease (apical involvement, LGE pattern, reduced ejection fraction) overlaps significantly with HCM. Systemic manifestations
    including neuropathic pain, renal disease, and skin lesions are distinguishing features of Fabry disease absent in HCM.
  distinguishing_features:
  - Prominent basal inferolateral late gadolinium enhancement (LGE) pattern (~50% of Fabry patients)
  - Acroparesthesia and pain crises (absent in HCM)
  - Angiokeratomas and cornea verticillata (pathognomonic for Fabry disease)
  - Progressive renal disease with proteinuria and decline in GFR (rare in HCM)
  - X-linked inheritance pattern (HCM typically autosomal dominant)
  - Elevated lyso-Gb3 biomarker (diagnostic for Fabry disease)
  - Prominent papillary muscles are characteristic of Fabry disease
  evidence:
  - reference: PMID:33922740
    reference_title: "Fabry Disease and the Heart: A Comprehensive Review."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: "Hypertrophic cardiomyopathy (HCM) is the main cardiac manifestation of FD"
    explanation: "Establishes HCM as the primary cardiac differential diagnosis for Fabry disease"

- name: Cardiac Amyloidosis
  disease_term:
    preferred_term: Amyloidosis
    term:
      id: MONDO:0019065
      label: amyloidosis
  description: >
    Cardiac amyloidosis presents with heart failure, arrhythmias, and LGE patterns similar to Fabry disease. Both conditions can cause
    concentric or apical hypertrophy, conduction abnormalities, and restrictive physiology. Systolic dysfunction may occur in both.
    The apical sparing pattern seen on imaging can occur in both amyloidosis and Fabry disease, making differentiation challenging
    without additional diagnostic markers.
  distinguishing_features:
  - Extracardiac systemic manifestations (neuropathic pain, angiokeratomas, renal disease) are typical of Fabry disease but absent in cardiac amyloidosis
  - Distinctive cornea verticillata, a whorl-like corneal opacity on slit-lamp examination, is characteristic of Fabry disease
  - Young age of symptom onset is characteristic of Fabry disease (often in childhood); cardiac amyloidosis is more common in elderly
  - Male predominance with severe phenotype indicates X-linked inheritance typical of Fabry disease
  - Elevated lyso-Gb3 biomarker is diagnostic for Fabry disease
  - Skin or conjunctival biopsy showing amyloid (amyloidosis) versus genetic testing for GLA mutations (Fabry disease) provides definitive diagnosis
  evidence:
  - reference: PMID:33922740
    reference_title: "Fabry Disease and the Heart: A Comprehensive Review."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: "An apical sparing pattern on longitudinal strain has also been described in FD, similarly to amyloidosis"
    explanation: "Identifies cardiac amyloidosis as an important differential diagnosis based on overlapping imaging patterns"

- name: Myocarditis
  disease_term:
    preferred_term: Myocarditis
    term:
      id: MONDO:0004496
      label: myocarditis
  description: >
    Myocarditis frequently occurs in Fabry disease (reported in 56% of patients) and can also present as an independent disorder.
    Both can cause acute or subacute cardiac dysfunction, ventricular dysfunction, arrhythmias, and myocardial inflammation on imaging.
    Myocarditis in Fabry disease results from chronic Gb3 accumulation in cardiomyocytes, while primary myocarditis is typically triggered
    by viral infections, autoimmune mechanisms, or drug reactions. The distinction is critical for treatment planning.
  distinguishing_features:
  - Myocarditis in Fabry disease is chronic and progressive (from lysosomal substrate accumulation), whereas primary myocarditis is acute/subacute
  - Extracardiac features including neuropathic pain, angiokeratomas, renal disease, and cornea verticillata are absent in isolated myocarditis
  - Elevated lyso-Gb3 biomarker is diagnostic for Fabry disease
  - Family history showing X-linked inheritance pattern indicates Fabry disease, whereas primary myocarditis typically presents sporadically
  - Left ventricular hypertrophy pattern is characteristic of Fabry disease, while acute myocarditis presents with dilated cardiomyopathy
  - Prodromal viral illness preceding acute myocarditis is typically absent in Fabry disease
  evidence:
  - reference: PMID:33922740
    reference_title: "Fabry Disease and the Heart: A Comprehensive Review."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: "Endomyocardial biopsies have shown myocarditis in 56% of FD patients"
    explanation: "Establishes the high prevalence of myocardial inflammation in Fabry disease and importance of differential diagnosis"

- name: Chagas Disease
  disease_term:
    preferred_term: Chagas disease
    term:
      id: MONDO:0001444
      label: Chagas disease
  description: >
    Chagas disease, caused by Trypanosoma cruzi, can present with cardiac manifestations including cardiomyopathy, arrhythmias, and
    sudden cardiac death, overlapping with Fabry disease cardiac phenotypes. Both can cause left ventricular dysfunction and conduction
    abnormalities. Chronic Chagas disease produces cardiomyopathy with LGE patterns that can mimic Fabry disease. However, systemic
    manifestations differ significantly.
  distinguishing_features:
  - Acroparesthesia and pain crises are characteristic of Fabry disease but not seen in Chagas disease
  - Angiokeratomas and cornea verticillata are pathognomonic for Fabry disease
  - Renal involvement with progressive proteinuria and chronic kidney disease is typical of Fabry disease but absent in Chagas disease
  - Geographic/epidemiological risk differs (Chagas disease endemic to Central/South America; Fabry disease worldwide with X-linked inheritance)
  - Gastrointestinal involvement (megaesophagus, megacolon) is typical of Chagas disease but not seen in Fabry disease
  - Serological testing for Trypanosoma cruzi antibodies versus genetic testing for GLA mutations provides definitive diagnosis
  evidence:
  - reference: PMID:33922740
    reference_title: "Fabry Disease and the Heart: A Comprehensive Review."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: "this LGE pattern is not exclusive of FD and may also be found in myocarditis, Chagas disease, and sarcoidosis [52]."
    explanation: "Highlights the imaging overlap between Fabry disease and Chagas disease as cardiac differentials"

- name: Sarcoidosis
  disease_term:
    preferred_term: Sarcoidosis
    term:
      id: MONDO:0019338
      label: sarcoidosis
  description: >
    Sarcoidosis is a multisystem granulomatous disorder that can involve heart (cardiac sarcoidosis), kidneys, nervous system, and skin,
    creating potential overlap with Fabry disease systemic manifestations. Both can cause cardiomyopathy, arrhythmias, conduction abnormalities,
    renal disease, and neuropathy. Cardiac sarcoidosis with LGE on imaging can superficially resemble Fabry disease cardiomyopathy.
    Neurological involvement (stroke, neuropathy) occurs in both conditions.
  distinguishing_features:
  - Acroparesthesia with pain crises is characteristic of Fabry disease, whereas sarcoidosis causes other neuropathy types
  - Angiokeratomas and cornea verticillata are pathognomonic for Fabry disease and absent in sarcoidosis
  - Pulmonary involvement with hilar lymphadenopathy is typical of sarcoidosis but absent in Fabry disease
  - Cutaneous manifestations differ (angiokeratomas in Fabry disease versus erythema nodosum or lupus pernio in sarcoidosis)
  - Calcium metabolism abnormalities (hypercalcemia, hypercalciuria) are typical of sarcoidosis but absent in Fabry disease
  - Elevated lyso-Gb3 biomarker is diagnostic for Fabry disease, while elevated ACE and serum calcium suggest sarcoidosis
  - Skin or conjunctival biopsy showing granulomas versus genetic testing for GLA mutations provides definitive diagnosis
  evidence:
  - reference: PMID:33922740
    reference_title: "Fabry Disease and the Heart: A Comprehensive Review."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: "this LGE pattern is not exclusive of FD and may also be found in myocarditis, Chagas disease, and sarcoidosis [52]."
    explanation: "Establishes sarcoidosis as a multisystem differential diagnosis for Fabry disease with overlapping imaging patterns"

📚

References & Deep Research

References

1

PMID:20301469

Fabry Disease.

No top-level findings curated for this source.

Deep Research

2

Disorder ▸

Disorder

Name: Fabry disease
Category: Mendelian
Existing deep-research providers: falcon
Existing evidence reference count in YAML: 37

Key Pathophysiology Nodes

Lysosomal alpha-galactosidase A deficiency and Gb3 accumulation
Endoplasmic reticulum stress and unfolded protein response
Mitochondrial dysfunction and oxidative stress
Autophagy impairment
Innate immune activation and inflammation
Endothelial dysfunction and vascular remodeling
Fibrosis and extracellular matrix remodeling
Deep research literature mapping

Citation Inventory (for evidence mapping)

DOI:10.1016/j.heliyon.2024.e34357
DOI:10.1172/jci157782
DOI:10.1186/s12967-024-05756-w
DOI:10.20517/rdodj.2023.37
DOI:10.3389/fcvm.2024.1420067
DOI:10.3389/fimmu.2024.1307558
DOI:10.3390/cells13080654
DOI:10.3390/ijms251910329

Falcon ▸

Pathophysiology description

Edison Scientific Literature 22 citations 2026-01-08T11:24:37.159706

Pathophysiology description Fabry disease is an X‑linked lysosomal storage disorder caused by pathogenic variants in GLA that reduce or abolish α‑galactosidase A activity, leading to lysosomal accumulation of glycosphingolipids, principally globotriaosylceramide (Gb3) and its deacylated derivative globotriaosylsphingosine (lyso‑Gb3). Substrate accumulation initiates a network of stress responses: endoplasmic reticulum (ER) stress and the unfolded protein response (UPR) from misfolded GLA variants; impaired autophagic flux and broader lysosomal dysfunction; mitochondrial injury with bioenergetic failure and reactive oxygen species (ROS) production; and activation of innate immune pathways including NF‑κB and the NLRP3 inflammasome. Inflammatory mediators (e.g., IL‑1β, IL‑6, TNF‑α) and complement activation fragments (C3a, C5a) propagate endothelial dysfunction, leukocyte adhesion, and tissue injury. Profibrotic signaling (notably TGF‑β) drives extracellular matrix deposition and fibrosis that can become partially independent of the initiating lipid stimulus. Organ manifestations arise from injury to vulnerable cell types, particularly podocytes in kidney, cardiomyocytes and the cardiac conduction system, vascular endothelium and smooth muscle, and neurons; these processes underlie proteinuric chronic kidney disease, hypertrophic/fibrotic cardiomyopathy with arrhythmia risk, and cerebrovascular disease. Notably, disease drivers extend beyond storage alone: podocyte injury persists despite Gb3 clearance under enzyme replacement therapy (ERT), with α‑synuclein (SNCA) accumulation implicated as a lysosomal toxicity mediator. Recent work also highlights bioenergetic deficits and oxidative stress correlating with cardiac hypertrophy. (feriozzi2024theinflammatorypathogenetic pages 9-11, feriozzi2024theinflammatorypathogenetic pages 7-9, kurdi2024inflammationinfabry pages 8-10, snanoudj2024genomewideexpressionanalysis pages 6-8, feriozzi2024theinflammatorypathogenetic pages 5-7)

Core Pathophysiology - Primary mechanisms - GLA deficiency → Gb3/lyso‑Gb3 accumulation in lysosomes; lyso‑Gb3 is closely associated with disease severity and exerts direct cytotoxicity on podocytes and neurons. (feriozzi2024theinflammatorypathogenetic pages 9-11) - ER stress/UPR due to misfolded α‑Gal A variants; persistent UPR activates pro‑apoptotic and inflammatory pathways (NF‑κB/MAPK). (kurdi2024inflammationinfabry pages 8-10, feriozzi2024theinflammatorypathogenetic pages 7-9) - Autophagy impairment and global lysosomal dysfunction with accumulation of damaged proteins/organelles. (kurdi2024inflammationinfabry pages 8-10, snanoudj2024genomewideexpressionanalysis pages 6-8) - Mitochondrial dysfunction and oxidative stress: reduced ATP/PCr, complex I/III impairment, elevated oxidative damage; lyso‑Gb3 can enhance ROS via RIPK3 signaling. (kurdi2024inflammationinfabry pages 8-10) - Inflammation and complement: activation of innate immune pathways including NLRP3 (IL‑1β/IL‑18, gasdermin D), and elevated C3a/C5a despite ERT, especially with anti‑drug antibodies. (kurdi2024inflammationinfabry pages 8-10, coelhoribeiro2024inflammationandexosomes pages 15-16) - Endothelial dysfunction: adhesion molecule upregulation (VCAM1/ICAM1), eNOS uncoupling, microvascular remodeling; vascular smooth muscle proliferation attributed to lyso‑Gb3. (coelhoribeiro2024inflammationandexosomes pages 15-16, gervasarruga2024insilicomodeling pages 7-8, feriozzi2024theinflammatorypathogenetic pages 5-7) - Profibrotic signaling: TGF‑β–linked extracellular matrix deposition in kidney (mesangial, interstitial) and heart. (feriozzi2024theinflammatorypathogenetic pages 9-11, feriozzi2024theinflammatorypathogenetic pages 7-9) - Organ‑specific injury: persistent podocyte lysosomal dysfunction and damage despite ERT, mediated in part by α‑synuclein accumulation. (feriozzi2024theinflammatorypathogenetic pages 5-7)

Dysregulated molecular pathways
NF‑κB, MAPK, Notch1 activation by Gb3/lyso‑Gb3; NLRP3 inflammasome; impaired mTOR activity with autophagic flux disruption; oxidative stress pathways; complement cascade activation. (feriozzi2024theinflammatorypathogenetic pages 7-9, kurdi2024inflammationinfabry pages 8-10, snanoudj2024genomewideexpressionanalysis pages 6-8, coelhoribeiro2024inflammationandexosomes pages 15-16)
Affected cellular processes
Protein folding and ER quality control (UPR/ERAD), autophagy/lysophagy, mitophagy and mitochondrial respiration, endothelial nitric oxide signaling, leukocyte adhesion/extravasation, extracellular matrix turnover and fibrosis. (kurdi2024inflammationinfabry pages 8-10, snanoudj2024genomewideexpressionanalysis pages 6-8, coelhoribeiro2024inflammationandexosomes pages 15-16, feriozzi2024theinflammatorypathogenetic pages 9-11)

Key Molecular Players - Genes/Proteins (HGNC or equivalent) - GLA (α‑galactosidase A): causal; deficiency initiates substrate accumulation; target of ERT/chaperone/gene therapy. (feriozzi2024theinflammatorypathogenetic pages 9-11) - SNCA (α‑synuclein): mediates persistent lysosomal dysfunction and podocyte injury; inhibition improves lysosomal structure/function in Fabry podocytes. (feriozzi2024theinflammatorypathogenetic pages 5-7) - VEGFA: elevated in Fabry patients; correlates with albuminuria and cardiac biomarkers; marker of endothelial dysfunction. (coelhoribeiro2024inflammationandexosomes pages 15-16) - Complement C3/C5 (C3a/C5a fragments): elevated in serum despite ERT, especially in nonsense variants with anti‑drug antibodies; indicates complement‑driven inflammation. (coelhoribeiro2024inflammationandexosomes pages 15-16) - Cytokines: IL‑6, IL‑10, TGF‑β1, TNF‑α; increased and associated with renal/cardiac involvement. (coelhoribeiro2024inflammationandexosomes pages 15-16, kurdi2024inflammationinfabry pages 8-10, feriozzi2024theinflammatorypathogenetic pages 9-11) - Adhesion molecules: VCAM1, ICAM1; implicated in leukocyte recruitment and endothelial dysfunction. (gervasarruga2024insilicomodeling pages 7-8, coelhoribeiro2024inflammationandexosomes pages 15-16)

Chemical Entities (CHEBI)
Globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso‑Gb3): storage lipids and circulating biomarkers; lyso‑Gb3 exerts direct cytotoxic and signaling effects. (feriozzi2024theinflammatorypathogenetic pages 9-11)
Cell Types (CL)
Podocytes: principal renal target; autophagy impairment, lysosomal toxicity, foot process effacement, podocyturia. (snanoudj2024genomewideexpressionanalysis pages 6-8, feriozzi2024theinflammatorypathogenetic pages 5-7)
Endothelial cells and vascular smooth muscle cells: endothelial dysfunction and VSMC proliferation/remodeling. (coelhoribeiro2024inflammationandexosomes pages 15-16, feriozzi2024theinflammatorypathogenetic pages 5-7)
Cardiomyocytes and conduction system cells: hypertrophy, inflammation, fibrosis, arrhythmogenic substrate. (kurdi2024inflammationinfabry pages 8-10)
Neurons (peripheral and central): sensitization, neurovascular involvement. (coelhoribeiro2024inflammationandexosomes pages 15-16)
Anatomical Locations (UBERON)
Kidney (glomerulus; tubulointerstitium): proteinuria, fibrosis, CKD progression. (feriozzi2024theinflammatorypathogenetic pages 9-11, snanoudj2024genomewideexpressionanalysis pages 6-8)
Heart (myocardium; conduction tissue; microvasculature): LV hypertrophy, fibrosis, arrhythmia. (kurdi2024inflammationinfabry pages 8-10)
Brain/cerebral vasculature: microvascular dysfunction; stroke risk. (gervasarruga2024insilicomodeling pages 7-8)

Biological Processes (GO, representative) - Lysosomal catabolic process; glycosphingolipid metabolic process; response to ER stress; unfolded protein response; autophagy and mitophagy; regulation of mitochondrial membrane potential; reactive oxygen species metabolic process; NF‑κB signaling; NLRP3 inflammasome activation; complement activation; leukocyte adhesion to endothelium; nitric oxide–mediated signaling; extracellular matrix organization; TGF‑β signaling and epithelial‑to‑mesenchymal transition/myofibroblast activation. (kurdi2024inflammationinfabry pages 8-10, feriozzi2024theinflammatorypathogenetic pages 7-9, snanoudj2024genomewideexpressionanalysis pages 6-8, coelhoribeiro2024inflammationandexosomes pages 15-16, feriozzi2024theinflammatorypathogenetic pages 9-11)

Cellular Components (GO, representative) - Lysosome and late endosome; endoplasmic reticulum; ER–Golgi intermediate compartment; autophagosome–lysosome; mitochondrion (cristae, respiratory chain complexes); plasma membrane lipid rafts; endothelial glycocalyx; extracellular matrix. (kurdi2024inflammationinfabry pages 8-10, snanoudj2024genomewideexpressionanalysis pages 6-8, coelhoribeiro2024inflammationandexosomes pages 15-16)

Disease Progression - Initiation: GLA variant → α‑Gal A deficiency with early Gb3/lyso‑Gb3 accumulation in endothelial cells, podocytes, cardiomyocytes, neurons. (feriozzi2024theinflammatorypathogenetic pages 9-11) - Cellular stress phase: ER stress/UPR, autophagy blockade, mitochondrial dysfunction and ROS; innate immune activation (NLRP3, NF‑κB), complement activation. (kurdi2024inflammationinfabry pages 8-10, coelhoribeiro2024inflammationandexosomes pages 15-16) - Tissue remodeling: endothelial dysfunction and VSMC proliferation, adhesion molecule upregulation; mesangial and interstitial fibrosis (TGF‑β–driven); cardiac hypertrophy and interstitial fibrosis; these changes can become partly substrate‑independent. (feriozzi2024theinflammatorypathogenetic pages 7-9, coelhoribeiro2024inflammationandexosomes pages 15-16) - Clinical manifestations: proteinuria → CKD; LV hypertrophy → arrhythmia and heart failure; cerebrovascular disease (TIA/stroke). Persistent podocyte injury despite Gb3 clearance suggests a pathophysiologic “point of no return” if treatment is delayed. (feriozzi2024theinflammatorypathogenetic pages 5-7, feriozzi2024theinflammatorypathogenetic pages 9-11)

Phenotypic Manifestations and Mechanistic Links - Renal: early albuminuria/proteinuria progressing to CKD; mechanistic drivers include podocyte autophagy/lysosomal dysfunction, lyso‑Gb3 toxicity, TGF‑β–mediated fibrosis, and persistent inflammatory signaling. (snanoudj2024genomewideexpressionanalysis pages 6-8, feriozzi2024theinflammatorypathogenetic pages 9-11) - Cardiac: concentric LV hypertrophy, inflammation and fibrosis, arrhythmias; linked to cardiomyocyte lipid accumulation, oxidative stress/bioenergetic failure, inflammation and fibrosis; arrhythmogenic substrate evolves across phases (accumulation → hypertrophy → inflammation → fibrosis). (kurdi2024inflammationinfabry pages 8-10) - Vascular/Cerebrovascular: endothelial dysfunction, microvascular remodeling, pro‑thrombotic milieu; stroke/TIA risk. (coelhoribeiro2024inflammationandexosomes pages 15-16, gervasarruga2024insilicomodeling pages 7-8) - Neurologic and pain: neuronal sensitization likely from lyso‑Gb3 effects and lysosomal/autophagic dysfunction. (coelhoribeiro2024inflammationandexosomes pages 15-16)

Recent Developments (2023–2024), Applications, Expert Opinions, and Statistics - Persistent injury beyond storage: Serial human kidney biopsies and CRISPR GLA‑KO podocytes show ERT reduces Gb3 but does not reverse podocyte injury; α‑synuclein accumulation identified as a key mediator; genetic/pharmacologic SNCA inhibition improved lysosomal structure/function beyond ERT. This reconceptualizes Fabry nephropathy and suggests adjunct targets. Journal of Clinical Investigation, 2023; DOI: 10.1172/JCI157782. (feriozzi2024theinflammatorypathogenetic pages 5-7) - Inflammation/complement despite ERT: In 17 classical male FD patients, strong complement activation was demonstrated (elevated C3a/C5a) before and after ERT; levels increased particularly in nonsense variants with anti‑drug antibodies; cytokines (IL‑6, IL‑10, TGF‑β1) were elevated and associated with renal involvement, supporting inflammation as a therapeutic target. Frontiers in Immunology, 2024; DOI: 10.3389/fimmu.2024.1307558. (coelhoribeiro2024inflammationandexosomes pages 15-16) - Integrative mechanism review (cardiac focus): ER stress/UPR, autophagy impairment, mitochondrial dysfunction and oxidative stress interact to promote remodeling, fibrosis and arrhythmias; treatment effectiveness remains limited, underscoring need for novel strategies. Current Heart Failure Reports, 2024; DOI: 10.1007/s11897-024-00645-1. (kurdi2024inflammationinfabry pages 8-10) - In vitro podocyte transcriptomics: GLA‑edited human podocytes show differential expression consistent with oxidative stress, ER folding/UPR (SIL1), autophagy/mTOR disruption, ECM remodeling, and innate immune activation via TLRs by Gb3/lyso‑Gb3. Heliyon, 2024; DOI: 10.1016/j.heliyon.2024.e34357. (snanoudj2024genomewideexpressionanalysis pages 6-8) - Human models and translation: Patient‑derived organoids display decreased α‑Gal A, Gb3 storage, impaired vascularization (rescued by ERT), and glutathione depletion (restorable); overview of ongoing/registered trials (e.g., AAV and lentiviral gene therapies, GCS inhibitors, SGLT2 inhibitor adjuncts). Journal of Translational Medicine, 2024; DOI: 10.1186/s12967-024-05756-w. (borisch2024humaninvitro pages 11-12)

Current therapies and mechanistic/biomarker implications (real‑world implementations) - Enzyme replacement therapies (ERT): agalsidase alfa/beta and pegunigalsidase alfa restore α‑Gal A activity and reduce Gb3/lyso‑Gb3. However, cellular signaling alterations and fibrosis may persist; anti‑drug antibodies can provoke complement activation. Frontiers in Immunology, 2024 (complement/ADA); translational organoid and review data emphasize early initiation. (coelhoribeiro2024inflammationandexosomes pages 15-16, borisch2024humaninvitro pages 11-12) - Pharmacological chaperone therapy (migalastat): stabilizes amenable mutant GLA and improves lysosomal trafficking; PK modeling in ESRD suggests a 123 mg every‑other‑week regimen around hemodialysis achieves target exposure with minimal accumulation, informing use in advanced CKD. PLOS One, 2024; DOI: 10.1371/journal.pone.0314030. (kurdi2024inflammationinfabry pages 8-10) - Gene therapy: Preclinical AAV‑ and lentiviral‑based strategies demonstrate sustained α‑Gal A expression and clearance of Gb3/lyso‑Gb3 in plasma, kidney and heart; early Canadian lentiviral clinical experience monitored comprehensive glycosphingolipid biomarker profiles over five years. Gene Therapy 2023; Mol Ther Methods Clin Dev 2024; Rare Disease and Orphan Drugs Journal 2024. (borisch2024humaninvitro pages 11-12) - Biomarkers: lyso‑Gb3 remains a central diagnostic and therapeutic biomarker; emerging inflammatory/endothelial markers (VEGFA, GDF‑15, MPO, ADAMTS‑13, TNF‑α) provide complementary disease‑activity signatures and may track ERT effects. International Journal of Molecular Sciences, 2024. (coelhoribeiro2024inflammationandexosomes pages 15-16)

Direct quotations (supporting key statements) - “Substrate accumulation (Gb3 and lyso‑Gb3) triggers inflammation and ER stress/UPR… Lysosomal Gb3 accumulation impairs autophagy… Mitochondrial dysfunction and bioenergetic impairment… The NLRP3 inflammasome is implicated, leading to caspase‑1–dependent IL‑1β/IL‑18 release.” Frontiers in Cardiovascular Medicine, 2024. (kurdi2024inflammationinfabry pages 8-10) - “Elevated globotriaosylsphingosine is a hallmark of Fabry disease… α‑Gal A missense variants… can lead to ER stress and induction of the unfolded protein response… Defective lysosomal storage… modifies mitochondrial structure, metabolism and turnover.” Rare Disease and Orphan Drugs Journal, 2024. (feriozzi2024theinflammatorypathogenetic pages 9-11) - “Strong activation of the complement system… evidenced by high C3a and C5a serum levels… in contrast to the strong reduction of lyso‑Gb3 under ERT, C3a and C5a markedly increased… most of whom developed anti‑drug antibodies.” Frontiers in Immunology, 2024. (coelhoribeiro2024inflammationandexosomes pages 15-16) - “Long‑term use of ERT reduced Gb3 accumulation in podocytes but did not reverse podocyte injury… α‑synuclein accumulation as a key event mediating podocyte injury… inhibition of SNCA improved lysosomal structure and function.” Journal of Clinical Investigation, 2023. (feriozzi2024theinflammatorypathogenetic pages 5-7)

Gene/protein annotations with ontology terms - GLA (HGNC:4296); α‑galactosidase A (UniProt: P06280); GO:0005759 mitochondrion; GO:0006914 autophagy; GO:0006986 response to unfolded protein; GO:0007165 signal transduction; GO:0006954 inflammatory response; GO:0006956 complement activation. (kurdi2024inflammationinfabry pages 8-10, feriozzi2024theinflammatorypathogenetic pages 9-11) - SNCA (HGNC:11138); GO:0005773 vacuole/lysosome; GO:0006914 autophagy; implicated in lysosomal dysfunction in podocytes. (feriozzi2024theinflammatorypathogenetic pages 5-7) - VEGFA (HGNC:12680); GO:0001525 angiogenesis; elevated as endothelial dysfunction biomarker. (coelhoribeiro2024inflammationandexosomes pages 15-16) - VCAM1 (HGNC:12663), ICAM1 (HGNC:5344); GO:0007155 cell adhesion; endothelial leukocyte adhesion. (gervasarruga2024insilicomodeling pages 7-8) - TNF (HGNC:11892), IL6 (HGNC:6018), TGFB1 (HGNC:11766); GO:0006954 inflammatory response; GO:0006959 humoral immune response; GO:0006957 complement pathway (contextual); GO:0007165 signal transduction; GO:0001501 skeletal system development (TGFB1 fibrosis context). (kurdi2024inflammationinfabry pages 8-10, feriozzi2024theinflammatorypathogenetic pages 9-11)

Phenotype associations (HP terms) - HP:0000093 Proteinuria; HP:0000112 Chronic kidney disease; HP:0001639 Cardiomyopathy; HP:0001707 Arrhythmia; HP:0001297 Stroke; HP:0000975 Angiokeratoma; HP:0001250 Peripheral neuropathy; mechanistic links as above. (feriozzi2024theinflammatorypathogenetic pages 9-11, kurdi2024inflammationinfabry pages 8-10, gervasarruga2024insilicomodeling pages 7-8)

Cell type involvement (CL terms) - CL:0000653 Podocyte; CL:0000115 Endothelial cell; CL:0000746 Cardiomyocyte; CL:0000746 conduction variants; CL:0000749 Vascular smooth muscle cell; CL:0000540 Neuron. (snanoudj2024genomewideexpressionanalysis pages 6-8, coelhoribeiro2024inflammationandexosomes pages 15-16)

Anatomical locations (UBERON terms) - UBERON:0002113 Kidney; UBERON:0000948 Heart; UBERON:0000955 Brain; UBERON:0001981 Cerebral vasculature. (feriozzi2024theinflammatorypathogenetic pages 9-11, gervasarruga2024insilicomodeling pages 7-8)

Chemical entities (CHEBI) - CHEBI:XXXXX Globotriaosylceramide (Gb3); CHEBI:XXXXX Globotriaosylsphingosine (lyso‑Gb3). (feriozzi2024theinflammatorypathogenetic pages 9-11)

Evidence items with PMIDs/URLs/dates - Kurdi H, et al. Inflammation in Fabry disease: stages, molecular pathways, and therapeutic implications. Front Cardiovasc Med. 2024 Jun; URL: https://doi.org/10.3389/fcvm.2024.1420067 (mechanisms: UPR, autophagy, mitochondria, NLRP3, oxidative stress; cardiac links). (kurdi2024inflammationinfabry pages 8-10) - Feriozzi S, Rozenfeld P. The inflammatory pathogenetic pathways of Fabry nephropathy. Rare Dis Orphan Drugs J. 2024 Apr; URL: https://doi.org/10.20517/rdodj.2023.37 (lyso‑Gb3 toxicity, ER stress/UPR, autophagy/mitochondria, fibrosis; podocyte and tubular mechanisms). (feriozzi2024theinflammatorypathogenetic pages 9-11, feriozzi2024theinflammatorypathogenetic pages 7-9) - Coelho‑Ribeiro B, et al. Inflammation and Exosomes in Fabry Disease Pathogenesis. Cells. 2024 Apr; URL: https://doi.org/10.3390/cells13080654 (endothelial dysfunction, adhesion molecules, oxidative stress; therapy context). (coelhoribeiro2024inflammationandexosomes pages 15-16) - Gervas‑Arruga J, et al. In silico modeling… IJMS. 2024 Sep; URL: https://doi.org/10.3390/ijms251910329 (adhesion molecules, endothelial dysfunction, biomarker candidates). (gervasarruga2024insilicomodeling pages 7-8) - Snanoudj S, et al. Genome‑wide expression analysis in a Fabry disease human podocyte cell line. Heliyon. 2024 Jul; URL: https://doi.org/10.1016/j.heliyon.2024.e34357 (podocyte transcriptomics: UPR/autophagy/ECM/innate immunity). (snanoudj2024genomewideexpressionanalysis pages 6-8) - Borisch C, et al. Human in vitro models for Fabry disease. J Transl Med. 2024 Oct; URL: https://doi.org/10.1186/s12967-024-05756-w (organoid mechanisms; ongoing trials and applications). (borisch2024humaninvitro pages 11-12) - Braun F, et al. Accumulation of α‑synuclein mediates podocyte injury in Fabry nephropathy. J Clin Invest. 2023 Jun; URL: https://doi.org/10.1172/jci157782 (ERT reduces Gb3 but not podocyte injury; SNCA as mediator). (feriozzi2024theinflammatorypathogenetic pages 5-7) - Laffer B, et al. Complement activation and cellular inflammation in Fabry disease patients despite ERT. Front Immunol. 2024 Jan; URL: https://doi.org/10.3389/fimmu.2024.1307558 (C3a/C5a elevation; cytokines; ADA context). (coelhoribeiro2024inflammationandexosomes pages 15-16)

Artifacts | Category | Name | Ontology namespace.term | Role/notes | Evidence (Context IDs) | |---|---|---|---|---| | Gene | GLA | HGNC:GLA | Causal gene encoding alpha-galactosidase A; loss-of-function causes substrate accumulation | (feriozzi2024theinflammatorypathogenetic pages 9-11, feriozzi2024theinflammatorypathogenetic pages 7-9) | | Protein | alpha-galactosidase A | UniProt:GLA (alpha-galactosidase A) | Lysosomal hydrolase deficient in Fabry disease; target of ERT/chaperone/gene therapies | (feriozzi2024theinflammatorypathogenetic pages 9-11, feriozzi2024theinflammatorypathogenetic pages 7-9) | | Metabolite | Globotriaosylceramide (Gb3) | CHEBI:globotriaosylceramide (Gb3) | Primary accumulating glycosphingolipid that disrupts lysosomal function and cells | (feriozzi2024theinflammatorypathogenetic pages 9-11, coelhoribeiro2024inflammationandexosomes pages 15-16) | | Metabolite | Globotriaosylsphingosine (lyso-Gb3) | CHEBI:globotriaosylsphingosine (lyso-Gb3) | Deacylated Gb3 derivative; biomarker and direct mediator of cytotoxicity/inflammation | (feriozzi2024theinflammatorypathogenetic pages 9-11, coelhoribeiro2024inflammationandexosomes pages 15-16) | | Gene/Protein | Alpha-synuclein (SNCA) | HGNC:SNCA | Identified as mediator of persistent podocyte lysosomal dysfunction and candidate therapeutic target | (feriozzi2024theinflammatorypathogenetic pages 5-7) | | Gene/Protein | VEGFA | HGNC:VEGFA | Angiogenic factor upregulated in endothelial dysfunction and proposed as vascular biomarker | (coelhoribeiro2024inflammationandexosomes pages 15-16, gervasarruga2024insilicomodeling pages 7-8) | | Proteins/Fragments | Complement C3a / C5a | HGNC:C3, HGNC:C5 (C3a/C5a) | Evidence of complement activation (elevated C3a/C5a) contributing to inflammation despite ERT | (coelhoribeiro2024inflammationandexosomes pages 15-16, kurdi2024inflammationinfabry pages 8-10) | | Cytokine | IL-6 | HGNC:IL6 | Pro-inflammatory cytokine elevated in FD-related inflammation and renal/cardiac injury | (feriozzi2024theinflammatorypathogenetic pages 5-7, kurdi2024inflammationinfabry pages 8-10) | | Cytokine | TNF-alpha | HGNC:TNF | Pro-inflammatory mediator implicated in organ damage and inflammatory signaling | (feriozzi2024theinflammatorypathogenetic pages 5-7, kurdi2024inflammationinfabry pages 8-10) | | Cytokine / Growth factor | TGF-beta1 | HGNC:TGFB1 | Profibrotic mediator linked to mesangial ECM deposition and interstitial fibrosis | (feriozzi2024theinflammatorypathogenetic pages 5-7, feriozzi2024theinflammatorypathogenetic pages 9-11) | | Adhesion molecule | VCAM1 | HGNC:VCAM1 | Upregulated adhesion molecule promoting leukocyte recruitment and endothelial dysfunction | (gervasarruga2024insilicomodeling pages 7-8, coelhoribeiro2024inflammationandexosomes pages 15-16) | | Adhesion molecule | ICAM1 | HGNC:ICAM1 | Endothelial adhesion molecule involved in leukocyte adhesion/extravasation | (gervasarruga2024insilicomodeling pages 7-8, coelhoribeiro2024inflammationandexosomes pages 15-16) | | Cell type | Podocyte | CL:podocyte | Principal renal cell target; Gb3/lyso-Gb3–driven injury, autophagy impairment, podocyturia and proteinuria | (snanoudj2024genomewideexpressionanalysis pages 6-8, feriozzi2024theinflammatorypathogenetic pages 5-7) | | Cell type | Endothelial cell | CL:endothelial_cell | Early vascular target; endothelial dysfunction, eNOS uncoupling, adhesion-molecule upregulation | (coelhoribeiro2024inflammationandexosomes pages 15-16, kurdi2024inflammationinfabry pages 8-10) | | Cell type | Cardiomyocyte | CL:cardiomyocyte | Cardiac lipid deposition → hypertrophy, inflammation, fibrosis, arrhythmogenic substrate | (kurdi2024inflammationinfabry pages 8-10, coelhoribeiro2024inflammationandexosomes pages 15-16) | | Cell type | Vascular smooth muscle cell | CL:vascular_smooth_muscle_cell | Lyso-Gb3–driven proliferation and vascular wall remodeling | (feriozzi2024theinflammatorypathogenetic pages 5-7) | | Cell type | Neuron | CL:neuron | Peripheral/central neuronal sensitization and CNS involvement linked to lyso-Gb3 and lysosomal dysfunction | (coelhoribeiro2024inflammationandexosomes pages 15-16, gervasarruga2024insilicomodeling pages 7-8) | | Anatomy | Kidney | UBERON:kidney | Major organ of Fabry nephropathy (podocyte loss, proteinuria, CKD progression) | (feriozzi2024theinflammatorypathogenetic pages 5-7, snanoudj2024genomewideexpressionanalysis pages 6-8) | | Anatomy | Heart | UBERON:heart | Organ affected by sphingolipid deposition: hypertrophy, fibrosis, arrhythmia, heart failure | (kurdi2024inflammationinfabry pages 8-10, coelhoribeiro2024inflammationandexosomes pages 15-16) | | Anatomy | Brain / cerebral vasculature | UBERON:brain_vasculature | Cerebrovascular involvement (stroke risk), microvascular dysfunction and neuronal effects | (gervasarruga2024insilicomodeling pages 7-8, coelhoribeiro2024inflammationandexosomes pages 15-16) |

Table: A compact ontology-mapped table of genes, proteins, metabolites, cell types and organs implicated in Fabry disease with brief roles and matched evidence IDs for provenance; useful for knowledge-base ingestion and mechanistic annotation. Citations link to collected context items supporting each entry.

Notes and limitations - GO, CL, UBERON, CHEBI identifiers are provided at the term level for integration; specific numeric IDs for CHEBI Gb3/lyso‑Gb3 should be completed during curation. Where direct PMIDs are not provided in the excerpt, DOI/URL and journal/date are supplied; underlying primary studies are cited within the reviews. The complement and SNCA findings are supported by recent primary evidence. Remaining open questions include the extent to which inflammation becomes substrate‑independent and the optimal timing/combination of anti‑inflammatory or complement‑targeting therapies alongside disease‑specific treatments. (kurdi2024inflammationinfabry pages 8-10, coelhoribeiro2024inflammationandexosomes pages 15-16, feriozzi2024theinflammatorypathogenetic pages 5-7)

References

(feriozzi2024theinflammatorypathogenetic pages 9-11): Sandro Feriozzi and Paula Rozenfeld. The inflammatory pathogenetic pathways of fabry nephropathy. Rare Disease and Orphan Drugs Journal, Apr 2024. URL: https://doi.org/10.20517/rdodj.2023.37, doi:10.20517/rdodj.2023.37. This article has 4 citations.
(feriozzi2024theinflammatorypathogenetic pages 7-9): Sandro Feriozzi and Paula Rozenfeld. The inflammatory pathogenetic pathways of fabry nephropathy. Rare Disease and Orphan Drugs Journal, Apr 2024. URL: https://doi.org/10.20517/rdodj.2023.37, doi:10.20517/rdodj.2023.37. This article has 4 citations.
(kurdi2024inflammationinfabry pages 8-10): Hibba Kurdi, Lucia Lavalle, James C. C. Moon, and Derralynn Hughes. Inflammation in fabry disease: stages, molecular pathways, and therapeutic implications. Frontiers in Cardiovascular Medicine, Jun 2024. URL: https://doi.org/10.3389/fcvm.2024.1420067, doi:10.3389/fcvm.2024.1420067. This article has 21 citations and is from a peer-reviewed journal.
(snanoudj2024genomewideexpressionanalysis pages 6-8): Sarah Snanoudj, Céline Derambure, Cheng Zhang, Nguyen Thi Hai Yen, Céline Lesueur, Sophie Coutant, Lénaïg Abily-Donval, Stéphane Marret, Hong Yang, Adil Mardinoglu, Soumeya Bekri, and Abdellah Tebani. Genome-wide expression analysis in a fabry disease human podocyte cell line. Heliyon, 10:e34357, Jul 2024. URL: https://doi.org/10.1016/j.heliyon.2024.e34357, doi:10.1016/j.heliyon.2024.e34357. This article has 6 citations and is from a peer-reviewed journal.
(feriozzi2024theinflammatorypathogenetic pages 5-7): Sandro Feriozzi and Paula Rozenfeld. The inflammatory pathogenetic pathways of fabry nephropathy. Rare Disease and Orphan Drugs Journal, Apr 2024. URL: https://doi.org/10.20517/rdodj.2023.37, doi:10.20517/rdodj.2023.37. This article has 4 citations.
(coelhoribeiro2024inflammationandexosomes pages 15-16): Bruna Coelho-Ribeiro, Helena G. Silva, Belém Sampaio-Marques, Alexandra G. Fraga, Olga Azevedo, Jorge Pedrosa, and Paula Ludovico. Inflammation and exosomes in fabry disease pathogenesis. Cells, 13:654, Apr 2024. URL: https://doi.org/10.3390/cells13080654, doi:10.3390/cells13080654. This article has 12 citations and is from a poor quality or predatory journal.
(gervasarruga2024insilicomodeling pages 7-8): Javier Gervas-Arruga, Miguel Ángel Barba-Romero, Jorge Julián Fernández-Martín, Jorge Francisco Gómez-Cerezo, Cristina Segú-Vergés, Giacomo Ronzoni, and Jorge J. Cebolla. In silico modeling of fabry disease pathophysiology for the identification of early cellular damage biomarker candidates. International Journal of Molecular Sciences, 25:10329, Sep 2024. URL: https://doi.org/10.3390/ijms251910329, doi:10.3390/ijms251910329. This article has 6 citations and is from a poor quality or predatory journal.
(borisch2024humaninvitro pages 11-12): Carla Borisch, Thomas Thum, Christian Bär, and Jeannine Hoepfner. Human in vitro models for fabry disease: new paths for unravelling disease mechanisms and therapies. Journal of Translational Medicine, Oct 2024. URL: https://doi.org/10.1186/s12967-024-05756-w, doi:10.1186/s12967-024-05756-w. This article has 9 citations and is from a peer-reviewed journal.

Ask OpenScientist

OpenScientist Report

Mappings

Definitions

Inheritance

Subtypes

Mechanistic Hypotheses

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Biochemical Markers

Differential Diagnoses

Experimental Models

Computational Models

Source YAML

References & Deep Research

References

Deep Research

Disorder

Key Pathophysiology Nodes

Citation Inventory (for evidence mapping)